TWI831202B - Vegfr fusion protein pharmaceutical composition - Google Patents
Vegfr fusion protein pharmaceutical composition Download PDFInfo
- Publication number
- TWI831202B TWI831202B TW111118082A TW111118082A TWI831202B TW I831202 B TWI831202 B TW I831202B TW 111118082 A TW111118082 A TW 111118082A TW 111118082 A TW111118082 A TW 111118082A TW I831202 B TWI831202 B TW I831202B
- Authority
- TW
- Taiwan
- Prior art keywords
- fusion protein
- concentration
- formula
- formulation
- pharmaceutical
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 230
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 199
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 94
- 238000000034 method Methods 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims description 94
- 238000009472 formulation Methods 0.000 claims description 74
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 67
- 235000018102 proteins Nutrition 0.000 claims description 65
- 102000004169 proteins and genes Human genes 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 61
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 61
- 239000000872 buffer Substances 0.000 claims description 59
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 57
- 201000011190 diabetic macular edema Diseases 0.000 claims description 57
- 235000001014 amino acid Nutrition 0.000 claims description 48
- 229940024606 amino acid Drugs 0.000 claims description 47
- 150000001413 amino acids Chemical class 0.000 claims description 47
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 38
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 38
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 38
- 208000002780 macular degeneration Diseases 0.000 claims description 37
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 35
- 230000002062 proliferating effect Effects 0.000 claims description 35
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 34
- 229920005862 polyol Polymers 0.000 claims description 34
- 150000003077 polyols Chemical class 0.000 claims description 34
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 34
- 229940068977 polysorbate 20 Drugs 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 33
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 29
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 29
- 239000011780 sodium chloride Substances 0.000 claims description 28
- 229930006000 Sucrose Natural products 0.000 claims description 27
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 27
- 239000005720 sucrose Substances 0.000 claims description 27
- 230000002792 vascular Effects 0.000 claims description 26
- 239000004094 surface-active agent Substances 0.000 claims description 24
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 21
- 208000010412 Glaucoma Diseases 0.000 claims description 19
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 18
- 208000001344 Macular Edema Diseases 0.000 claims description 18
- 206010025415 Macular oedema Diseases 0.000 claims description 18
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 18
- 206010029113 Neovascularisation Diseases 0.000 claims description 18
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims description 18
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 18
- 208000035307 Vitreous adhesions Diseases 0.000 claims description 18
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 18
- 201000010230 macular retinal edema Diseases 0.000 claims description 18
- 206010016654 Fibrosis Diseases 0.000 claims description 16
- 210000004204 blood vessel Anatomy 0.000 claims description 16
- 230000004761 fibrosis Effects 0.000 claims description 16
- 208000030533 eye disease Diseases 0.000 claims description 15
- 239000001488 sodium phosphate Substances 0.000 claims description 14
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 14
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 208000017442 Retinal disease Diseases 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 11
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 11
- 206010038923 Retinopathy Diseases 0.000 claims description 11
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 11
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 11
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 11
- 229940068968 polysorbate 80 Drugs 0.000 claims description 11
- 229920000053 polysorbate 80 Polymers 0.000 claims description 11
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 11
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
- 235000018417 cysteine Nutrition 0.000 claims description 10
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- 241001111421 Pannus Species 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 9
- 206010046851 Uveitis Diseases 0.000 claims description 9
- 235000003704 aspartic acid Nutrition 0.000 claims description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 235000013922 glutamic acid Nutrition 0.000 claims description 9
- 239000004220 glutamic acid Substances 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 9
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000001103 potassium chloride Substances 0.000 claims description 9
- 235000011164 potassium chloride Nutrition 0.000 claims description 9
- 208000032544 Cicatrix Diseases 0.000 claims description 8
- 206010065630 Iris neovascularisation Diseases 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 201000001949 Retinal Vasculitis Diseases 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 8
- 230000002980 postoperative effect Effects 0.000 claims description 8
- 231100000241 scar Toxicity 0.000 claims description 8
- 230000037387 scars Effects 0.000 claims description 8
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- 201000000159 corneal neovascularization Diseases 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 235000017281 sodium acetate Nutrition 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 235000010356 sorbitol Nutrition 0.000 claims description 7
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 6
- 229940044519 poloxamer 188 Drugs 0.000 claims description 6
- 229920001993 poloxamer 188 Polymers 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 150000004804 polysaccharides Chemical class 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 201000002154 Pterygium Diseases 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 210000001525 retina Anatomy 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 206010025421 Macule Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 229960003339 sodium phosphate Drugs 0.000 claims 1
- 108010044426 integrins Proteins 0.000 abstract description 46
- 102000006495 integrins Human genes 0.000 abstract description 46
- 230000033115 angiogenesis Effects 0.000 abstract description 23
- 239000002870 angiogenesis inducing agent Substances 0.000 abstract description 10
- 230000037361 pathway Effects 0.000 abstract description 8
- 239000013022 formulation composition Substances 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 66
- 125000003275 alpha amino acid group Chemical group 0.000 description 44
- 230000027455 binding Effects 0.000 description 42
- 238000012360 testing method Methods 0.000 description 42
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 229920000642 polymer Polymers 0.000 description 27
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 101800001224 Disintegrin Proteins 0.000 description 25
- 125000005647 linker group Chemical group 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 20
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 20
- 108091008605 VEGF receptors Proteins 0.000 description 17
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 17
- 102000023732 binding proteins Human genes 0.000 description 17
- 108091008324 binding proteins Proteins 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 238000003860 storage Methods 0.000 description 16
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 15
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000014759 maintenance of location Effects 0.000 description 15
- 230000002207 retinal effect Effects 0.000 description 15
- 239000000539 dimer Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 238000002296 dynamic light scattering Methods 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 239000007979 citrate buffer Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- 229960001340 histamine Drugs 0.000 description 10
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 229960002591 hydroxyproline Drugs 0.000 description 7
- 229940076783 lucentis Drugs 0.000 description 7
- 229960002429 proline Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 6
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241000282560 Macaca mulatta Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108091008606 PDGF receptors Proteins 0.000 description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000013400 design of experiment Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 108010006654 Bleomycin Proteins 0.000 description 5
- 108700021041 Disintegrin Proteins 0.000 description 5
- 231100000491 EC50 Toxicity 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 229960001561 bleomycin Drugs 0.000 description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000014429 Insulin-like growth factor Human genes 0.000 description 4
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000022873 Ocular disease Diseases 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 108010081667 aflibercept Proteins 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 102000058223 human VEGFA Human genes 0.000 description 4
- 229940098197 human immunoglobulin g Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 102000029719 integrin binding proteins Human genes 0.000 description 4
- 108091009291 integrin binding proteins Proteins 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000012905 visible particle Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 3
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 229940120638 avastin Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940051306 eylea Drugs 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 238000013534 fluorescein angiography Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 229920006158 high molecular weight polymer Polymers 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 3
- 229960004378 nintedanib Drugs 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000003998 snake venom Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102000009840 Angiopoietins Human genes 0.000 description 2
- 108010009906 Angiopoietins Proteins 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102100029761 Cadherin-5 Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000002111 Neuropilin Human genes 0.000 description 2
- 108050009450 Neuropilin Proteins 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- -1 Ussuristatin Proteins 0.000 description 2
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 2
- 101710099833 Venom protein Proteins 0.000 description 2
- 241000271897 Viperidae Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000013357 binding ELISA Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012537 formulation buffer Substances 0.000 description 2
- 238000012395 formulation development Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000004114 interleukin 20 Human genes 0.000 description 2
- 108090000681 interleukin 20 Proteins 0.000 description 2
- 229940124829 interleukin-23 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229930185360 leucophyllin Natural products 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008646 thermal stress Effects 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical group O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- 101000666940 Agkistrodon piscivorus piscivorus Disintegrin applaggin Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 108700036276 KH902 fusion Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 101710096250 Lachesin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
- 101500020249 Protobothrops mucrosquamatus Snake venom metalloproteinase TM-3 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000030555 Pygmy Diseases 0.000 description 1
- 102000005583 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 108010036006 albolabrin Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000012512 bulk drug substance Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 1
- TTZWEOINXHJHCY-UHFFFAOYSA-N carapanaubine Natural products O=C1NC(C(=C(OC)C=C2)OC)=C2C11CCN2CC3C(C)OC=C(C(=O)OC)C3CC21 TTZWEOINXHJHCY-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 229950005748 conbercept Drugs 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 108010025752 echistatin Proteins 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010070423 elegantin Proteins 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- TVCAZGSWNBZVJN-UHFFFAOYSA-M ethyl-[2-(2-hydroxy-2,2-diphenylacetyl)oxyethyl]-dimethylazanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(O)(C(=O)OCC[N+](C)(C)CC)C1=CC=CC=C1 TVCAZGSWNBZVJN-UHFFFAOYSA-M 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 108010072872 flavostatin Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 108010040488 jarastatin Proteins 0.000 description 1
- 108010059557 kistrin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 108010000222 polyserine Proteins 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010049985 rhodostomin Proteins 0.000 description 1
- 108010003419 saxatilin Proteins 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 108020001568 subdomains Proteins 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 108010039519 triflavin Proteins 0.000 description 1
- 108010060000 trigramin Proteins 0.000 description 1
- 108010028892 trimucrin Proteins 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000011123 type I (borosilicate glass) Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 108010080213 vascular factor Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- YEIGUXGHHKAURB-VAMGGRTRSA-N viridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@@]2(C)[C@H](O)[C@H](OC)C(=O)C3=COC1=C23 YEIGUXGHHKAURB-VAMGGRTRSA-N 0.000 description 1
- 108010086097 viridin Proteins 0.000 description 1
- YEIGUXGHHKAURB-UHFFFAOYSA-N viridine Natural products O=C1C2=C3CCC(=O)C3=CC=C2C2(C)C(O)C(OC)C(=O)C3=COC1=C23 YEIGUXGHHKAURB-UHFFFAOYSA-N 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本發明係關於一種抑制血管性因子活化路徑(angiogenic factor-activated pathway)的融合蛋白醫藥組合物。具體而言,本發明係關於抑制血管性因子活化路徑的融合蛋白、該等融合蛋白的組合物、以及用於製造及使用彼等的方法。 The present invention relates to a fusion protein pharmaceutical composition that inhibits the angiogenic factor-activated pathway. Specifically, the present invention relates to fusion proteins that inhibit vascular factor activation pathways, compositions of such fusion proteins, and methods for making and using the same.
血管新生係自既存血管形成新血管的過程,其在數種生理過程中皆扮演重要的角色,該生理過程包括胚胎發育以及組織及傷口修復(Folkman J 等人,Angiogenic factors.Science 1987;235:442-7)。血管新生之生理步驟已被清楚了解,包含胞外基質之分解、內皮細胞之增生、黏附、遷移、及重組成管道通路、壁細胞之募集及分化、以及胞外基質之產生(Carmeliet P等人,Nature.2011;473:298-307)。病理性的血管新生可發生在腫瘤形成、眼部病症(例如,糖尿病視網膜病變、糖尿病黃斑水腫、視網膜/脈絡膜新生血管、滲出性老年性黃斑退化、及新生血管性青光眼)、關節炎、牛皮癬、纖維化疾病、發炎性疾病、動脈粥狀硬化(atherosclerosis)及動脈硬化(arteriosclerosis)(Polverini PJ.Crit Rev Oral Biol Med.1995;6(3):230-47;Perrotta P et al.Vascular Pharmacology.2019;112:72-78)。 Angiogenesis is the process of forming new blood vessels from existing blood vessels and plays an important role in several physiological processes, including embryonic development and tissue and wound repair (Folkman J et al., Angiogenic factors. Science 1987; 235: 442-7). The physiological steps of angiogenesis are well understood and include the breakdown of extracellular matrix, proliferation, adhesion, migration, and reorganization of endothelial cells into conduit pathways, recruitment and differentiation of mural cells, and production of extracellular matrix (Carmeliet P et al. , Nature. 2011;473:298-307). Pathological angiogenesis can occur in tumor formation, ocular disorders (eg, diabetic retinopathy, diabetic macular edema, retinal/choroidal neovascularization, exudative age-related macular degeneration, and neovascular glaucoma), arthritis, psoriasis, Fibrotic diseases, inflammatory diseases, atherosclerosis and arteriosclerosis (Polverini PJ. Crit Rev Oral Biol Med. 1995; 6(3): 230-47; Perrotta P et al. Vascular Pharmacology. 2019;112:72-78).
病理性血管新生更加的多樣且混亂,通常呈現彎曲的血管組織、不同大小的低氧縫隙(hypoxic void),不均勻且不完整的血管壁及內壁(lining)、 以及無效的灌流(Jain RK.,Nat Med.2003;9(6):685-93)。疾病中之新血管形成的該些特殊表徵,使得靶向血管新生之治療具有挑戰性。雖然抗VEGF療法,例如:樂舒晴(Lucentis®)、采視明(Eylea®)、或藥品仿單標示外使用(off-label use)的癌思停(Avastin®)一般可穩定或改善視覺功能,但在用抗VEGF治療兩年內,所有經治療之眼睛中大約半數會產生次視網膜結痂(纖維化),這被視為癒後不成功的其中一個原因(Daniel E等人,Ophthalmology.2014;121(3):656-66)。在次視網膜纖維化中的許多關鍵參與者,很可能是參與在纖維化過程(細胞增生、遷移及ECM重塑)中的生長因子及基質細胞蛋白(matricellular protein)。儘管其具有複雜性,隨著我們對血管新生過程的知識增加,抑制血管新生藥物的發展依然是頗受關注的區域。 Pathological angiogenesis is more diverse and chaotic, usually showing curved vascular tissue, hypoxic voids of different sizes, uneven and incomplete vessel walls and linings, and ineffective perfusion (Jain RK ., Nat Med. 2003;9(6):685-93). These unique features of neovascularization in disease make treatments targeting angiogenesis challenging. Although anti-VEGF therapies such as Lucentis ® , Eylea ® , or off-label use of Avastin ® generally stabilize or improve vision, function, but within two years of anti-VEGF treatment, approximately half of all treated eyes develop subretinal scarring (fibrosis), which is considered to be one of the reasons for unsuccessful recovery (Daniel E et al., Ophthalmology .2014;121(3):656-66). Many of the key players in subretinal fibrosis are likely to be growth factors and matricellular proteins involved in the fibrotic process (cell proliferation, migration, and ECM remodeling). Despite its complexity, the development of drugs that inhibit angiogenesis remains an area of considerable interest as our knowledge of the angiogenic process increases.
近年來,在新生血管(neovascularization)過程中的許多關鍵參與者已被確認,其中血管內皮生長因子(vascular endothelial growth factor,VEGF)家族扮演至為關鍵的角色。人類VEGF家族共有6個成員:VEGF-A、VEGF-B、VEGF-C、VEGF-D、VEGF-E、及胎盤生長因子(placental growth factor,PlGF)。除此之外,VEGF-A、VEGF-B及PlGF之多種同功體係透過選擇性RNA剪接來產生(Sullivan等人,MAbs,2002,2(2):165-75)。VEGF-A係參與血管新生之主要因子;其與VEGFR-1及VEGFR-2二者結合。藉由阻礙VEGF-A訊息傳遞來抑制血管新生的策略已建立成功的治療方式,該治療方式係用於治療特定的癌症以及視網膜新生血管與缺血性疾病。(Major等人,J Pharmacol Exp Ther.,1997,283(1):402-10;Willet等人,Nat.Med.2004,10:145-7;Papadopoulos等人,Angiogenesis,2012,15(2):171-85;Aiello等人,PNAS,1995,92:10457-61)。 In recent years, many key players in the process of neovascularization have been identified, among which the vascular endothelial growth factor (VEGF) family plays a critical role. There are six members of the human VEGF family: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor (PlGF). In addition, various isoforms of VEGF-A, VEGF-B and PlGF are produced through alternative RNA splicing (Sullivan et al., MAbs, 2002, 2(2): 165-75). VEGF-A is the main factor involved in angiogenesis; it binds to both VEGFR-1 and VEGFR-2. Strategies to inhibit angiogenesis by blocking VEGF-A signaling have established successful therapeutic modalities for the treatment of certain cancers as well as retinal neovascularization and ischemic diseases. (Major et al., J Pharmacol Exp Ther., 1997, 283(1): 402-10; Willet et al., Nat. Med. 2004, 10: 145-7; Papadopoulos et al., Angiogenesis, 2012, 15(2) :171-85; Aiello et al., PNAS, 1995, 92: 10457-61).
其他生長因子、細胞激素(cytokine)、化學激活素(chemokine)包括:血小板衍生生長因子(Platelet-Derived Growth Factor,PDGF)、轉變生長因子-β(Transforming Growth Factor-β,TGF-β)、表皮生長因子(Epidermal Growth Factor,EGF)、神經生長因子(Nerve Growth Factor,NGF)、缺氧誘導因子(Hypoxia-Induced Factor,HIF)、鹼性成纖維母細胞生長因子或成纖維母細胞生長因子(bFGF或FGF-2)、結締組織生長因子(Connective-Tissue Growth Factor,CTGF)、顆粒球巨噬細胞株刺激因子(Granulocyte-Macrophage Colony-Stimulating Factor,GM-CSF)、類胰島素生長因子(Insulin-Like Growth Factor,IGF)、肝細胞生長因子/分散因子(Hepatocyte Growth Factors/Scatter Factor,HGF/SF)、腫瘤壞死因子-α(Tumor Necrosis Factor alpha,TNF-α)、基質細胞衍生因子-1(Stromal cell-derived factor-1,SDF-1)、介白素-1(Interleukin 1,IL-1)、介白素-6(IL-6)、介白素-8(IL-8)、介白素-17(IL-17)、介白素-18(IL-18)、介白素-20(IL-20)、介白素-23(IL-23)、化學誘質(例如C-C基序配體(CCL28、CCL21)及C-X-C基序配體(CXCL1、CXCL5))、巨噬細胞遷移抑制因子(Macrophage migration Inhibitory Factor,MIF)、及免疫細胞表面蛋白(例如分化簇(Clusters of Differentiation,CD))。該等因子在血管新生相關之疾病中已被報告會過度表現,並扮演關鍵性的角色(Elshabrawy等人,Angiogenesis(2015)18:433-448;Somanath P R等人,Cell Biochem Biophys.2009;53(2):53-64,Eliceiri B P.,Circ Res.2001 Dec 7;89(12):1104-10)。靶向該等因子以減少其下游路徑的活化可降低血管新生相關之疾病。 Other growth factors, cytokines, and chemokines include: Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-β (TGF-β), epidermal growth factor Growth factor (Epidermal Growth Factor (EGF), nerve growth factor (NGF), hypoxia-induced factor (HIF), basic fibroblast growth factor or fibroblast growth factor (bFGF or FGF-2 ), Connective-Tissue Growth Factor (CTGF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Insulin-Like Growth Factor (IGF) ), Hepatocyte Growth Factors/Scatter Factor (HGF/SF), Tumor Necrosis Factor alpha (TNF-α), Stromal cell-derived factor-1 -1, SDF-1), interleukin 1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-17 ( IL-17), interleukin-18 (IL-18), interleukin-20 (IL-20), interleukin-23 (IL-23), chemical inducers (such as C-C motif ligand (CCL28) , CCL21) and C-X-C motif ligands (CXCL1, CXCL5)), macrophage migration inhibitory factor (MIF), and immune cell surface proteins (such as Clusters of Differentiation (CD)). These factors have been reported to be overexpressed and play critical roles in angiogenesis-related diseases (Elshabrawy et al., Angiogenesis (2015) 18: 433-448; Somanath P R et al., Cell Biochem Biophys. 2009; 53 (2):53-64, Eliceiri B P., Circ Res. 2001 Dec 7;89(12):1104-10). Targeting these factors to reduce activation of their downstream pathways may reduce angiogenesis-related diseases.
整合蛋白係細胞表面受體的一個家族,其亦被發現在內皮細胞表面過度表現,並被認為在血管新生期間會促進新形成之血管的生長及存活。整合蛋白係異二聚體型細胞表面受體,其與胞外基質蛋白交互作用,並對許多生物學的過程而言至關重要。在許多細胞型中整合蛋白的表現係參與在腫瘤發展,且其與生長因子受體交互溝通(crosstalk)的能力使其成為引人注目的治療標的(Staunton D E等人,Adv Immunol.2006;91:111-57;Avraamides,C.J.等人,Nat Rev Cancer 2008;8:604-617;Somanath P R等人,Cell Biochem Biophys.2009;53(2): 53-64)。特別的是整合蛋白αvβ3在腫瘤細胞及血管新生的內皮細胞二者中皆會調升(upregulate),且其對腫瘤細胞遷移、血管新生、及細胞訊息失調而言係重要的。因此,整合蛋白αvβ3之拮抗劑正被廣泛地研究其抑制血管新生及抗腫瘤的性質(Desgrosellier JS等人,Nat Rev Cancer.2010;10:9-22)。 Integrins are a family of cell surface receptors that are also found to be overexpressed on the surface of endothelial cells and are thought to promote the growth and survival of newly formed blood vessels during angiogenesis. Integrins are heterodimeric cell surface receptors that interact with extracellular matrix proteins and are critical for many biological processes. The expression of integrins in many cell types is involved in tumor development, and their ability to crosstalk with growth factor receptors makes them a compelling therapeutic target (Staunton D E et al., Adv Immunol. 2006; 91 : 111-57; Avraamides, C.J. et al., Nat Rev Cancer 2008; 8: 604-617; Somanath P R et al., Cell Biochem Biophys. 2009; 53(2): 53-64). In particular, integrin αvβ3 is upregulated in both tumor cells and angiogenic endothelial cells, and is important for tumor cell migration, angiogenesis, and cell signaling dysregulation. Therefore, antagonists of integrin αvβ3 are being extensively studied for their inhibitory angiogenesis and anti-tumor properties (Desgrosellier JS et al., Nat Rev Cancer. 2010; 10:9-22).
去整合蛋白(disintegrin)係於蝮蛇家族之蛇毒中發現的胜肽,且其主要抑制β1-及β3-相關之整合蛋白。一開始去整合蛋白被辨識為整合蛋白αIIbβ3之抑制劑,接著被發現可與其他整合蛋白以高親合力結合,並阻斷整合蛋白與含RGD之蛋白的交互作用。去整合蛋白含有47至84個胺基酸、具有約4-7條雙硫鍵、並帶有相同的RGD模體(motif)(McLane MA等人,Proc Soc Exp Biol Med 1998 219:109-119;Niewiarowski S等人,Semin Hematol 1994 31:289-300;Calvete JJ.,Curr Pharm Des.2005 11:829-835;Blobel CP等人,Curr Opin Cell Biol 1992 4:760-765)。去整合蛋白家族中的保守性RGD序列,在辨認整合蛋白中扮演最重要的角色。已發現去整合蛋白與24種整合蛋白中的8種交互作用,並抑制整合蛋白調節(integrin-mediated)之細胞增殖、黏附、遷移、及血管新生(McLane MA等人,Front Biosci.2008 13:6617-6637;Swenson S等人,Curr Pharm Des.2007 13:2860-2871)。動物研究顯示去整合蛋白靶向新生血管內皮及轉移型腫瘤,說明其用於癌症治療的潛力。含RGD之蛋白與整合蛋白的專一性結合,係其構型及RGD模體周圍的序列二者的功能。許多研究已顯示在含RGD蛋白之RGD模體二側的殘基,會影響其對整合蛋白的結合專一性及親合力(Scarborough RM等人,J Biol Chem 1993;268:1058-1065;Rahman S等人,Biochem J 1998;335:247-257)。 Disintegrin is a peptide found in the venom of the pit viper family, and it mainly inhibits β1- and β3-related integrins. Initially identified as an inhibitor of integrin αIIbβ3, disintegrin was subsequently found to bind with high affinity to other integrins and block the interaction of integrins with RGD-containing proteins. Disintegrin proteins contain 47 to 84 amino acids, have about 4-7 disulfide bonds, and carry the same RGD motif (McLane MA et al., Proc Soc Exp Biol Med 1998 219: 109-119 ; Niewiarowski S et al., Semin Hematol 1994 31: 289-300; Calvete JJ., Curr Pharm Des. 2005 11: 829-835; Blobel CP et al., Curr Opin Cell Biol 1992 4: 760-765). The conserved RGD sequence in the integrin family plays the most important role in identifying integrins. Disintegrin has been found to interact with 8 of 24 integrins and inhibit integrin-mediated cell proliferation, adhesion, migration, and angiogenesis (McLane MA et al., Front Biosci. 2008 13: 6617-6637; Swenson S et al. Curr Pharm Des. 2007 13: 2860-2871). Animal studies show that disintegrin targets neovascular endothelium and metastatic tumors, suggesting its potential for cancer treatment. The specific binding of RGD-containing proteins to integrins is a function of both their configuration and the sequences surrounding the RGD motif. Many studies have shown that the residues on both sides of the RGD motif of RGD-containing proteins affect its binding specificity and affinity for integrins (Scarborough RM et al., J Biol Chem 1993; 268: 1058-1065; Rahman S et al., Biochem J 1998;335:247-257).
血管新生係一複雜的生物學過程,牽涉多種生長因子及其訊息傳遞受體,且靶向在訊息傳遞路徑(signaling cascade)中的單一分子可能無法對疾病(例如癌症)中不受控之血管新生提供有效的臨床治療。因此,發展可協同結 合數種關鍵之血管新生因子,以有效抑制血管新生及疾病進程之創新療法的需求將不斷的增加。 Angiogenesis is a complex biological process involving multiple growth factors and their signaling receptors, and targeting a single molecule in the signaling cascade may not be able to target uncontrolled blood vessels in diseases such as cancer. Xinsheng provides effective clinical care. Therefore, development can be combined with The need for innovative therapies that combine several key angiogenic factors to effectively inhibit angiogenesis and disease progression will continue to increase.
本文係提供融合蛋白的醫藥配方、以及使用該等配方的方法。 This article provides pharmaceutical formulations of fusion proteins and methods of using such formulations.
於一通用態樣中,本申請係關於一種醫藥配方,該配方包含:a)一濃度為0.5毫克/毫升(mg/mL)至120mg/mL之融合蛋白;b)一濃度為1%至10%(重量/體積)之多元醇或醇類,該多元醇或醇類係選自由以下所組成之群組:蔗糖、海藻糖、甘露醇、山梨糖醇、苯甲醇、聚乙烯醇、及聚乙二醇(PEG)400-12000;c)一濃度為10毫莫耳(mM)至50mM之緩衝劑,該緩衝劑係選自由以下所組成之群組:磷酸鈉、組胺酸、檸檬酸鈉、醋酸鈉、碳酸氫鈉、及檸檬酸三鈉二水合物(trisodium citrate dihydrate);以及d)一濃度為0.01%至4%(重量/體積)之界面活性劑,其中,該配方的pH值為5.5至7.5,且該配方視需要地更包含一選自由以下所組成之群組的多醣:羧甲基纖維素鈉、微晶纖維素、或透明質酸鈉。 In a general form, the present application relates to a pharmaceutical formulation, which contains: a) a fusion protein at a concentration of 0.5 mg/mL to 120 mg/mL; b) a concentration of 1% to 10 % (weight/volume) of polyols or alcohols selected from the group consisting of: sucrose, trehalose, mannitol, sorbitol, benzyl alcohol, polyvinyl alcohol, and polyvinyl alcohol. Ethylene glycol (PEG) 400-12000; c) a buffer with a concentration of 10 millimol (mM) to 50mM, which buffer is selected from the group consisting of: sodium phosphate, histidine, citric acid Sodium, sodium acetate, sodium bicarbonate, and trisodium citrate dihydrate; and d) a surfactant with a concentration of 0.01% to 4% (weight/volume), wherein the pH of the formula The value is 5.5 to 7.5, and the formula optionally further includes a polysaccharide selected from the group consisting of sodium carboxymethyl cellulose, microcrystalline cellulose, or sodium hyaluronate.
根據本申請之實施態樣,該界面活性劑係選自由以下所組成之群組:聚山梨糖醇酯20、聚山梨糖醇酯80、及泊洛沙姆188,較佳為聚山梨糖醇酯20。 According to the embodiment of the present application, the surfactant is selected from the group consisting of: polysorbate 20, polysorbate 80, and poloxamer 188, preferably polysorbate Ester 20.
根據本申請之實施態樣,該界面活性劑的濃度為0.03%。 According to the embodiment of the present application, the concentration of the surfactant is 0.03%.
根據本申請之實施態樣,該融合蛋白的濃度為1mg/mL至90mg/mL,較佳為20mg/mL至80mg/mL,更佳地,該融合蛋白的濃度為40mg/mL。 According to the embodiment of the present application, the concentration of the fusion protein is 1 mg/mL to 90 mg/mL, preferably 20 mg/mL to 80 mg/mL, and more preferably, the concentration of the fusion protein is 40 mg/mL.
根據本申請之實施態樣,該多元醇係海藻糖且濃度為25mM至250mM,較佳為190mM。 According to an embodiment of the present application, the polyol is trehalose and the concentration is 25mM to 250mM, preferably 190mM.
根據本申請之實施態樣,該緩衝劑係組胺酸且濃度為10mM至40mM,較佳為20mM至30mM,更佳地,該組胺酸的濃度為25mM。 According to an embodiment of the present application, the buffer is histidine and the concentration is 10mM to 40mM, preferably 20mM to 30mM, and more preferably, the concentration of histidine is 25mM.
根據本申請之實施態樣,該融合蛋白係自N-端至C-端以如下順序包含:a)一血管內皮生長因子受體(VEGFR)的細胞外結構域;b)一人類免疫球蛋白G的Fc結構域;以及c)一結合整合蛋白之蛋白(integrin binding protein)或其片段。 According to an embodiment of the present application, the fusion protein includes in the following order from N-terminus to C-terminus: a) an extracellular domain of vascular endothelial growth factor receptor (VEGFR); b) a human immunoglobulin The Fc domain of G; and c) an integrin binding protein or a fragment thereof.
根據本申請之實施態樣,該融合蛋白係包含SEQ ID NO:15、SEQ ID NO:16、SEQ ID NO:17、或SEQ ID NO:18。 According to an embodiment of the present application, the fusion protein includes SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18.
根據本申請之實施態樣,該pH值為5.5至7.0,較佳地,該pH值為6.0。 According to the implementation aspect of the present application, the pH value is 5.5 to 7.0, preferably, the pH value is 6.0.
根據本申請之實施態樣,該配方在-70℃、-20℃、及/或5℃下安定性維持至少24個月。 According to the implementation aspect of the present application, the formula maintains stability at -70°C, -20°C, and/or 5°C for at least 24 months.
根據本申請之實施態樣,該配方在-70℃、-20℃、及/或2℃至8℃下(較佳在2℃至8℃下)至少9個月後係保持蛋白質的純度及活性(potency)。 According to the implementation aspect of the present application, the formula maintains the purity of the protein after at least 9 months at -70°C, -20°C, and/or 2°C to 8°C (preferably at 2°C to 8°C). Potency.
根據本申請之實施態樣,該配方更包含一濃度為10mM至50mM的鹽類。 According to an embodiment of the present application, the formula further includes a salt with a concentration of 10mM to 50mM.
根據本申請之實施態樣,該配方更包含至少一種胺基酸,該胺基酸的濃度為10mM至50mM。 According to an embodiment of the present application, the formula further includes at least one amino acid, and the concentration of the amino acid is 10mM to 50mM.
根據本申請之實施態樣,該鹽類係選自氯化鈉、氯化鎂、氯化鈣、或氯化鉀。 According to an embodiment of the present application, the salt is selected from sodium chloride, magnesium chloride, calcium chloride, or potassium chloride.
根據本申請之實施態樣,該胺基酸係選自由以下所組成之群組:精胺酸、甲硫胺酸、脯胺酸、組胺酸、半胱胺酸、離胺酸、甘胺酸、天門冬胺酸、色胺酸、麩胺酸、及異白胺酸。 According to an embodiment of the present application, the amino acid is selected from the group consisting of: arginine, methionine, proline, histidine, cysteine, lysine, and glyamine acid, aspartic acid, tryptophan, glutamic acid, and isoleucine.
根據本申請之實施態樣,該醫藥配方可用於一治療眼部疾病的方法。 According to the implementation aspect of the present application, the pharmaceutical formula can be used in a method of treating eye diseases.
根據本申請之實施態樣,該眼部疾病係選自新生血管(neovascularization)或缺血性眼色素層炎、視網膜血管炎、血管樣痕、色素性視網膜炎、角膜新生血管、虹膜新生血管、新生血管性青光眼、青光眼術後纖維化、增殖性玻璃體視網膜病變(proliferative vitreoretinopathy,PVR)、脈絡膜新生血管(choroidal neovascularization,CNV)、視神經盤新生血管、視網膜新生血管、玻璃體新生血管(vitreal neovascularization)、血管翳(pannus)、翼狀贅肉(pterygium)、血管性視網膜病變(vascular retinopathy)、無糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、有糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、糖尿病黃斑水腫(DME)、滲出性(濕性)及非滲出性(乾性)之老年性黃斑退化(AMD)、黃斑水腫、視網膜靜脈阻塞後黃斑水腫(RVO)、視網膜靜脈阻塞(RVO)、中心性視網膜靜脈阻塞(CRVO)、分支性視網膜靜脈阻塞(BRVO)、視網膜血管瘤狀增殖(RAP)、息肉狀脈絡膜血管病變(PCV)、玻璃體黃斑沾黏(VMA)、及/或玻璃體黃斑牽引症(VMT)。 According to an embodiment of the present application, the eye disease is selected from the group consisting of neovascularization or ischemic uveitis, retinal vasculitis, vascular scars, retinitis pigmentosa, corneal neovascularization, iris neovascularization, Neovascular glaucoma, postoperative glaucoma fibrosis, proliferative vitreoretinopathy (PVR), choroidal neovascularization (CNV), optic disc neovascularization, retinal neovascularization, vitreous neovascularization, Pannus, pterygium, vascular retinopathy, diabetic retinopathy (DR, non-proliferative and proliferative DR) without diabetic macular edema (DME), diabetic macular edema ( DME) diabetic retinopathy (DR, non-proliferative and proliferative DR), diabetic macular edema (DME), exudative (wet) and non-exudative (dry) age-related macular degeneration (AMD), macular edema, Postretinal vein occlusion macular edema (RVO), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branched retinal vein occlusion (BRVO), retinal angiomatous proliferation (RAP), polypoidal choroidal vasculopathy ( PCV), vitreomacular adhesion (VMA), and/or vitreomacular traction (VMT).
根據本申請之實施態樣,該配方係以每眼0.03至10毫克(mg)的劑量投予,較佳為每眼3.0至6.0mg,更佳地,該配方係以每眼4mg的劑量投予。 According to the implementation aspect of the present application, the formula is administered at a dose of 0.03 to 10 milligrams (mg) per eye, preferably 3.0 to 6.0 mg per eye, and more preferably, the formula is administered at a dose of 4 mg per eye. give.
根據本申請之實施態樣,該配方係以每眼4mg的劑量投予。 According to an aspect of the present application, the formulation is administered at a dose of 4 mg per eye.
本申請之另一通用態樣係關於一種醫藥配方,該配方包含:a)一濃度為40mg/mL之融合蛋白;b)25mM之組胺酸;c)190mM之海藻糖、蔗糖、或甘露醇;以及d)0.03%之聚山梨糖醇酯20或聚山梨糖醇酯80, 其中,該配方的pH值為6.0。 Another general aspect of the present application relates to a pharmaceutical formulation, which contains: a) a fusion protein at a concentration of 40 mg/mL; b) 25 mM histamine; c) 190 mM trehalose, sucrose, or mannitol ; and d) 0.03% polysorbate 20 or polysorbate 80, Among them, the pH value of this formula is 6.0.
本說明書足以使熟習此技術領域者能夠實行本發明。除了本文所示及描述外,由先前的描述,本發明之多種修飾對熟習此技術領域者而言係顯而易見的,並落入後附申請專利範圍內。本文所引用之所有出版品、專利、及專利申請案之全文併於此處以供參考。 This description is sufficient to enable those skilled in the art to practice the invention. In addition to what is shown and described herein, various modifications of the present invention will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The full texts of all publications, patents, and patent applications cited herein are hereby incorporated by reference.
例示性實施態樣之前述及其他目的、方面、特徵及優點,將因參照下列描述及配合附圖,而變得更顯而易見並更易於理解。 The aforementioned and other objects, aspects, features and advantages of the exemplary embodiments will become more apparent and easier to understand with reference to the following description and accompanying drawings.
圖1為自血管滲漏區域之基線的平均百分比變化圖表,其係對恆河猴(rhesus monkey)之雷射誘導的脈絡膜新生血管模型進行每眼0.6、1.0、及1.9mg之融合蛋白1的單次玻璃體內注射(intravitreal injection)。數據以平均值±標準誤差呈現。所有的劑量皆在第0天時以單次玻璃體內劑量投予。Lucentis®(0.5mg)係作為系統適用性(system suitability)及陽性對照。經分析的所有雷射斑點皆為第III/IV級(Grade III/IV)。%血管滲漏=(基線滲漏區域-治療滲漏區域)÷(基線滲漏區域)×100%;統計分析係透過Mann-Whitney U檢定而進行空白組(vehicle group)及治療組的比較,*為p<0.05,在1.9mg之組別中的a係表示已移除會影響統計顯著性(p=0.057)之來自一罹患數種眼部發炎之猴子的數據。n=每組4隻眼睛。 Figure 1 is a graph of the average percentage change from baseline in the area of vascular leakage in a laser-induced choroidal neovascularization model of rhesus monkeys treated with 0.6, 1.0, and 1.9 mg of fusion protein 1 per eye. Single intravitreal injection. Data are presented as mean ± standard error. All doses were administered as a single intravitreal dose on Day 0. Lucentis® (0.5mg) was used as system suitability and positive control. All analyzed laser spots were Grade III/IV. % vascular leakage = (baseline leakage area - treatment leakage area) ÷ (baseline leakage area) × 100%; statistical analysis was performed using the Mann-Whitney U test to compare the vehicle group and the treatment group. * is p<0.05, a in the 1.9mg group indicates that data from a monkey suffering from several types of ocular inflammation have been removed that would affect statistical significance (p=0.057). n = 4 eyes per group.
圖2為透過光同調斷層掃描(optical coherence tomography)確定之平均視網膜厚度的圖表,其係對恆河猴之雷射誘導的脈絡膜新生血管模型進行每眼0.6、1.0、及1.9mg之融合蛋白1的單次玻璃體內注射。數據以平均值±標準誤差呈現。所有的劑量皆在第0天時以單次玻璃體內劑量投予。Lucentis®(0.5mg)係作為系統適用性及陽性對照。經分析的所有雷射斑點皆為第III/IV級。%視網膜厚度=(基線視網膜厚度-治療視網膜厚度)÷(基線視網膜厚度-試 驗前視網膜厚度)×100%;統計分析係透過Mann-Whitney U檢定而進行空白組及治療組的比較,*為p<0.05,在1.9mg之組別中的a係表示已移除會影響統計顯著性(p=0.057)之來自一罹患數種眼部發炎之猴子的數據。n=每組4隻眼睛。 Figure 2 is a graph of mean retinal thickness determined by optical coherence tomography using 0.6, 1.0, and 1.9 mg of fusion protein 1 per eye in a laser-induced choroidal neovascularization model in rhesus monkeys. of a single intravitreal injection. Data are presented as mean ± standard error. All doses were administered as a single intravitreal dose on Day 0. Lucentis® (0.5mg) was used as system suitability and positive control. All laser spots analyzed were Class III/IV. % retinal thickness = (baseline retinal thickness - treatment retinal thickness) ÷ (baseline retinal thickness - pre-test retinal thickness) × 100%; statistical analysis was performed to compare the blank group and the treatment group through the Mann-Whitney U test, * is p <0.05, a in the 1.9mg group indicates that data from a monkey suffering from several types of ocular inflammation have been removed which would affect statistical significance (p=0.057). n = 4 eyes per group.
圖3為Masson三色染色法的圖表,其係對經所述處理之恆河猴雷射誘導脈絡膜新生血管模型的第III/IV級病灶進行染色。數據以平均值±標準誤差呈現。在第29天時進行摘出術(Enucleation)。所選擇之第4級病灶的雷射斑點係透過Masson三色染色法進行分析。使用學生t檢定分析來比較空白組與治療組,*為p<0.05,n=每組4隻眼睛。 Figure 3 is a diagram of Masson's trichrome staining method for staining grade III/IV lesions in the laser-induced choroidal neovascularization model of rhesus monkeys. Data are presented as mean ± standard error. Enucleation was performed on the 29th day. The laser spots of selected grade 4 lesions were analyzed by Masson's trichrome staining. Student's t-test analysis was used to compare blank to treatment groups, * is p<0.05, n=4 eyes per group.
圖4為博萊黴素(bleomycin)誘導之C57BL/6小鼠肺纖維化模型的肺羥脯胺酸水平圖表,其係如所述般地進行治療(每一治療組n=8隻動物且該sham對照組n=4)。$為p<0.05,治療組與sham對照組比較,未配對學生t檢定;*為p<0.05,治療組與空白組比較,單因子變異數分析(One-way ANOVA)及Dunnett檢定。在融合蛋白1的組別中,一隻動物的數據因為在第3天時不明原因的提早死亡而未採用。 Figure 4 is a graph of lung hydroxyproline levels in the bleomycin-induced C57BL/6 mouse model of pulmonary fibrosis, which were treated as described (n=8 animals per treatment group and The sham control group n=4). $ means p<0.05, comparison between the treatment group and the sham control group, unpaired Student's t test; * means p<0.05, comparison between the treatment group and the blank group, one-way ANOVA and Dunnett's test. In the fusion protein 1 group, data from one animal were not used due to unexplained premature death on day 3.
圖5A至圖5F為融合蛋白1分別在pH7.0之磷酸鹽緩衝液(圖5A)、pH6.5之磷酸鹽緩衝液(圖5B)、pH6.5之組胺酸緩衝液(圖5C)、pH6.0之組胺酸緩衝液(圖5D)、pH6.0之檸檬酸緩衝液(圖5E)、及pH5.5之檸檬酸緩衝液(圖5F)中之擴散係數的點圖。該擴散係數是透過動態光散射(DLS)確定。 Figures 5A to 5F show fusion protein 1 in phosphate buffer at pH 7.0 (Figure 5A), phosphate buffer at pH 6.5 (Figure 5B), and histidine buffer at pH 6.5 (Figure 5C), respectively. , pH 6.0 histidine buffer (Figure 5D), pH 6.0 citrate buffer (Figure 5E), and pH 5.5 citrate buffer (Figure 5F). The diffusion coefficient is determined by dynamic light scattering (DLS).
圖6A至圖6B為對40mg/mL及80mg/mL之融合蛋白1在二種波長下分析的濁度測量圖表。圖6A係描繪波長660奈米(nm)及圖6B係描繪波長320nm。NaPi=磷酸鈉,Cit=檸檬酸,及His=組胺酸。 Figures 6A to 6B are turbidity measurement charts of 40 mg/mL and 80 mg/mL fusion protein 1 analyzed at two wavelengths. Figure 6A depicts a wavelength of 660 nanometers (nm) and Figure 6B depicts a wavelength of 320 nm. NaPi = sodium phosphate, Cit = citric acid, and His = histamine.
圖7A至圖7E為融合蛋白1之以考馬斯藍(Coomassie Blue)染色膠體的非還原聚丙烯醯氨凝膠電泳(SDS-PAGE)。圖7A及圖7B包括在4℃或40℃下於檸檬酸緩衝液中溫育一段時間之40mg/mL及80mg/mL的融合蛋白1,起始 (泳道2及3)、第4天(泳道4及5)、第7天(泳道6及7)、以及第14天(泳道8及9)。圖7C及圖7D包括在4℃或40℃下於組胺酸緩衝液中溫育一段時間之40mg/mL及80mg/mL的融合蛋白1,起始(泳道2及3)、第4天(泳道4及5)、第7天(泳道6及7)、以及第14天(泳道8及9)。圖7E包括在第28天時在4℃或40℃下於組胺酸緩衝液或檸檬酸緩衝液中溫育一段時間之40mg/mL及80mg/mL的融合蛋白1。NaPi=磷酸鈉,Cit=檸檬酸,及His=組胺酸。每一個樣品孔槽中皆置入3微克(μg)的蛋白。 Figures 7A to 7E are non-reducing polyacrylamide gel electrophoresis (SDS-PAGE) of fusion protein 1 stained with Coomassie Blue. Figures 7A and 7B include 40 mg/mL and 80 mg/mL of fusion protein 1 incubated in citrate buffer for a period of time at 4°C or 40°C, starting with (lanes 2 and 3), day 4 (lanes 4 and 5), day 7 (lanes 6 and 7), and day 14 (lanes 8 and 9). Figures 7C and 7D include 40 mg/mL and 80 mg/mL of fusion protein 1 in histidine buffer incubated at 4°C or 40°C for a period of time initially (lanes 2 and 3), day 4 ( lanes 4 and 5), day 7 (lanes 6 and 7), and day 14 (lanes 8 and 9). Figure 7E includes 40 mg/mL and 80 mg/mL of Fusion Protein 1 on day 28 incubated for a period of time at 4°C or 40°C in histidine buffer or citrate buffer. NaPi = sodium phosphate, Cit = citric acid, and His = histamine. Place 3 micrograms (μg) of protein into each sample well.
圖8A至圖8E為融合蛋白1之以考馬斯藍染色膠體的還原聚丙烯醯氨凝膠電泳。圖8A及圖8B包括在4℃或40℃下於檸檬酸緩衝液中溫育一段時間之40mg/mL及80mg/mL的融合蛋白1,起始(泳道2及3)、第4天(泳道4及5)、第7天(泳道6及7)、以及第14天(泳道8及9)。圖8C及圖8D包括在4℃或40℃下於組胺酸緩衝液中溫育一段時間之40mg/mL及80mg/mL的融合蛋白1,起始(泳道2及3)、第4天(泳道4及5)、第7天(泳道6及7)、以及第14天(泳道8及9)。圖8E包括在第28天時在4℃或40℃下於組胺酸緩衝液或檸檬酸緩衝液中溫育一段時間之40mg/mL及80mg/mL的融合蛋白1。NaPi=磷酸鈉,Cit=檸檬酸,及His=組胺酸。每一個樣品孔槽中皆置入3μg的蛋白。 Figures 8A to 8E show reducing polyacrylamide gel electrophoresis of fusion protein 1 using Coomassie blue-stained colloid. Figures 8A and 8B include 40 mg/mL and 80 mg/mL of Fusion Protein 1 in citrate buffer incubated for a period of time at 4°C or 40°C, initially (lanes 2 and 3), day 4 (lane 4 and 5), day 7 (lanes 6 and 7), and day 14 (lanes 8 and 9). Figures 8C and 8D include 40 mg/mL and 80 mg/mL of Fusion Protein 1 in histidine buffer incubated for a period of time at 4°C or 40°C, initially (lanes 2 and 3), day 4 ( lanes 4 and 5), day 7 (lanes 6 and 7), and day 14 (lanes 8 and 9). Figure 8E includes 40 mg/mL and 80 mg/mL of Fusion Protein 1 on day 28 incubated for a period of time at 4°C or 40°C in histidine buffer or citrate buffer. NaPi = sodium phosphate, Cit = citric acid, and His = histamine. Place 3 μg of protein into each sample well.
圖9為1mg/mL之融合蛋白1的熱安定性圖表,其係調配於25mM之組胺酸緩衝液、190mM之海藻糖、0.03%之PS20(pH 6.0)中並透過差示掃描熱分析儀(Differential Scanning Calorimeter,DSC)測定。 Figure 9 is a thermal stability chart of 1mg/mL fusion protein 1, which was formulated in 25mM histidine buffer, 190mM trehalose, 0.03% PS20 (pH 6.0) and passed through a differential scanning thermal analyzer (Differential Scanning Calorimeter, DSC) measurement.
圖10為對荷蘭黑帶兔使用如所述濃度之融合蛋白1的單次劑量投予圖表,其係抑制人類VEGF-A165所誘導的視網膜血管滲透性。 Figure 10 is a graph of the inhibition of human VEGF-A 165 -induced retinal vascular permeability in Dutch black belt rabbits following single dose administration of Fusion Protein 1 at the concentrations indicated.
除非另外定義,此處所用之所有技術及科學術語係具有與本發明所屬技術領域中具通常知識者通常所了解之相同意義。 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
於本文中,除非內文另外明確指出,否則單數型式之「一」、「該」係包括複數型式。因此,舉例而言,涉及「一結合結構域」係包括複數的結合結構域及其為熟習此項技術領域者所知的同等物。 In this document, the singular forms "a", "the" and "the" include the plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "a binding domain" includes the plural binding domains and their equivalents known to those skilled in the art.
於本文中,可交換使用術語「多胜肽」及「蛋白質」來表示長鏈胜肽,其具有天然蛋白質的胺基酸序列、或有一或多個突變(例如,一或多個胺基酸殘基的刪除(deletion)、添加(addition)、及/或取代(substitution))的胺基酸序列。 As used herein, the terms "polypeptide" and "protein" are used interchangeably to refer to long-chain peptides that have the amino acid sequence of a native protein or one or more mutations (e.g., one or more amino acid Deletion, addition, and/or substitution of residues) in the amino acid sequence.
「融合蛋白」意指具有二或更多以共價連接之部分(portion)的蛋白,其中該各部分係衍生自不同的蛋白。 "Fusion protein" means a protein having two or more covalently linked portions, where the portions are derived from different proteins.
本發明提供一種醫藥配方,其係包含一融合蛋白,該融合蛋白包含結合整合蛋白的胜肽、其他結合蛋白的胜肽以靶向血管新生因子、及Fc結構域,其中該結合整合蛋白的胜肽係選自由以下所組成之群組:去整合蛋白(參見美國專利號7,943,728及PCT申請號PCT/US 15/46322對胺基酸序列之描述,該些文獻之全文併於此處以供參考)、抗整合蛋白αvβx抗體(參見美國專利號6,160,099及8,350,010對胺基酸序列之描述,該些文獻之全文併於此處以供參考)、抗整合蛋白α5β1抗體、靶向整合蛋白同功體αvβx或α5β1之纖維黏連蛋白(參見美國公開號2015/0218251對胺基酸序列之描述,該些文獻之全文併於此處以供參考)以及其結合整合蛋白的片段;其中x係1、3、5、6或8。 The present invention provides a pharmaceutical formula, which contains a fusion protein, the fusion protein includes a peptide that binds to integrin, other peptides that bind to proteins to target angiogenesis factors, and an Fc domain, wherein the peptide that binds to integrin The peptide is selected from the group consisting of: disintegrins (see U.S. Patent No. 7,943,728 and PCT Application No. PCT/US 15/46322 for descriptions of amino acid sequences, the entire contents of which are incorporated herein by reference) or Fibronectin of α5β1 (see US Publication No. 2015/0218251 for a description of the amino acid sequence, the full text of which is hereby incorporated by reference) and its integrin-binding fragments; where x is 1, 3, 5 , 6 or 8.
於本文中,術語「抗體」意指免疫球蛋白分子,其包含四條多胜肽鏈(二條重鏈及二條輕鏈,之間藉由雙硫鍵連結)。全長重鏈包括一個可變區結構域(variable region domain)VH以及三個恆定區結構域(constant region domain)CH1、CH2、及CH3。VH結構域係在多胜肽的胺基端,且CH3結構域係在羧基端。全長輕鏈包括一個可變區結構域VL、及一個恆定區結構域CL。抗原結合片段(antigen binding fragment,Fab)包含一條輕鏈、以及一條重鏈的CH1 及可變區。Fab分子之重鏈不能與另一重鏈分子形成雙硫鍵。Fab’片段含有一輕鏈及一重鏈,該重鏈含有更多在CH1及CH2結構域之間的恆定區,致使二條重鏈之間可以形成鏈間雙硫鍵以形成雙體(diabody)。一可變片段(variable fragment,Fv)區係包含重鏈及輕鏈二者的可變區,但缺少恆定區。單鏈片段(single-chain fragment,scFv)係Fv分子,其中該重鏈及輕鏈可變區已藉由撓性連接子(flexible linker)連結以形成單多胜肽鏈(single polypeptide chain),其形成抗原結合區(antigen-binding region)。WO 88/01649、美國專利號4,946,778以及5,260,203中詳細討論單鏈抗體。於本文中,術語「抗體」係包括具有二條全長L-鏈及二條全長H-鏈的免疫球蛋白分子、及其片段(例如,抗原結合片段(Fab)、Fv區、scFv等)。 As used herein, the term "antibody" refers to an immunoglobulin molecule that contains four polypeptide chains (two heavy chains and two light chains linked by disulfide bonds). The full-length heavy chain includes one variable region domain (VH) and three constant region domains (CH1, CH2, and CH3). The VH domain is located at the amino terminus of the polypeptide, and the CH3 domain is located at the carboxyl terminus. The full-length light chain includes a variable region domain VL, and a constant region domain CL. Antigen binding fragment (Fab) contains a light chain and a heavy chain CH1 and variable area. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. The Fab' fragment contains a light chain and a heavy chain. The heavy chain contains more constant regions between the CH1 and CH2 domains, so that an interchain disulfide bond can be formed between the two heavy chains to form a diabody. A variable fragment (Fv) region contains the variable regions of both heavy and light chains, but lacks the constant region. A single-chain fragment (scFv) is an Fv molecule in which the heavy chain and light chain variable regions have been linked by a flexible linker to form a single polypeptide chain. It forms the antigen-binding region. Single chain antibodies are discussed in detail in WO 88/01649, US Patent Nos. 4,946,778 and 5,260,203. As used herein, the term "antibody" includes immunoglobulin molecules having two full-length L-chains and two full-length H-chains, and fragments thereof (eg, antigen-binding fragments (Fab), Fv regions, scFv, etc.).
術語「Fc結構域」意指單體或多聚體型式的分子或序列,其包含非抗原結合部分(non-antigen binding portion)的序列。Fc之原始免疫球蛋白來源較佳係源自人類,並可來自任意同功體,例如,IgG、IgA、IgM、IgE、或IgD。全長Fc由以下Ig重鏈區組成:介於CH1及CH2、CH2及CH3間的撓性鉸鏈區(flexible hinge region),其中該二鏈一般係藉由雙硫鍵於撓性鉸鏈區連結。 The term "Fc domain" means a molecule or sequence in monomeric or multimeric form that contains a non-antigen binding portion of the sequence. The source of the original immunoglobulin for Fc is preferably of human origin and can be from any isoform, for example, IgG, IgA, IgM, IgE, or IgD. The full-length Fc consists of the following Ig heavy chain regions: a flexible hinge region between CH1 and CH2, CH2 and CH3, in which the two chains are generally connected by a disulfide bond in the flexible hinge region.
本發明提供融合蛋白,其係包含結合整合蛋白的胜肽、及其他結合蛋白的胜肽,其中該結合整合蛋白的胜肽包括去整合蛋白及其結合整合蛋白的片段;該其他結合蛋白的胜肽係包含VEGF受體之胞外結構域及Fc結構域;其中該結合整合蛋白的胜肽包含至少一在RGD模體上或相鄰處的突變。根據本發明之實施態樣,去整合蛋白及其結合整合蛋白的片段具有選自由以下所組成之群組的胺基酸序列:SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3、SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6及SEQ ID NO:7,或一與SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3、SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6或SEQ ID NO:7具有至少85%序列同一性之胺基酸序列。 The present invention provides a fusion protein, which includes a peptide that binds to integrin and a peptide that binds to other proteins, wherein the peptide that binds to integrin includes a disintegrin and a fragment that binds to integrin; the peptide of the other binding protein The peptide system includes the extracellular domain and the Fc domain of the VEGF receptor; wherein the integrin-binding peptide includes at least one mutation on or adjacent to the RGD motif. According to an embodiment of the present invention, the disintegrin and its integrin-binding fragment have an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 , SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7, or together with SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4. The amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7 having at least 85% sequence identity.
於本文中,「去整合蛋白」意指一類富含半胱胺酸的蛋白質或多胜肽,其係整合蛋白之有效的可溶性配體。RGD模體係三胜肽(tri-peptide)精胺酸-甘胺酸-天冬胺酸(Arg-Gly-Asp),其在大部分的單體去整合蛋白中係保守的,且位於整合蛋白結合環(integrin-binding loop)上。本文所述之去整合蛋白係分離自蛇毒、或衍生自野生型,並具有至少一在RGD模體上或相鄰處的突變,以選擇性地結合至或靶向多種整合蛋白同功體。於本文中,術語「RGD模體相鄰處」意謂在給定之胜肽、多胜肽、蛋白質序列中之任意突變係出現在任意自RGD模體算來第15-20個胺基酸內的胺基酸殘基。 As used herein, "disintegrin" refers to a class of cysteine-rich proteins or polypeptides that are effective soluble ligands for integrins. The RGD template system tri-peptide arginine-glycine-aspartate (Arg-Gly-Asp) is conserved in most monomeric disintegrins and is located in integrins. On the integrin-binding loop. The disintegrins described herein are isolated from snake venom, or derived from wild type, and have at least one mutation on or adjacent to the RGD motif to selectively bind to or target multiple integrin isoforms. As used herein, the term "RGD motif adjacent" means that any mutation in a given peptide, polypeptide, or protein sequence occurs within any 15-20th amino acid sequence from the RGD motif. of amino acid residues.
在此亦考慮了去整合蛋白之其他胺基酸序列變異體。舉例而言,去整合蛋白的結合親合力及/或其他生物性質可藉由改變編碼該蛋白之胺基酸序列來改善。去整合蛋白突變體可藉由將適當的修飾引入編碼該蛋白的核酸序列中、或藉由胜肽合成引入修飾來製備。該等修飾包括突變,例如將該去整合蛋白之核酸或胺基酸序列進行刪除、插入、及/或取代。去整合蛋白的最終胺基酸構建體(construct)可藉由進行刪除、插入及取代之任意組合來達成,只要該最終構建體具有所需之特徵,例如結合至整合蛋白超家族成員及/或抑制整合蛋白活化之路徑。 Other amino acid sequence variants of disintegrin proteins are also considered here. For example, the binding affinity and/or other biological properties of a disintegrated protein can be improved by altering the amino acid sequence encoding the protein. Disintegrin mutants can be prepared by introducing appropriate modifications into the nucleic acid sequence encoding the protein, or by introducing modifications by peptide synthesis. Such modifications include mutations, such as deletion, insertion, and/or substitution of the nucleic acid or amino acid sequence of the disintegrating protein. The final amino acid construct that removes integrins can be achieved by making any combination of deletions, insertions, and substitutions, as long as the final construct has the desired characteristics, such as binding to integrin superfamily members and/or Inhibits the pathway of integrin activation.
對該蛋白質或多胜肽之生物性質的實質修飾係藉由選擇對維持以下各項有顯著不同效果的取代來實現:(a)取代區域之多胜肽骨架的構造,舉例而言,作為摺疊或螺旋構型、(b)分子在標靶位點的電荷或疏水性、或(c)支鏈之主體。 Substantial modification of the biological properties of the protein or polypeptide is achieved by selecting substitutions that have significantly different effects on maintaining: (a) the structure of the polypeptide backbone of the substituted region, for example, as a fold or the helical configuration, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the host of the branches.
一種用於辨別融合蛋白之某些殘基或區之較佳突變作用位置的方法係稱為「丙胺酸掃描突變(alanine scanning mutagenesis)」,如Science,1989,244:1081-1085中所描述。舉例而言,將一殘基或一群標靶殘基辨別出來(例如,帶電荷之殘基,諸如,Arg、Asp、His、Lys、及Glu),並以中性(最佳係甘胺 酸、丙胺酸或白胺酸)或相反帶電荷的胺基酸(從正電荷到負電荷,反之亦然)取代,以影響胺基酸與標靶結合伴侶之交互作用。接著,對取代呈現功能敏感性的該些胺基酸所在位置,藉由於該取代位點引入另一或其他變異體來改進。因此,雖然用於引入胺基酸序列變異的位點係預先決定的,但突變本身的性質不需要預先決定。舉例而言,為分析在給定位點之突變的性能,可在標靶密碼子或區實行隨機突變,並對表現出的融合多胜肽變異體進行所需活性篩選。舉例而言,可在融合蛋白或蛋白組分中添加半胱胺酸鍵以改善其安定性。 One method used to identify preferred locations for mutations in certain residues or regions of a fusion protein is called "alanine scanning mutagenesis", as described in Science, 1989, 244: 1081-1085. For example, a residue or a group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and characterized as neutral (preferably glyamine acid, alanine, or leucine) or oppositely charged amino acids (from positive charge to negative charge or vice versa) to affect the interaction of the amino acid with the target binding partner. Next, the positions of those amino acids that exhibit functional sensitivity to substitution are improved by introducing another or other variants at that substitution site. Thus, while the site used to introduce amino acid sequence variation is predetermined, the nature of the mutation itself need not be predetermined. For example, to analyze the performance of mutations at a given site, random mutations can be performed at target codons or regions, and fusion polypeptide variants that exhibit the desired activity can be screened. For example, cysteine bonds can be added to the fusion protein or protein components to improve its stability.
因此,本文提供之去整合蛋白突變體,可為本文所揭露之任意融合蛋白的組分。在一些實施態樣中,該去整合蛋白係包含與選自由以下所組成之群組的去整合蛋白胺基酸序列具有至少85%、至少90%、至少95%、或至少99%之序列同一性的胺基酸序列:馬來亞蝮素(Rhodostomin)(SEQ ID NO:1)、黃綠竹葉青素(Triflavin)(SEQ ID NO:3)、鉅鱗蝰素(Echistatin)(SEQ ID NO:4)、台灣龜殼花素(Trimucrin)(SEQ ID NO:5)、麗紋龜殼花蛇素(Elegantin)(SEQ ID NO:6)及赤尾鮐素(Trigramin)(SEQ ID NO:7)。在一些實施態樣中,去整合蛋白係包含一胺基酸序列,該胺基酸序列具有至少一在馬來亞蝮素(SEQ ID NO:1)、黃綠竹葉青素(SEQ ID NO:3)、鉅鱗蝰素(SEQ ID NO:4)、台灣龜殼花素(SEQ ID NO:5)、麗紋龜殼花蛇素(SEQ ID NO:6)或赤尾鮐素(SEQ ID NO:7)之RGD模體上或相鄰處的突變。在一些實施態樣中,去整合蛋白係包含與去整合蛋白突變體之胺基酸序列(SEQ ID NO:2)具有至少85%、至少90%、至少95%、或至少99%之序列同一性的胺基酸序列。在SEQ ID NO:2中的Xaa指出多個位置,該些位置可藉由插入、取代或刪除來進行修飾,以生產與野生型去整合蛋白不同的胺基酸序列變異體。根據一些實施例,位於SEQ ID NO:2位置50之Xaa,其對應到野生型馬來亞蝮素(SEQ ID NO:1)之RGD模體中的甘胺酸(Gly),可用甘胺酸之外的天然產生胺基酸取代,以產生 馬來亞蝮素變異體。在其他實施例中,SEQ ID NO:2中之一或多個Xaa亦可用原來在野生型馬來亞蝮素(SEQ ID NO:1)之對應位置上找到的胺基酸之外的天然產生胺基酸取代,以產生多種馬來亞蝮素變異體。還需說明的是,去整合蛋白變異體並不限於只包括SEQ ID NO:2中任意Xaa之單一突變,本發明之範圍亦包含在SEQ ID NO:2中Xaa的數個位置或在其他具一致序列的去整合蛋白(例如,SEQ ID NOs:3-7)中的對應位置產生多突變。 Therefore, the deintegrin mutants provided herein can be components of any fusion protein disclosed herein. In some embodiments, the disintegrin comprises at least 85%, at least 90%, at least 95%, or at least 99% sequence identity with a disintegrin amino acid sequence selected from the group consisting of: The specific amino acid sequence: Rhodostomin (SEQ ID NO: 1), Triflavin (SEQ ID NO: 3), Echistatin (SEQ ID NO: 4), Trimucrin (SEQ ID NO: 5), Elegantin (SEQ ID NO: 6) and Trigramin (SEQ ID NO: 7) . In some embodiments, the disintegrin protein system includes an amino acid sequence, the amino acid sequence has at least one amino acid sequence found in malayanin (SEQ ID NO: 1), yellow-green phyllocyanin (SEQ ID NO: 3). ), giganthophyllin (SEQ ID NO: 4), leucophyllin (SEQ ID NO: 5), leucophyllin (SEQ ID NO: 6) or erythrozoicin (SEQ ID NO: 7) Mutation on or adjacent to the RGD motif. In some embodiments, the disintegrin protein comprises at least 85%, at least 90%, at least 95%, or at least 99% sequence identity with the amino acid sequence of the disintegrin mutant (SEQ ID NO: 2). sexual amino acid sequence. Xaa in SEQ ID NO: 2 indicates multiple positions that can be modified by insertion, substitution, or deletion to produce amino acid sequence variants that are different from the wild-type disintegrin. According to some embodiments, Xaa located at position 50 of SEQ ID NO: 2, which corresponds to glycine (Gly) in the RGD motif of wild-type malasin (SEQ ID NO: 1), can be used with glycine Substitution of naturally occurring amino acids other than those to produce Malayan parasitin variant. In other embodiments, one or more Xaa's in SEQ ID NO: 2 may also be made using naturally occurring amino acids other than the amino acids originally found at the corresponding positions of wild-type malasin (SEQ ID NO: 1). Amino acid substitutions were made to produce multiple malayanin variants. It should also be noted that the deintegrin variant is not limited to include only a single mutation of any Xaa in SEQ ID NO: 2. The scope of the present invention also includes several positions of Xaa in SEQ ID NO: 2 or other specific mutations. Multiple mutations occur at corresponding positions in the consensus sequence of the disintegrin (eg, SEQ ID NOs: 3-7).
馬來亞蝮素變異體已被描述於美國專利號7,943,728及PCT申請號PCT/US15/46322,且其序列係併於此處以供參考。舉例言之,PCT/US15/46322係描述該去整合蛋白變異體包含一突變RGD環(具有選自由SEQ ID NO:24至SEQ ID NO:26所組成之群組的胺基酸序列)、以及至少一種突變連接子(具有選自由SEQ ID NO:29至SEQ ID NO:41所組成之群組的胺基酸序列)、以及一突變C末端(具有選自由SEQ ID NO:42至SEQ ID NO:47所組成之群組的胺基酸序列)。更佳地,該去整合蛋白變異體包含如本文中所描述之該突變RGD環、該突變連接子及該突變C末端。 Malayan pyrin variants have been described in U.S. Patent No. 7,943,728 and PCT Application No. PCT/US15/46322, and their sequences are incorporated herein by reference. For example, PCT/US15/46322 describes that the disintegrin variant includes a mutant RGD loop (having an amino acid sequence selected from the group consisting of SEQ ID NO: 24 to SEQ ID NO: 26), and At least one mutated linker (having an amino acid sequence selected from the group consisting of SEQ ID NO: 29 to SEQ ID NO: 41), and a mutated C-terminus (having an amino acid sequence selected from the group consisting of SEQ ID NO: 42 to SEQ ID NO : Amino acid sequence of the group consisting of 47). More preferably, the disintegrin variant comprises the mutated RGD loop, the mutated linker and the mutated C-terminus as described herein.
具有一或多個除了RGD模體外(例如在連接子區域或C末端)之修飾的馬來亞蝮素變異體或去整合蛋白變異體展現結合至αvβ3、αvβ5、αvβ6、α5β1或αIIbβ3的能力與選擇性。舉例言之,具有連接子區域突變(39X40X41X42X43X)之馬來亞蝮素變異體,其中該SRAGK(SEQ ID NO:50)係透過置換胺基酸KKKRT(SEQ ID NO:51)、KKART(SEQ ID NO:52)、MKKGT(SEQ ID NO:53)、IEEGT(SEQ ID NO:54)、LKEGT(SEQ ID NO:55)、AKKRT(SEQ ID NO:56)、KAKRT(SEQ ID NO:57)、KKART(SEQ ID NO:58)、KKKAT(SEQ ID NO:59)、KKKRA(SEQ ID NO:60)、KAKRA(SEQ ID NO:61)、或SKAGT(SEQ ID NO:62),且其對於整合蛋白的最大效果依序如下:αvβ3(約14倍)>α5β1(約5倍)>αIIbβ3(約2倍)。 Malayanin variants or disintegrin variants with one or more modifications other than the RGD motif (e.g., in the linker region or the C-terminus) exhibit the ability to bind to αvβ3, αvβ5, αvβ6, α5β1, or αIIbβ3 and Selectivity. For example, a malayanin variant with a linker region mutation (39X40X41X42X43X), in which the SRAGK (SEQ ID NO: 50) is replaced by the amino acids KKKRT (SEQ ID NO: 51), KKART (SEQ ID NO: 51), NO: 52), MKKGT (SEQ ID NO: 53), IEEGT (SEQ ID NO: 54), LKEGT (SEQ ID NO: 55), AKKRT (SEQ ID NO: 56), KAKRT (SEQ ID NO: 57), KKART (SEQ ID NO: 58), KKKAT (SEQ ID NO: 59), KKKRA (SEQ ID NO: 60), KAKRA (SEQ ID NO: 61), or SKAGT (SEQ ID NO: 62), and for integration The maximum effects of proteins are as follows: αvβ3 (approximately 14 times) > α5β1 (approximately 5 times) > αIIbβ3 (approximately 2 times).
具有C末端區域突變(66X67X68X69X70X)之馬來亞蝮素變異體,其中該RYH係透過置換胺基酸RYH(SEQ ID NO:63)、RNGL(SEQ ID NO:64)、RGLYG(SEQ ID NO:65)、RGLY(SEQ ID NO:66)、RDLYG(SEQ ID NO:67)、RDLY(SEQ ID NO:68)、RNGLYG(SEQ ID NO:69)、或RNPWNG(SEQ ID NO:70),且其對於整合蛋白的最大效果依序如下:αIIbβ3(約13倍)>αvβ5(約8倍)=αvβ6(約8倍)>αvβ3(約4倍)>α5β1(約2倍)。表1係顯示SEQ ID NOs:24至49的序列,以及其在SEQ ID NO:1上的對應位置。 A malayanin variant with a C-terminal region mutation (66X67X68X69X70X), in which the RYH is obtained by replacing the amino acids RYH (SEQ ID NO: 63), RNGL (SEQ ID NO: 64), and RGLYG (SEQ ID NO: 65), RGLY (SEQ ID NO: 66), RDLYG (SEQ ID NO: 67), RDLY (SEQ ID NO: 68), RNGLYG (SEQ ID NO: 69), or RNPWNG (SEQ ID NO: 70), and Its maximum effect on integrins is as follows: αIIbβ3 (approximately 13 times) > αvβ5 (approximately 8 times) = αvβ6 (approximately 8 times) > αvβ3 (approximately 4 times) > α5β1 (approximately 2 times). Table 1 shows the sequences of SEQ ID NOs: 24 to 49, and their corresponding positions on SEQ ID NO: 1.
雖然去整合蛋白之變異體大多參考上述胺基酸序列來討論,編碼蛇毒蛋白之多胜肽序列或核苷酸序列、及其具有至少一RGD模體上或相鄰處之突變的變異體亦可被包含在本發明之範圍中,其中該蛇毒蛋白係例如白唇竹葉青蛇素(Albolabrin)、百步蛇素(Applagin)、墨西哥西海岸響尾蛇素(Basilicin)、矛頭蝮素(Batroxostatin)、鼓腹巨蛇素(Bitistatin)、西部亞種響尾蛇素(Cereberin)、角響尾蛇素(Cerastin)、西部菱背響尾蛇素(Crotatroxin)、南美響尾蛇素(Duressin)、黃綠龜殼花蛇素(Flavoridin)、黃綠龜殼花蛇毒解離素(Flavostatin)、日本蝮蛇素(Halysin)、西伯利亞蝮蛇毒解離素(Halystatin)、巴西蝮素(Jararacin)、巴西蝮蛇毒解離素(Jarastatin)、馬來亞紅口蝮素(Kistrin)、亞馬遜巨蝮素(Lachesin)、西部亞種響尾蛇素(Lutosin)、黑尾響尾蛇素(Molossin)、韓國亞種短尾蝮素(Salmosin)、白眉蝮素(Saxatilin)、北美侏儒響尾蛇素(Tergeminin)、黃綠龜殼花蛇毒解離素(Trimestatin)、台灣龜殼花去整合蛋白(Trimutase)、烏蘇里蝮素(Ussuristatin)、及草原響尾蛇素(Viridin)。 Although variants of disintegrin proteins are mostly discussed with reference to the above amino acid sequences, polypeptide sequences or nucleotide sequences encoding snake venom proteins, and variants having at least one mutation on or adjacent to the RGD motif are also discussed. Can be included in the scope of the present invention, wherein the snake venom protein is, for example, Albolabrin, Applagin, Basilicin, Batroxostatin, Batroxostatin, Bitistatin, Cereberin, Cerastin, Crotatroxin, Duressin, Flavoridin, Yellow Flavostatin, Japanese Halysin, Siberian Halystatin, Jararacin, Brazilian Jarastatin, Malayan Red Mouth Viper Kistrin, Lachesin, Western subspecies Lutosin, Molossin, Korean subspecies Salmosin, Saxatilin, North American pygmy Tergeminin, Trimestatin, Trimutase, Ussuristatin, and Viridin.
不受理論所限制,本文在此考慮了去整合蛋白藉由結合至整合蛋白超家族成員,以阻斷其與多價整合蛋白受體交互作用,來抑制整合蛋白活化之路徑。在一些方面,去整合蛋白結合至整合蛋白超家族成員,包括但不限於整合蛋白同功體:αvβ1、αvβ3、αvβ5、αvβ6、αvβ8、α5β1、及/或αvIIbβ3。 Without being bound by theory, this article considers the pathway by which disintegrins inhibit integrin activation by binding to integrin superfamily members to block their interaction with multivalent integrin receptors. In some aspects, disintegrins bind to integrin superfamily members, including, but not limited to, integrin isoforms: αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1, and/or αvIIbβ3.
根據本發明,融合蛋白之其他結合蛋白的胜肽可為受體蛋白,該受體蛋白結合至選自由以下所組成之群組的標靶:腫瘤抗原、腫瘤壞死因子(TNF)受體超家族成員、刺蝟因子(Hedgehog)家族成員、受體酪胺酸激酶、蛋白多醣相關之分子、腫瘤生長因子-β(TGF-β)超家族成員、Wnt相關之分子及血管新生標靶。 According to the present invention, the peptide of the other binding protein of the fusion protein can be a receptor protein that binds to a target selected from the group consisting of: tumor antigens, tumor necrosis factor (TNF) receptor superfamily Members, Hedgehog family members, receptor tyrosine kinases, proteoglycan-related molecules, tumor growth factor-β (TGF-β) superfamily members, Wnt-related molecules and angiogenesis targets.
根據本發明之一些實施態樣,其他結合蛋白的胜肽可專一性地結合至血管新生標靶,其包括但不限於血管生成素(ANG)、酪胺酸蛋白激酶(Eph)、 成纖維母細胞生長因子(FGF)、神經纖毛蛋白(NRP)、血纖維蛋白溶酶原活化物、血小板衍生生長因子(PDGF)、轉變生長因子-β(TGF-β)、血管內皮生長因子(VEGF)、血管內皮鈣黏蛋白(VE-cadherin)、腫瘤壞死因子-α(TNF-α)、類胰島素生長因子(IGF-1)及前述的受體。因此,根據本發明實施態樣,其他結合蛋白的胜肽可包括受體蛋白之胞外部分,其結合至並拮抗該血管新生標靶。在其他實施態樣中,其他結合蛋白的胜肽可結合至血管新生因子受體之胞外部分。 According to some embodiments of the present invention, other protein-binding peptides can specifically bind to angiogenesis targets, including but not limited to angiopoietin (ANG), tyrosine protein kinase (Eph), Fibroblast growth factor (FGF), neuropilin (NRP), plasminogen activator, platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor ( VEGF), vascular endothelial cadherin (VE-cadherin), tumor necrosis factor-α (TNF-α), insulin-like growth factor (IGF-1) and the aforementioned receptors. Therefore, according to embodiments of the present invention, other protein-binding peptides may include extracellular portions of receptor proteins that bind to and antagonize the angiogenesis target. In other embodiments, other binding protein peptides can bind to the extracellular portion of the angiogenic factor receptor.
在一些實施態樣中,其他結合蛋白的胜肽可係結合至VEGF配體的抗VEGF抗體(參見WO2015/200905對胺基酸序列之描述,該文獻之全文併於此處以供參考)、或結合至VEGF受體的抗VEGFR1或抗VEGFR2抗體(參見美國專利號5,874,542對胺基酸序列之描述,該文獻之全文併於此處以供參考)。在其他實施態樣中,其他結合蛋白的胜肽亦可係結合至PDGF配體的抗PDGF抗體(參見美國專利號5,094,941對胺基酸序列之描述,該文獻之全文併於此處以供參考)、或結合至PDGF受體的抗PDGFRβ抗體(參見美國專利號9,265,827對胺基酸序列之描述,該文獻之全文併於此處以供參考)。 In some embodiments, the other protein-binding peptide may be an anti-VEGF antibody that binds to a VEGF ligand (see WO2015/200905 for a description of the amino acid sequence, the entirety of which is incorporated herein by reference), or Anti-VEGFR1 or anti-VEGFR2 antibodies that bind to the VEGF receptor (see US Pat. No. 5,874,542 for a description of the amino acid sequence, the entirety of which is incorporated herein by reference). In other embodiments, other protein-binding peptides may also be anti-PDGF antibodies that bind to PDGF ligands (see U.S. Pat. No. 5,094,941 for a description of the amino acid sequence, the entirety of which is incorporated herein by reference) , or an anti-PDGFRβ antibody that binds to the PDGF receptor (see U.S. Pat. No. 9,265,827 for a description of the amino acid sequence, the entirety of which is incorporated herein by reference).
在某些實施態樣中,其他結合蛋白的胜肽作為以下VEGF受體(VEGFR)之任意一者結合至相同的VEGF:VEGFR1、VEGFR2、及VEGFR3。在一些實施態樣中,其他結合蛋白的胜肽係包含VEGFR之至少一胞外部分,該VEGFR係本文所述之任意VEGFR。舉例而言,其他結合蛋白的胜肽係包含VEGFR1之至少一胞外部分、或VEGFR2之至少一胞外部分。在另一實施例中,其他結合蛋白的胜肽係包含VEGFR1之一胞外部分,例如類免疫球蛋白結構域2(D2)、及VEGFR2之一胞外部分,例如類免疫球蛋白結構域3(D3)。在一些方面,其他結合蛋白的胜肽係包含VEGFR1之一胞外部分(其包含SEQ ID NO:8之胺基酸序列)、及VEGFR2之一胞外部分(其包含SEQ ID NO:9之胺基酸序 列)。在一些方面,其他結合蛋白的胜肽係包含VEGFR1及VEGFR2之胞外部分的融合體,其包含SEQ ID NO:10之胺基酸序列、或與SEQ ID NO:10具有至少85%序列同一性之胺基酸序列。 In certain embodiments, peptides of other binding proteins bind to the same VEGF as any of the following VEGF receptors (VEGFR): VEGFR1, VEGFR2, and VEGFR3. In some embodiments, the peptide of the other binding protein includes at least an extracellular portion of a VEGFR, which is any VEGFR described herein. For example, peptides of other binding proteins include at least one extracellular portion of VEGFR1, or at least one extracellular portion of VEGFR2. In another embodiment, the peptides of other binding proteins include an extracellular portion of VEGFR1, such as immunoglobulin-like domain 2 (D2), and an extracellular portion of VEGFR2, such as immunoglobulin-like domain 3. (D3). In some aspects, the peptides of other binding proteins include an extracellular portion of VEGFR1 that includes the amino acid sequence of SEQ ID NO: 8, and an extracellular portion of VEGFR2 that includes the amine of SEQ ID NO: 9 acid sequence List). In some aspects, the peptides of other binding proteins comprise a fusion of the extracellular portions of VEGFR1 and VEGFR2, which comprise the amino acid sequence of SEQ ID NO: 10, or have at least 85% sequence identity with SEQ ID NO: 10 The amino acid sequence.
在其他實施態樣中,其他結合蛋白的胜肽作為以下PDGF受體(PDGFR)之任一者結合至相同的PDGF:PDGFR-α、及PDGFR-β。在一些實施態樣中,其他結合蛋白的胜肽係包含PDGFR之至少一胞外部分,該PDGFR係本文所述之任意PDGFR。舉例而言,其他結合蛋白的胜肽係包含PDGFR-α之至少一胞外部分、或PDGFR-β之至少一胞外部分。在另一實施例中,其他結合蛋白的胜肽係包含PDGFR-β之一胞外部分,例如類免疫球蛋白結構域1至3。在一些態樣,其他結合蛋白的胜肽係包含PDGFR之胞外部分,其包含SEQ ID NO:11之胺基酸序列、或與SEQ ID NO:11具有至少85%序列同一性之胺基酸序列。 In other embodiments, peptides of other binding proteins bind to the same PDGF as any of the following PDGF receptors (PDGFR): PDGFR-alpha, and PDGFR-beta. In some embodiments, the peptide of the other binding protein includes at least an extracellular portion of a PDGFR, which is any PDGFR described herein. For example, other binding protein peptides include at least one extracellular portion of PDGFR-α, or at least one extracellular portion of PDGFR-β. In another embodiment, other binding protein peptides comprise an extracellular portion of PDGFR-β, such as immunoglobulin-like domains 1 to 3. In some aspects, the peptide of the other binding protein includes an extracellular portion of PDGFR that includes the amino acid sequence of SEQ ID NO: 11, or an amino acid with at least 85% sequence identity to SEQ ID NO: 11 sequence.
根據其他實施態樣,本發明亦提供融合蛋白,其係包含結合整合蛋白之胜肽、人類或人源化恆定亞區、及其他結合蛋白的胜肽,其中該結合整合蛋白之胜肽係包括在RGD模體上或相鄰處具有至少一突變之SEQ ID NO:1的胺基酸序列、與SEQ ID NO:1具有至少85%序列同一性之胺基酸序列、或SEQ ID NO:2之胺基酸序列;該人類或人源化恆定亞區係包含免疫球蛋白CH2結構域及免疫球蛋白CH3結構域;該其他結合蛋白的胜肽具有VEGFR1之類免疫球蛋白D2及VEGFR2之類免疫球蛋白D3。在融合蛋白的另一實施態樣中,結合整合蛋白的胜肽具有與SEQ ID NO:2至少85%之序列同一性。 According to other embodiments, the present invention also provides a fusion protein that includes an integrin-binding peptide, a human or humanized constant subregion, and other protein-binding peptides, wherein the integrin-binding peptide includes The amino acid sequence of SEQ ID NO: 1 having at least one mutation on or adjacent to the RGD motif, an amino acid sequence having at least 85% sequence identity with SEQ ID NO: 1, or SEQ ID NO: 2 The amino acid sequence; the human or humanized constant subregion includes an immunoglobulin CH2 domain and an immunoglobulin CH3 domain; the peptides of the other binding proteins have immunoglobulin D2 and VEGFR2 such as VEGFR1 Immunoglobulin D3. In another embodiment of the fusion protein, the integrin-binding peptide has at least 85% sequence identity with SEQ ID NO: 2.
就多胜肽或核酸序列而言,術語「序列同一性百分比(%)」係定義為:在比對序列並在需要時引入間隙(gap)以達到最大序列同一性百分比之後,在保守性置換(conservative substitution)不被視為序列同一性的一部分之情況下,候選序列中與參照的多胜肽或核酸序列中相同的胺基酸殘基或核苷酸的百分比。為了測定胺基酸或核酸序列同一性百分比所進行的比對,可用多種本 技術領域中之方式達成,例如,使用公開之電腦軟體程式,舉例而言,如該等描述於Current Protocols in Molecular Biology(Ausubel等人,eds.,1987)中的電腦軟體程式,以及包括BLAST、BLAST-2、ALIGN、或Megalign(DNASTAR)軟體。熟習此項技術領域者可選定用於測量比對之適當參數,包括對欲比較序列之全長達到最大化比對所需的演算法。就本文之目的而言,給定胺基酸序列A對比給定胺基酸序列B之胺基酸序列同一性百分比,係如下計算:100乘以分數X/Y,其中X係藉由序列比對程式在程式比對A及B時,評分為相同的胺基酸殘基的數目,且其中Y係B中胺基酸殘基的總數。應了解,當胺基酸序列A之長度與胺基酸序列B之長度不相等時,A對B的胺基酸序列同一性百分比不會與B對A的胺基酸序列同一性百分比相等。 With respect to polypeptide or nucleic acid sequences, the term "percent sequence identity (%)" is defined as: conservative substitutions after aligning the sequences and introducing gaps where necessary to achieve the maximum percent sequence identity. (conservative substitution) The percentage of amino acid residues or nucleotides in a candidate sequence that are identical to the reference polypeptide or nucleic acid sequence without being considered part of the sequence identity. For the purpose of determining percent amino acid or nucleic acid sequence identity, a variety of Methods in the technical field can be achieved, for example, by using publicly available computer software programs, such as those described in Current Protocols in Molecular Biology (Ausubel et al., eds., 1987), and including BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. One skilled in the art can select appropriate parameters for measuring alignment, including algorithms required to maximize alignment over the full length of the sequences to be compared. For the purposes of this article, the percent amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B is calculated as follows: 100 multiplied by the fraction X/Y, where When the program compares A and B, the score is the number of identical amino acid residues, and Y is the total number of amino acid residues in B. It should be understood that when the length of amino acid sequence A is not equal to the length of amino acid sequence B, the percent amino acid sequence identity of A to B will not be equal to the percent amino acid sequence identity of B to A.
本發明提供二聚體融合蛋白,其係包含二融合蛋白,其中各融合蛋白包含本文所揭露的任意融合蛋白。在一實施態樣中,二聚體融合蛋白係包含二個完全相同的融合蛋白。在另一實施態樣中,二聚體融合蛋白可包含二個不同的融合蛋白。本文所揭露之融合蛋白可透過多聚化結構域形成二或更多個完全相同之融合蛋白多聚體或異種(heterologous)融合蛋白,該結構域包括人類或人源化抗體之恆定亞區。在一些實施態樣中,人類或人源化抗體之恆定亞區係選自由以下所組成之群組:IgG Fc區、IgA Fc區、IgM Fc區、IgD Fc區、及IgE Fc區。在另一實施態樣中,人類或人源化抗體之恆定亞區係選自由以下所組成之群組:IgG1 Fc區、IgG2 Fc區、IgG3 Fc區、及IgG4 Fc區。在一些態樣,亞區包含IgG1、IgG2、IgG3、或IgG4之CH2區及CH3區。編碼包含Fc區之免疫球蛋白的胺基酸序列,係為本技術領域所熟知。 The present invention provides dimeric fusion proteins, which comprise two fusion proteins, wherein each fusion protein comprises any fusion protein disclosed herein. In one embodiment, the dimeric fusion protein contains two identical fusion proteins. In another embodiment, a dimeric fusion protein may comprise two different fusion proteins. The fusion proteins disclosed herein can form two or more identical fusion protein multimers or heterologous fusion proteins through a multimerization domain that includes the constant subregion of a human or humanized antibody. In some embodiments, the constant subregion of a human or humanized antibody is selected from the group consisting of: IgG Fc region, IgA Fc region, IgM Fc region, IgD Fc region, and IgE Fc region. In another embodiment, the constant subregion of the human or humanized antibody is selected from the group consisting of: IgG1 Fc region, IgG2 Fc region, IgG3 Fc region, and IgG4 Fc region. In some aspects, the subregions include the CH2 and CH3 regions of IgGl, IgG2, IgG3, or IgG4. Amino acid sequences encoding immunoglobulins containing Fc regions are well known in the art.
融合蛋白的組分可互相直接連結,或透過連接子連結。一般而言,術語「連接子」意為一或多個分子(例如,核酸、胺基酸、或非胜肽部分(non-peptide moiety)),其可插入於一或多個組分結構域之間。舉例而言,連接子可 用於在組分之間提供所需之受關注位點,以便於操作。連接子亦可提供來使宿主細胞提升融合蛋白表現量、減少立體阻礙(steric hindrance)致使該組分可取得其最適的三級結構、及/或適當地與其標靶分子交互作用。連接子序列可包括一或多個天然連結至受體組分的胺基酸、或可係添加來用於提升融合蛋白表現量之序列,以提供特別所需之受關注位點、以使組分結構域形成最適的三級結構、及/或以提升組分與其標靶分子的交互作用。 The components of the fusion protein can be linked to each other directly or through a linker. Generally speaking, the term "linker" means one or more molecules (e.g., nucleic acids, amino acids, or non-peptide moieties) that can be inserted into one or more component domains. between. For example, a linker can Used to provide desired sites of interest between components for ease of manipulation. Linkers can also be provided to enable the host cell to increase the expression of the fusion protein, reduce steric hindrance so that the component can obtain its optimal tertiary structure, and/or interact appropriately with its target molecule. The linker sequence may include one or more amino acids that are naturally linked to the receptor component, or may be a sequence added to enhance the expression of the fusion protein to provide specifically desired sites of interest to allow the assembly of The sub-domains form the optimal tertiary structure and/or enhance the interaction between the components and their target molecules.
較佳的情況為連接子增加融合蛋白組分之撓性,而不干擾在該融合蛋白中之各功能性組分的結構。在一些實施態樣中,連接子部分係長度為2至100個胺基酸之胜肽連接子。例示性連接子包括具有至少二個胺基酸殘基之線性胜肽,例如:Gly-Gly、Gly-Ala-Gly、Gly-Pro-Ala、Gly(G)n、及Gly-Ser(GS)連接子。本文所述之GS連接子包括但不限於(GS)n、(GSGSG)n、(G2S)n、G2S2G、(G2SG)n、(G3S)n、(G4S)n、(GGSGG)nGn、及GSG4SG4SG,其中n係1或1以上。(G)n連接子的一個例子包括G9連接子。適合的線性胜肽包括聚甘胺酸(polyglycine)、聚絲胺酸(polyserine)、聚脯胺酸(polyproline)、聚丙胺酸(polyanaline)、及由丙胺醯基(alanyl)及/或絲胺醯基(serinyl)及/或脯胺醯基(prolinyl)及/或甘胺醯基(glycyl)之胺基酸殘基所組成的寡胜肽(oligopepetide)。連接子部分可用來連接本文所揭露之融合蛋白的任意組分。在一些實施態樣中,連接子係用在受體蛋白之胞外部分、及免疫球蛋白之恆定亞區之間。在其他實施態樣中,連接子係用在去整合蛋白或其變異體、及免疫球蛋白之恆定亞區之間。在某些實施態樣中,融合蛋白包含一位在受體蛋白之胞外部分、及去整合蛋白或其變異體之間的連接子;及一位在去整合蛋白或其變異體、及免疫球蛋白之恆定亞區之間的連接子。如本發明所體現,融合蛋白可包含至少一條但不多於四條之連接子。 Preferably, the linker increases the flexibility of the fusion protein components without disturbing the structure of the functional components in the fusion protein. In some embodiments, the linker portion is a peptide linker ranging from 2 to 100 amino acids in length. Exemplary linkers include linear peptides with at least two amino acid residues, such as: Gly-Gly, Gly-Ala-Gly, Gly-Pro-Ala, Gly(G)n, and Gly-Ser(GS) connector. GS linkers described herein include, but are not limited to, (GS)n, (GSGSG)n, (G 2 S)n, G 2 S 2 G, (G 2 SG)n, (G 3 S)n, (G 4 S)n, (GGSGG)nGn, and GSG 4 SG 4 SG, where n is 1 or more. An example of a (G)n linker includes the G9 linker. Suitable linear peptides include polyglycine, polyserine, polyproline, polyanaline, and those composed of alanyl and/or serine Oligopepetide composed of amino acid residues of serinyl and/or prolinyl and/or glycyl groups. The linker moiety can be used to connect any of the components of the fusion proteins disclosed herein. In some embodiments, a linker is used between the extracellular portion of the receptor protein and the constant subregion of the immunoglobulin. In other embodiments, a linker is used between a disintegrin, or a variant thereof, and a constant subregion of an immunoglobulin. In some embodiments, the fusion protein includes a linker between the extracellular portion of the receptor protein and the disintegrin or a variant thereof; and a linker between the disintegrin or a variant thereof, and the immune The linker between the constant subregions of globulin. As embodied in the present invention, the fusion protein may comprise at least one but no more than four linkers.
本文所述之融合蛋白可包含或不包含使融合蛋白自宿主細胞分泌出來的訊息胜肽。編碼該訊息胜肽的核酸序列,能夠可操作地連接至編碼感興趣之蛋白的核酸序列。在一些實施態樣中,該融合蛋白包含訊息胜肽。在一些實施態樣中,融合蛋白並不包含訊息胜肽。 The fusion proteins described herein may or may not contain a messaging peptide that causes the fusion protein to be secreted from the host cell. The nucleic acid sequence encoding the message peptide can be operably linked to the nucleic acid sequence encoding the protein of interest. In some embodiments, the fusion protein includes a message peptide. In some embodiments, the fusion protein does not include a message peptide.
此外,本發明所述之融合蛋白可包含結合蛋白的胜肽之經修飾型態。舉例而言,融合蛋白組分可具有轉譯後修飾,包括例如對任意結合蛋白的胜肽進行醣化、唾液酸化、乙醯化、及磷酸化。 In addition, the fusion proteins of the present invention may comprise modified versions of peptides that bind the protein. For example, the fusion protein components may have post-translational modifications including, for example, glycation, sialylation, acetylation, and phosphorylation of any peptides that bind the protein.
雖然,實施態樣已大致描述包含於融合蛋白中的二條結合蛋白的胜肽,本發明亦包含併入二條以上結合蛋白的胜肽之融合蛋白,以在抑制血管新生過程之方面提供任何加成的或協同的效果。舉例而言,可有一額外的結合蛋白的胜肽,其結合至其他血管新生標靶、或作為血管新生因子拮抗劑而連接至現存之二條結合蛋白的胜肽。 Although the embodiments have been generally described as containing peptides of two binding proteins in a fusion protein, the present invention also encompasses fusion proteins incorporating peptides of more than two binding proteins to provide any additive in inhibiting the angiogenesis process. or synergistic effect. For example, there can be an additional protein-binding peptide that binds to another angiogenesis target, or a peptide that acts as an angiogenesis factor antagonist and is linked to two existing protein-binding peptides.
用於本文中所揭露之醫藥配方的融合蛋白可使用一般所知的方法來純化及辨識,例如在免疫親合或離子交換管柱上進行分餾;乙醇沉澱法;反相高壓液相層析(HPLC);在矽膠上或陽離子交換樹脂(例如,DEAE)上進行色層分析法;色層交集法(chromatofocusing);SDS-PAGE;硫酸銨沉澱法;膠體過濾法(例如,葡萄糖凝膠G-75(Sephadex G-75));疏水親合力樹脂,使用固化在基質上之適合之結合伴侶的配體親合力、離心、酵素免疫檢定法(Enzyme-Linked Immunosorbent Assay,ELISA)、BIACore、西方墨點法、胺基酸及核酸定序、及生物活性。在一些實施態樣中,融合蛋白係在宿主細胞內表現,並使用一種或多種標準純化技術之組合自其中純化,該等技術包括但不限於蛋白A親合力層析、蛋白G親合力層析、緩衝液置換、粒徑排阻層析、超過濾、及透析。因此,回收之融合蛋白實質上是純的。在另一實施態樣中,回收之融合蛋白係以下之任一者:純度至少為90%、95%、96%、97%、98%、或99%。 Fusion proteins used in the pharmaceutical formulations disclosed herein can be purified and identified using commonly known methods, such as fractionation on immunoaffinity or ion exchange columns; ethanol precipitation; reversed-phase high-pressure liquid chromatography ( HPLC); chromatography on silica or cation exchange resin (e.g., DEAE); chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; colloid filtration (e.g., glucose gel G- 75 (Sephadex G-75)); hydrophobic affinity resin, using ligand affinity of a suitable binding partner solidified on the matrix, centrifugation, enzyme immunoassay (Enzyme-Linked Immunosorbent Assay, ELISA), BIACore, Western Ink Spot method, amino acid and nucleic acid sequencing, and biological activity. In some embodiments, the fusion protein is expressed within a host cell and purified therefrom using one or a combination of standard purification techniques, including, but not limited to, Protein A affinity chromatography, Protein G affinity chromatography. , buffer exchange, particle size exclusion chromatography, ultrafiltration, and dialysis. Therefore, the recovered fusion protein is essentially pure. In another embodiment, the recovered fusion protein is any of the following: at least 90%, 95%, 96%, 97%, 98%, or 99% pure.
本文所揭露之融合蛋白或融合蛋白之組分,可對生物活性做定性或評估,該等生物活性包括但不限於對目標結合伴侶之親合力、競爭性結合、抑制性活性、細胞增生之抑制、腫瘤生長之抑制、及血管新生之抑制。在一些實施態樣中,本文所揭露之融合蛋白或融合蛋白之組分可在體外及體內進行生物活性評估。許多用於評估結合親合力之方法係為本技術領域所知,並透過滴定法可用於辨識融合蛋白或融合蛋白之組分對結合伴侶之結合親合力。結合動力學可以表示為穩態平衡結合常數,以解離常數(dissociation constant,KD)值或最大有效濃度之一半(half maximal effective concentration,EC50)表示。 The fusion proteins or components of the fusion proteins disclosed herein can be used to characterize or evaluate biological activities. Such biological activities include but are not limited to affinity for target binding partners, competitive binding, inhibitory activity, and inhibition of cell proliferation. , inhibition of tumor growth, and inhibition of angiogenesis. In some embodiments, the fusion proteins or components of the fusion proteins disclosed herein can be evaluated for biological activity in vitro and in vivo. Many methods for assessing binding affinity are known in the art and can be used to identify the binding affinity of a fusion protein or components of a fusion protein for a binding partner through titration methods. Binding kinetics can be expressed as a steady-state equilibrium binding constant, expressed as a dissociation constant (K D ) value or half maximal effective concentration (EC 50 ).
在本文之某些實施態樣中,融合蛋白對活性之抑制(例如,對血管新生因子活性及/或整合蛋白活性之抑制)具有小於或等於1微莫耳(μM)、100奈米莫耳(nM)、10nM、1nM、0.1nM、0.01nM、或0.001nM的EC50。在本文之任意實施態樣中,融合蛋白對結合伴侶(血管新生因子及/或整合蛋白)具有小於1.0mM、500μM、100μM、50μM、10μM、5μM、1μM、500nM、100nM、50nM、10nM、5nM、1nM、500皮莫耳(pM)、100pM、50pM、10pM、或5pM的KD值,包括該些數字之間的任意值。 In certain embodiments herein, the fusion protein inhibits activity (e.g., inhibits angiogenic factor activity and/or integrin activity) with an activity of less than or equal to 1 micromolar (μM), 100 nmol (nM), 10 nM, 1 nM, 0.1 nM, 0.01 nM, or 0.001 nM EC50. In any embodiment herein, the fusion protein has a binding partner (angiogenic factor and/or integrin) of less than 1.0mM, 500μM, 100μM, 50μM, 10μM, 5μM, 1μM, 500nM, 100nM, 50nM, 10nM, 5nM K D values of , 1 nM, 500 picomoles (pM), 100 pM, 50 pM, 10 pM, or 5 pM, including any value between these numbers.
在某些實施態樣中,該融合蛋白的等電點(pI)為4.0至9.0。在某些實施態樣中,該融合蛋白的等電點(pI)為4.0、4.1、4.2、4.3、4.4、4.5、4.6、4.7、4.7、4.8、4.9、5.0、5.1、5.2、5.2、5.3、5.4、5.5、5.6、5.7、5.8、5.9、6.0、6.1、6.2、6.3、6.4、6.5、6.6、6.7、6.8、6.9、7.0、7.1、7.2、7.3、7.4、7.5、7.6、7.7、7.8、7.9、8.0、8.1、8.2、9.3、8.4、8.5、8.6、8.7、8.8、8.9、9.0、或該些數字之間的任意值。較佳地,該融合蛋白的等電點(pI)為8.17。 In certain embodiments, the fusion protein has an isoelectric point (pI) of 4.0 to 9.0. In certain embodiments, the fusion protein has an isoelectric point (pI) of 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.2, 5.3 ,5.4,5.5,5.6,5.7,5.8,5.9,6.0,6.1,6.2,6.3,6.4,6.5,6.6,6.7,6.8,6.9,7.0,7.1,7.2,7.3,7.4,7.5,7.6,7.7,7.8 , 7.9, 8.0, 8.1, 8.2, 9.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, or any value in between. Preferably, the isoelectric point (pI) of the fusion protein is 8.17.
本發明亦提供一醫藥組合物,其係包含融合蛋白,該融合蛋白係包含結合整合蛋白的胜肽、其他結合蛋白的胜肽以靶向血管新生因子、及Fc結構域,其中該結合整合蛋白的胜肽係選自由以下所組成之群組:去整合蛋白、抗整 合蛋白αvβx抗體、抗整合蛋白α5β1抗體、靶向整合蛋白αvβx或α5β1之纖維黏連蛋白、及其結合整合蛋白的片段,其中x係1、3、5、6或8。本發明組合物包含治療有效劑量之融合蛋白。 The present invention also provides a pharmaceutical composition, which includes a fusion protein that includes an integrin-binding peptide, other protein-binding peptides to target angiogenesis factors, and an Fc domain, wherein the integrin-binding peptide The peptides are selected from the group consisting of: disintegrin, anti-integrin Integrin αvβx antibodies, anti-integrin α5β1 antibodies, fibronectin targeting integrin αvβx or α5β1, and fragments thereof that bind to integrin, wherein x is 1, 3, 5, 6 or 8. The compositions of the invention comprise a therapeutically effective dose of the fusion protein.
術語「治療有效劑量」意謂具治療活性之化合物引起所需之生物或臨床效果所需要之量。根據本發明之實施態樣,「治療有效劑量」係可達到有利影響或所需結果(包括臨床結果)之足夠的量。治療有效劑量可以一次或多次給藥中投予。依照疾病狀態,治療有效劑量係足夠改善、穩定、或延緩疾病發展的量。根據本發明之特定實施態樣,治療有效劑量係治療或預防不正常血管新生之病症(例如其表徵為新生血管、血管滲透性、水腫、發炎、視網膜病變、纖維化或癌症之疾病)所需之融合蛋白量。 The term "therapeutically effective dose" means the amount of a therapeutically active compound required to produce the desired biological or clinical effect. According to aspects of the present invention, a "therapeutically effective dose" is an amount sufficient to achieve a beneficial effect or desired result, including clinical results. The therapeutically effective dose may be administered in one or more administrations. Depending on the disease state, a therapeutically effective dose is an amount sufficient to ameliorate, stabilize, or delay the progression of the disease. According to certain embodiments of the invention, a therapeutically effective dose is required to treat or prevent disorders of abnormal angiogenesis, such as disorders characterized by neovascularization, vascular permeability, edema, inflammation, retinopathy, fibrosis, or cancer. The amount of fusion protein.
術語「活性(potency)」係指該融合蛋白在臨床投予劑量下產生預期之功能的能力。 The term "potency" refers to the ability of the fusion protein to produce the expected function at clinically administered doses.
本文中之術語「醫藥配方」係指包括醫藥上可接受之載劑的配方,該醫藥上可接受之載體係例如用以於治療/醫療用途中將VEGF受體融合蛋白(例如aflibercept或conbercept)投予至一個體。 The term "pharmaceutical formulation" as used herein refers to a formulation including a pharmaceutically acceptable carrier, such as a VEGF receptor fusion protein (such as aflibercept or conbercept) for therapeutic/medical use. Invested in an individual.
本文中之術語「純度(purity)」係指該融合蛋白不存在汙染物。本文中所指汙染物包括除了所預期之融合蛋白分子以外的蛋白質種類,其係產生自化合物製造過程中的雜質及/或所製造之蛋白質化合物的降解。 The term "purity" as used herein refers to the absence of contaminants in the fusion protein. Contaminants as referred to herein include proteinaceous species other than the intended fusion protein molecule that result from impurities in the manufacturing process of the compound and/or degradation of the protein compound being manufactured.
在一些實施態樣中,包含融合蛋白之醫藥組合物係包含在緩衝液中調配的融合蛋白,其蛋白質濃度自0.5至100mg/mL,較佳為40至80mg/mL,例如40、50、60、70或80mg/mL,最佳為40±4mg/mL。在其他較佳實施態樣中,融合蛋白係以高於40mg/mL之蛋白濃度在緩衝液中調配。 In some embodiments, the pharmaceutical composition containing the fusion protein contains the fusion protein formulated in a buffer, and the protein concentration is from 0.5 to 100 mg/mL, preferably from 40 to 80 mg/mL, such as 40, 50, 60 , 70 or 80mg/mL, the best is 40±4mg/mL. In other preferred embodiments, the fusion protein is formulated in a buffer at a protein concentration higher than 40 mg/mL.
在特定的實施態樣中,緩衝液係pH值為5.5至7.0、更佳為6.0至6.5、甚至更佳為6.0的緩衝液。在特定的實施態樣中,該緩衝液為pH值為6.5至8、 更佳為7至7.5、甚至更佳為7.2的磷酸鹽緩衝液。該磷酸鹽緩衝液係包含5至20mM之磷酸鈉,例如5、10、15、或20mM之磷酸鈉,更佳為10mM之磷酸鈉;20至60mM之氯化鈉,更佳為40mM之氯化鈉;1至10%重量/體積(w/v)之蔗糖,更佳為5%重量/體積之蔗糖;以及0.01至0.05%重量/體積之界面活性劑,更佳為0.03%重量/體積之聚山梨醇酯20。 In a specific embodiment, the buffer solution has a pH value of 5.5 to 7.0, more preferably 6.0 to 6.5, even more preferably 6.0. In a specific implementation, the buffer has a pH value of 6.5 to 8, More preferably, it is a phosphate buffer solution of 7 to 7.5, even more preferably 7.2. The phosphate buffer contains 5 to 20mM sodium phosphate, such as 5, 10, 15, or 20mM sodium phosphate, more preferably 10mM sodium phosphate; 20 to 60mM sodium chloride, more preferably 40mM chloride Sodium; 1 to 10% w/v sucrose, preferably 5% w/v sucrose; and 0.01 to 0.05% w/v surfactant, preferably 0.03% w/v Polysorbate 20.
在特定的實施態樣中,該醫藥配方係包含一選自由以下所組成之群組的多元醇或醇類:蔗糖、海藻糖、甘露醇、山梨糖醇、苯甲醇、聚乙烯醇、及聚乙二醇(PEG)400-12000,且其濃度為1%至10%(重量/體積),例如1%、2%、3%、4%、5%、6%、7%、8%、9%、或10%(重量/體積)。 In a specific embodiment, the pharmaceutical formulation includes a polyol or alcohol selected from the group consisting of: sucrose, trehalose, mannitol, sorbitol, benzyl alcohol, polyvinyl alcohol, and polyvinyl alcohol. Ethylene glycol (PEG) 400-12000, and its concentration is 1% to 10% (weight/volume), such as 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (weight/volume).
在較佳的實施態樣中,該多元醇係濃度為25mM至250mM的海藻糖,例如25mM、50mM、75mM、100mM、125mM、150mM、175mM、200mM、225mM、或250mM。在其他較佳的實施態樣中,該多元醇係濃度為100至200mM的海藻糖,例如100mM、110mM、120mM、130mM、140mM、150mM、160mM、170mM、180mM、190mM、或200mM。在其他較佳的實施態樣中,該多元醇係濃度為190mM的海藻糖。 In a preferred embodiment, the polyol is trehalose with a concentration of 25mM to 250mM, such as 25mM, 50mM, 75mM, 100mM, 125mM, 150mM, 175mM, 200mM, 225mM, or 250mM. In other preferred embodiments, the polyol is trehalose with a concentration of 100 to 200mM, such as 100mM, 110mM, 120mM, 130mM, 140mM, 150mM, 160mM, 170mM, 180mM, 190mM, or 200mM. In other preferred embodiments, the polyol is trehalose with a concentration of 190 mM.
在特定的實施態樣中,該醫藥配方係包含一緩衝劑。在特定的實施態樣中,該緩衝劑係選自由以下所組成之群組:磷酸鈉、組胺酸、檸檬酸鈉、醋酸鈉、碳酸氫鈉、及檸檬酸三鈉二水合物(trisodium citrate dihydrate),且其濃度為10mM至50mM,例如10mM、20mM、30mM、40mM、或50mM。在較佳的實施態樣中,該緩衝劑的濃度為10mM至40mM,例如10mM、20mM、30mM、或40mM。在其他較佳的實施態樣中,該緩衝劑的濃度為20mM至30mM,例如20mM、21mM、22mM、23mM、24mM、25mM、26mM、27mM、28mM、29mM、或30mM。在其他較佳的實施態樣中,該緩衝劑的濃度為25mM。 In certain embodiments, the pharmaceutical formulation includes a buffer. In a specific embodiment, the buffering agent is selected from the group consisting of sodium phosphate, histidine, sodium citrate, sodium acetate, sodium bicarbonate, and trisodium citrate dihydrate. dihydrate), and its concentration is 10mM to 50mM, such as 10mM, 20mM, 30mM, 40mM, or 50mM. In a preferred embodiment, the concentration of the buffer is 10mM to 40mM, such as 10mM, 20mM, 30mM, or 40mM. In other preferred embodiments, the concentration of the buffer is 20mM to 30mM, such as 20mM, 21mM, 22mM, 23mM, 24mM, 25mM, 26mM, 27mM, 28mM, 29mM, or 30mM. In other preferred embodiments, the concentration of the buffer is 25mM.
在特定的實施態樣中,該醫藥配方更包含一選自由以下所組成之群組的多醣:羧甲基纖維素鈉、微晶纖維素、或透明質酸鈉。 In a specific embodiment, the pharmaceutical formula further includes a polysaccharide selected from the group consisting of sodium carboxymethyl cellulose, microcrystalline cellulose, or sodium hyaluronate.
在較佳的實施態樣中,該緩衝劑係濃度為10mM至40mM的組胺酸,例如10mM、20mM、30mM、或40mM。在其他較佳的實施態樣中,該組胺酸的濃度為20mM至30mM,例如20mM、21mM、22mM、23mM、24mM、25mM、26mM、27mM、28mM、29mM、或30mM。在其他較佳的實施態樣中,該組胺酸的濃度為25mM。 In a preferred embodiment, the buffer is histidine with a concentration of 10mM to 40mM, such as 10mM, 20mM, 30mM, or 40mM. In other preferred embodiments, the concentration of histidine is 20mM to 30mM, such as 20mM, 21mM, 22mM, 23mM, 24mM, 25mM, 26mM, 27mM, 28mM, 29mM, or 30mM. In other preferred embodiments, the concentration of histidine is 25mM.
在特定的實施態樣中,該醫藥配方係包含一界面活性劑。在較佳的實施態樣中,該界面活性劑的濃度為0.01至4%(重量/體積),例如0.01%、0.5%、1.0%、1.5%、2.0%、2.5%、3.0%、3.5%、或4.0%。在其他較佳的實施態樣中,該界面活性劑的濃度為0.01%至1.0%(重量/體積),例如0.01%、0.02%、0.03%、0.04%、0.05%、0.06%、0.07%、0.08%、0.09%、或1.0%(重量/體積)。在其他較佳的實施態樣中,該界面活性劑的濃度為0.03%(重量/體積)。 In certain embodiments, the pharmaceutical formulation includes a surfactant. In a preferred embodiment, the concentration of the surfactant is 0.01 to 4% (weight/volume), such as 0.01%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5% , or 4.0%. In other preferred embodiments, the concentration of the surfactant is 0.01% to 1.0% (weight/volume), such as 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 1.0% (weight/volume). In other preferred embodiments, the concentration of the surfactant is 0.03% (weight/volume).
在較佳的實施態樣中,該界面活性劑係選自由以下所組成之群組:聚山梨糖醇酯20、聚山梨糖醇酯80、及泊洛沙姆188,較佳為聚山梨糖醇酯20。在較佳的實施態樣中,該聚山梨糖醇酯20的濃度為0.03%(重量/體積)。 In a preferred embodiment, the surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, and poloxamer 188, preferably polysorbate. Alcohol ester 20. In a preferred embodiment, the concentration of polysorbate 20 is 0.03% (weight/volume).
在一些實施態樣中,該融合蛋白係於一醫藥配方中,該醫藥配方在-70℃至5℃下安定性維持至少二年,例如在-70℃、-60℃、-50℃、-40℃、-30℃、-20℃、-10℃、0℃、或5℃下。在一些實施態樣中,該融合蛋白係於一醫藥配方中,該醫藥配方在-70℃、-20℃、及/或5℃下安定性維持至少6個月、7個月、8個月、9個月、10個月、11個月、或更長。在較佳的實施態樣中,該融合蛋白係於一醫藥配方中,該醫藥配方在-70℃、-20℃、及/或5℃下安定性維持至少一年、二年、三年、四年、五年、六年、七年、八年、九年、或十年或更多。在其 他較佳的實施態樣中,該融合蛋白係於一醫藥配方中,該醫藥配方在-70℃、-20℃、及/或5℃下安定性維持至少二年。 In some embodiments, the fusion protein is in a pharmaceutical formulation that is stable at -70°C to 5°C for at least two years, such as -70°C, -60°C, -50°C, - 40℃, -30℃, -20℃, -10℃, 0℃, or 5℃. In some embodiments, the fusion protein is in a pharmaceutical formulation that maintains stability at -70°C, -20°C, and/or 5°C for at least 6 months, 7 months, or 8 months , 9 months, 10 months, 11 months, or longer. In a preferred embodiment, the fusion protein is in a pharmaceutical formula, and the pharmaceutical formula maintains stability at -70°C, -20°C, and/or 5°C for at least one, two, three, Four years, five years, six years, seven years, eight years, nine years, or ten years or more. In its In a preferred embodiment, the fusion protein is in a pharmaceutical formula, and the pharmaceutical formula maintains stability at -70°C, -20°C, and/or 5°C for at least two years.
在一些實施態樣中,該配方在-70℃至25℃下至少6個月後係保持蛋白質的純度及活性,例如在-70℃、-60℃、-50℃、-40℃、-30℃、-20℃、-10℃、0℃、或5℃或25℃下。在一些實施態樣中,該配方在-70℃、-20℃、2℃至8℃、及/或25℃下至少6個月後係保持蛋白質的純度及活性,例如6個月、7個月、8個月、9個月、10個月、11個月、一年、二年、三年、四年、五年、六年、七年、八年、九年、或十年或更多。 In some embodiments, the formulation maintains protein purity and activity after at least 6 months at -70°C to 25°C, such as -70°C, -60°C, -50°C, -40°C, -30°C. ℃, -20℃, -10℃, 0℃, or 5℃ or 25℃. In some embodiments, the formulation maintains protein purity and activity after at least 6 months at -70°C, -20°C, 2°C to 8°C, and/or 25°C, for example, 6 months, 7 months Months, 8 months, 9 months, 10 months, 11 months, one year, two years, three years, four years, five years, six years, seven years, eight years, nine years, or ten years or more many.
在一些實施態樣中,該配方更包含一鹽類。在一些實施態樣中,該鹽類係選自氯化鈉、氯化鎂、氯化鈣、或氯化鉀。 In some embodiments, the formula further includes a salt. In some embodiments, the salt is selected from sodium chloride, magnesium chloride, calcium chloride, or potassium chloride.
在特定的實施態樣中,該配方更包含至少一種胺基酸。在一些實施態樣中,該胺基酸係選自由以下所組成之群組:精胺酸、甲硫胺酸、脯胺酸、組胺酸、半胱胺酸、離胺酸、甘胺酸、天門冬胺酸、色胺酸、麩胺酸、及異白胺酸。 In specific embodiments, the formulation further includes at least one amino acid. In some embodiments, the amino acid is selected from the group consisting of: arginine, methionine, proline, histidine, cysteine, lysine, and glycine. , aspartic acid, tryptophan, glutamic acid, and isoleucine.
在一些實施態樣中,該醫藥配方係包含濃度為40mg/mL的融合蛋白、25mM之組胺酸、190mM之海藻糖、及0.03%之聚山梨糖醇酯20,其中該配方的pH值為6.0。 In some embodiments, the pharmaceutical formula includes fusion protein at a concentration of 40 mg/mL, 25 mM histidine, 190 mM trehalose, and 0.03% polysorbate 20, wherein the pH value of the formula is 6.0.
本發明亦提供一種製造本文中所列之任意配方的方法,其係包含將該配方中的各組分結合成一單一組合物的步驟。此一方法可包括將所獲配方添加至一小瓶或注射裝置中的步驟。該方法可額外包括無菌過濾步驟。此一方法之產物的任意組合物亦為本發明的一部分。舉例言之,本文中之實施態樣亦包括透過以下製備一配方的方法:將一基於組胺酸之緩衝液與一界面活性劑(例如聚山梨糖醇酯20)、一融合蛋白、海藻糖、以及視需要之一或多種其他組分(例如本文中所討論者)。 The invention also provides a method of making any of the formulations listed herein, comprising the step of combining the components of the formulation into a single composition. Such a method may include the step of adding the resulting formulation to a vial or injection device. The method may additionally include a sterile filtration step. Any compositions of the products of this process are also part of the invention. For example, embodiments herein also include methods of preparing a formulation by combining a histidine-based buffer with a surfactant (such as polysorbate 20), a fusion protein, trehalose , and optionally one or more other components (such as those discussed herein).
本發明亦關於使用根據本發明之組合物,在一個體或受試者中治療或預防整合蛋白相關之疾病的用途。「個體」或「受試者」係哺乳類。哺乳類包括但不限於馴養動物(例如:牛、羊、貓、狗、及馬)、靈長類(例如:人類及非人類靈長類(non-human primates)(例如猴子))、兔子及囓齒類(例如:小鼠及大鼠)。在一些實施態樣中,用於治療或預防疾病之一或多種方面或症狀的方法係包含,對一個體投予一有效量之包含融合蛋白的組合物。 The invention also relates to the use of a composition according to the invention for the treatment or prevention of integrin-related diseases in an individual or subject. The "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (such as cattle, sheep, cats, dogs, and horses), primates (such as humans and non-human primates (such as monkeys)), rabbits, and rodents species (e.g. mice and rats). In some embodiments, methods for treating or preventing one or more aspects or symptoms of a disease comprise administering to a subject an effective amount of a composition comprising a fusion protein.
本文所述之方法可用於治療多種疾病,包括但不限於發炎性疾病、眼部疾病、自體免疫疾病、或癌症。在一些實施態樣中,欲治療之疾病包括但不限於類風濕性關節炎、炎症性關節炎、骨關節炎、癌症、組織/器官纖維化、色素性視網膜炎、眼色素層炎(例如:前眼色素層炎或後眼色素層炎)、及特徵係新生血管或缺血性眼部疾病(例如:脈絡膜新生血管、虹膜新生血管、新生血管性青光眼、青光眼術後纖維化、增殖性玻璃體視網膜病變(PVR)、脈絡膜新生血管(CNV)、視神經盤新生血管、視網膜新生血管、玻璃體新生血管、血管翳、翼狀贅肉、血管性視網膜病變、無糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、有糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、糖尿病黃斑水腫(DME)、滲出性(濕性)及非滲出性(乾性)之老年性黃斑退化(AMD)、黃斑水腫、視網膜靜脈阻塞後黃斑水腫(RVO)、視網膜靜脈阻塞(RVO)、中心性視網膜靜脈阻塞(CRVO)、分支性視網膜靜脈阻塞(BRVO)、視網膜血管瘤狀增殖(RAP)、息肉狀脈絡膜血管病變(PCV)、玻璃體黃斑沾黏(VMA)、及/或玻璃體黃斑牽引症(VMT))。 The methods described herein can be used to treat a variety of diseases, including, but not limited to, inflammatory diseases, eye diseases, autoimmune diseases, or cancer. In some embodiments, the disease to be treated includes, but is not limited to, rheumatoid arthritis, inflammatory arthritis, osteoarthritis, cancer, tissue/organ fibrosis, retinitis pigmentosa, uveitis (e.g.: Anterior uveitis or posterior uveitis), and ocular diseases characterized by neovascularization or ischemia (e.g., choroidal neovascularization, iris neovascularization, neovascular glaucoma, postoperative glaucoma fibrosis, proliferative vitreous Retinopathy (PVR), choroidal neovascularization (CNV), optic disc neovascularization, retinal neovascularization, vitreous neovascularization, pannus, pterygoid, vascular retinopathy, diabetic retinopathy without diabetic macular edema (DME) ( DR, nonproliferative and proliferative DR), diabetic retinopathy with diabetic macular edema (DME) (DR, nonproliferative and proliferative DR), diabetic macular edema (DME), exudative (wet) and non-exudative Sexual (dry) age-related macular degeneration (AMD), macular edema, post-retinal vein occlusion macular edema (RVO), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branched retinal vein occlusion (BRVO) , retinal angiomatous proliferation (RAP), polypoidal choroidal vasculopathy (PCV), vitreomacular adhesion (VMA), and/or vitreomacular traction (VMT)).
本文所述之組合物可透過任意途徑投予至個體,途徑包括但不限於靜脈、腹膜、眼部、動脈、肺臟、口服、吸入、血管(intravesicular)、肌肉、氣管、皮下、脊髓(intrathecal)、經皮、經胸膜(transpleural)、局部、黏膜、 胃腸、關節(intraarticular)、腦池內(intracisternal)、心室內、顱內、尿道內、肝內、及腫瘤內。在一些實施態樣中,組合物係系統性投予(例如藉由靜脈注射)。在一些實施態樣中,組合物係局部投予(例如藉由動脈注射或眼內注射)。 The compositions described herein may be administered to an individual by any route, including, but not limited to, intravenous, peritoneal, ocular, arterial, pulmonary, oral, inhalational, intravesicular, intramuscular, tracheal, subcutaneous, intrathecal. , transcutaneous, transpleural, local, mucosal, Gastrointestinal, joint (intraarticular), intracisternal (intracisternal), intraventricular, intracranial, intraurethral, intrahepatic, and intratumoral. In some embodiments, the composition is administered systemically (eg, by intravenous injection). In some embodiments, the compositions are administered topically (eg, by intraarterial or intraocular injection).
在一些實施態樣中,組合物係直接投予至眼睛或眼睛組織。在一些實施態樣中,組合物係局部地投予至眼睛,舉例而言,眼藥水。在一些實施態樣中,組合物係藉由注射至眼睛(眼內注射)或至與眼部相連的組織來投予。組合物可被投予,舉例而言,藉由眼內注射、眼周注射、次視網膜注射、玻璃體內注射(intravitreal injection)、脈絡膜表面(superchoroidal)注射、經中膈(trans-septal)注射、鞏膜下(subscleral)注射、脈絡膜內注射、前房內(intracameral)注射、結膜下注射、坦諾囊下(sub-Tenon’s)注射、眼球後(retrobulbar)注射、眼球周邊(peribulbar)注射、或後鞏膜旁遞送(posterior juxtascleral delivery)。這些方法係為本技術領域所知。組合物可被投予至例如玻璃體、前房液、鞏膜、結膜、在鞏膜及結膜之間的部位、視網膜脈絡膜組織、黃斑、或其他在個體眼睛中或鄰近的部位。 In some embodiments, the composition is administered directly to the eye or eye tissue. In some embodiments, the composition is administered topically to the eye, for example, as eye drops. In some embodiments, the compositions are administered by injection into the eye (intraocular injection) or into tissue associated with the eye. The compositions may be administered, for example, by intraocular injection, periocular injection, subretinal injection, intravitreal injection, superchoroidal injection, trans-septal injection, Subscleral injection, intrachoroidal injection, intracameral injection, subconjunctival injection, sub-Tenon's injection, retrobulbar injection, peribulbar injection, or retrobulbar injection Posterior juxtascleral delivery. These methods are known in the art. The compositions may be administered, for example, to the vitreous humor, anterior chamber fluid, sclera, conjunctiva, the site between the sclera and the conjunctiva, retinal choroidal tissue, macula, or other sites in or adjacent to the eye of an individual.
在一些實施態樣中,該醫藥組合物係以每眼0.03至10mg的劑量投予至眼睛,例如0.03mg、0.04mg、0.05mg、0.06mg、0.07mg、0.08mg、0.09mg、0.1mg、0.2mg、0.3mg、0.4mg、0.5mg、0.6mg、0.7mg、0.8mg、0.9mg、1mg、2mg、3mg、4mg、5mg、6mg、7mg、8mg、9mg、或10mg。在較佳的實施態樣中,該醫藥組合物係以每眼3.0至6.0mg的劑量遞送至眼睛,例如3.0mg、3.5mg、4.0mg、4.5mg、5.0mg、5.5mg、或6mg。在其他較佳的實施態樣中,該醫藥組合物係以每眼4mg的劑量遞送至眼睛。 In some embodiments, the pharmaceutical composition is administered to the eyes at a dose of 0.03 to 10 mg per eye, such as 0.03 mg, 0.04 mg, 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.2mg, 0.3mg, 0.4mg, 0.5mg, 0.6mg, 0.7mg, 0.8mg, 0.9mg, 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, or 10mg. In a preferred embodiment, the pharmaceutical composition is delivered to the eye at a dose of 3.0 to 6.0 mg per eye, such as 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, or 6 mg. In other preferred embodiments, the pharmaceutical composition is delivered to the eye at a dose of 4 mg per eye.
組合物之最適有效量可憑經驗決定,且將取決於疾病之型態及嚴重性、投予途徑、疾病進程及個體之健康狀況、重量及身體部位。該等決定係在本技術領域者之通常知識範圍內。包含融合蛋白之組合物亦可以一週六次、一週 五次、一週四次、一週三次、一週二次、一週一次、二週一次、三週一次、一個月一次、二個月一次、三個月一次、六個月一次、九個月一次、或一年一次來投予。 The optimal effective amount of the composition can be determined empirically and will depend on the type and severity of the disease, the route of administration, the course of the disease and the health, weight and body region of the individual. Such decisions are within the common knowledge of those skilled in the art. Compositions containing fusion proteins can also be administered six times a week, Five times, four times a week, three times a week, twice a week, once a week, once every two weeks, once every three weeks, once a month, once every two months, once every three months, once every six months, once every nine months, Or give it once a year.
除非另外定義,此處所用之所有技術及科學術語係具有與本發明所屬技術領域中具通常知識者通常所了解之相同意義。雖然任何與本文所述類似或同等之方法及材料可用來實施或測試本發明,但較佳的為現在描述的方法及材料。所有本文所提到之供參考的出版品係併於本文中,以描述與該些被引用之出版品相關的方法及/或材料。 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the methods and materials now described are preferred. All publications mentioned herein by reference are herein incorporated by reference to describe the methods and/or materials associated with the cited publications.
實施態樣Implementation form
本申請包括但不限於以下所編列的實施態樣: This application includes but is not limited to the implementation forms listed below:
實施態樣1為一種醫藥配方,該醫藥配方包含:a)一濃度為0.5mg/mL至120mg/mL之融合蛋白;b)一濃度為1%至10%(重量/體積)之多元醇或醇類,該多元醇或醇類係選自由以下所組成之群組:蔗糖、海藻糖、甘露醇、山梨糖醇、苯甲醇、聚乙烯醇、及聚乙二醇(PEG)400-12000;c)一濃度為10mM至50mM之緩衝劑,該緩衝劑係選自由以下所組成之群組:磷酸鈉、組胺酸、檸檬酸鈉、醋酸鈉、碳酸氫鈉、及檸檬酸三鈉二水合物(trisodium citrate dihydrate);以及d)一濃度為0.01%至4%(重量/體積)之界面活性劑,其中,該配方的pH值為5.5至7.5,且該配方視需要地更包含一選自由以下所組成之群組的多醣:羧甲基纖維素鈉、微晶纖維素、或透明質酸鈉。 Embodiment 1 is a pharmaceutical formula, which contains: a) a fusion protein with a concentration of 0.5 mg/mL to 120 mg/mL; b) a polyol with a concentration of 1% to 10% (weight/volume) or Alcohols, the polyol or alcohols are selected from the group consisting of: sucrose, trehalose, mannitol, sorbitol, benzyl alcohol, polyvinyl alcohol, and polyethylene glycol (PEG) 400-12000; c) A buffer with a concentration of 10mM to 50mM, the buffer being selected from the group consisting of: sodium phosphate, histidine, sodium citrate, sodium acetate, sodium bicarbonate, and trisodium citrate dihydrate (trisodium citrate dihydrate); and d) a surfactant with a concentration of 0.01% to 4% (weight/volume), wherein the pH value of the formula is 5.5 to 7.5, and the formula further includes an optional A polysaccharide free from the group consisting of: sodium carboxymethyl cellulose, microcrystalline cellulose, or sodium hyaluronate.
實施態樣2為如實施態樣1之醫藥配方,其中該界面活性劑係選自由以下所組成之群組:聚山梨糖醇酯20、聚山梨糖醇酯80、及泊洛沙姆188,較佳為聚山梨糖醇酯20。 Embodiment 2 is a pharmaceutical formulation as in Embodiment 1, wherein the surfactant is selected from the group consisting of: polysorbate 20, polysorbate 80, and poloxamer 188, Polysorbate 20 is preferred.
實施態樣3為如實施態樣2之醫藥配方,其中該聚山梨糖醇酯為聚山梨糖醇酯20。 Embodiment 3 is a pharmaceutical formulation as in Embodiment 2, wherein the polysorbate is polysorbate 20.
實施態樣4為如實施態樣1至3中任一者之醫藥配方,其中該界面活性劑的濃度為0.03%(重量/體積)。 Embodiment 4 is a pharmaceutical formulation according to any one of embodiments 1 to 3, wherein the concentration of the surfactant is 0.03% (weight/volume).
實施態樣5為如實施態樣1至4中任一者之醫藥配方,其中該融合蛋白的濃度為1mg/mL至90mg/mL,較佳為20mg/mL至80mg/mL,更佳地,該融合蛋白的濃度為40mg/mL。 Embodiment 5 is a pharmaceutical formula according to any one of Embodiments 1 to 4, wherein the concentration of the fusion protein is 1 mg/mL to 90 mg/mL, preferably 20 mg/mL to 80 mg/mL, and more preferably, The concentration of this fusion protein is 40mg/mL.
實施態樣6為如實施態樣5之醫藥配方,其中該融合蛋白的濃度為40mg/mL。 Embodiment 6 is a pharmaceutical formula as in Embodiment 5, wherein the concentration of the fusion protein is 40 mg/mL.
實施態樣7為如實施態樣1至6中任一者之醫藥配方,其中該多元醇係海藻糖且濃度為25mM至250mM,較佳為190mM。 Embodiment 7 is a pharmaceutical formulation according to any one of embodiments 1 to 6, wherein the polyol is trehalose and the concentration is 25mM to 250mM, preferably 190mM.
實施態樣8為如實施態樣7之醫藥配方,其中海藻糖的濃度為190mM。 Embodiment 8 is a pharmaceutical formula as in Embodiment 7, wherein the concentration of trehalose is 190mM.
實施態樣9為如實施態樣1至8中任一者之醫藥配方,其中該緩衝劑係組胺酸且濃度為10mM至40mM,較佳為20mM至30mM,更佳地,該組胺酸的濃度為25mM。 Embodiment 9 is a pharmaceutical formula as in any one of embodiments 1 to 8, wherein the buffer is histamine and the concentration is 10mM to 40mM, preferably 20mM to 30mM, more preferably, the histamine The concentration is 25mM.
實施態樣10為如實施態樣9之醫藥配方,其中該組胺酸的濃度為25mM。 Embodiment 10 is the pharmaceutical formula as in Embodiment 9, wherein the concentration of histamine is 25mM.
實施態樣11為如實施態樣1至10中任一者之醫藥配方,其中該融合蛋白係自N-端至C-端以如下順序包含:a)一血管內皮生長因子受體(VEGFR)的細胞外結構域;b)一人類免疫球蛋白G的Fc結構域;以及c)一結合整合蛋白之蛋白或其片段。 Embodiment 11 is a pharmaceutical formulation according to any one of embodiments 1 to 10, wherein the fusion protein includes in the following order from N-terminus to C-terminus: a) a vascular endothelial growth factor receptor (VEGFR) an extracellular domain; b) an Fc domain of human immunoglobulin G; and c) an integrin-binding protein or fragment thereof.
實施態樣12為如實施態樣1至11中任一者之醫藥配方,其中該融合蛋白係包含SEQ ID NO:15、SEQ ID NO:16、SEQ ID NO:17、或SEQ ID NO:18。 Embodiment 12 is a pharmaceutical formulation according to any one of embodiments 1 to 11, wherein the fusion protein includes SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18 .
實施態樣13為如實施態樣1至12中任一者之醫藥配方,其中該pH值為5.5至7.0,較佳地,該pH值為6.0。 Embodiment 13 is a pharmaceutical formula according to any one of embodiments 1 to 12, wherein the pH value is 5.5 to 7.0, preferably, the pH value is 6.0.
實施態樣14為如實施態樣13之醫藥配方,其中該pH值為6.0。 Embodiment 14 is the pharmaceutical formula as in Embodiment 13, wherein the pH value is 6.0.
實施態樣15為如實施態樣1至14中任一者之醫藥配方,其中該配方在-70℃、-20℃、及/或2至8℃下安定性維持至少24個月。 Embodiment 15 is a pharmaceutical formulation according to any one of embodiments 1 to 14, wherein the formulation maintains stability at -70°C, -20°C, and/or 2 to 8°C for at least 24 months.
實施態樣16為如實施態樣1至15中任一者之醫藥配方,其中該配方在-70℃、-20℃、及/或2℃至8℃下(較佳在2℃至8℃下)至少6個月後係保持蛋白質的純度及活性。 Embodiment 16 is a pharmaceutical formulation as in any one of embodiments 1 to 15, wherein the formulation is at -70°C, -20°C, and/or 2°C to 8°C (preferably at 2°C to 8°C (Bottom) The purity and activity of the protein will be maintained after at least 6 months.
實施態樣17為如實施態樣1至16中任一者之醫藥配方,其中該配方更包含一濃度為10mM至50mM的鹽類。 Embodiment 17 is a pharmaceutical formula according to any one of Embodiments 1 to 16, wherein the formula further includes a salt with a concentration of 10mM to 50mM.
實施態樣18為如實施態樣17之醫藥配方,其中該鹽類係選自氯化鈉、氯化鎂、氯化鈣、或氯化鉀。 Embodiment 18 is a pharmaceutical formulation as in Embodiment 17, wherein the salt is selected from sodium chloride, magnesium chloride, calcium chloride, or potassium chloride.
實施態樣19為如實施態樣1至18中任一者之醫藥配方,其中該配方更包含至少一種胺基酸,該胺基酸的濃度為10mM至50mM。 Embodiment 19 is a pharmaceutical formulation according to any one of Embodiments 1 to 18, wherein the formulation further includes at least one amino acid, and the concentration of the amino acid is 10mM to 50mM.
實施態樣20為如實施態樣19之醫藥配方,其中該胺基酸係選自由以下所組成之群組:精胺酸、甲硫胺酸、脯胺酸、組胺酸、半胱胺酸、離胺酸、甘胺酸、天門冬胺酸、色胺酸、麩胺酸、及異白胺酸。 Embodiment 20 is a pharmaceutical formulation as in Embodiment 19, wherein the amino acid is selected from the group consisting of: arginine, methionine, proline, histidine, and cysteine , lysine, glycine, aspartic acid, tryptophan, glutamic acid, and isoleucine.
實施態樣21為如實施態樣1至20中任一者之醫藥配方,其中該配方係用於一治療眼部疾病的方法。 Embodiment 21 is a pharmaceutical formulation according to any one of Embodiments 1 to 20, wherein the formulation is used for a method of treating eye diseases.
實施態樣22為如實施態樣21之醫藥配方,其中該眼部疾病係選自新生血管或缺血性眼色素層炎、視網膜血管炎、血管樣痕、色素性視網膜炎、角 膜新生血管、虹膜新生血管、新生血管性青光眼、青光眼術後纖維化、增殖性玻璃體視網膜病變(PVR)、脈絡膜新生血管(CNV)、視神經盤新生血管、視網膜新生血管、玻璃體新生血管、血管翳、翼狀贅肉、血管性視網膜病變、無糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、有糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、糖尿病黃斑水腫(DME)、滲出性(濕性)及非滲出性(乾性)之老年性黃斑退化(AMD)、黃斑水腫、視網膜靜脈阻塞後黃斑水腫(RVO)、視網膜靜脈阻塞(RVO)、中心性視網膜靜脈阻塞(CRVO)、分支性視網膜靜脈阻塞(BRVO)、視網膜血管瘤狀增殖(RAP)、息肉狀脈絡膜血管病變(PCV)、玻璃體黃斑沾黏(VMA)、及/或玻璃體黃斑牽引症(VMT)。 Embodiment 22 is a pharmaceutical formulation as in Embodiment 21, wherein the eye disease is selected from the group consisting of neovascular or ischemic uveitis, retinal vasculitis, vascular scars, retinitis pigmentosa, angina. Membrane neovascularization, iris neovascularization, neovascular glaucoma, postoperative glaucoma fibrosis, proliferative vitreoretinopathy (PVR), choroidal neovascularization (CNV), optic disc neovascularization, retinal neovascularization, vitreous neovascularization, pannus , pterygoid, vascular retinopathy, diabetic retinopathy (DR, non-proliferative and proliferative DR) without diabetic macular edema (DME), diabetic retinopathy (DR, non-proliferative) with diabetic macular edema (DME) and proliferative DR), diabetic macular edema (DME), exudative (wet) and non-exudative (dry) age-related macular degeneration (AMD), macular edema, post-retinal vein occlusion macular edema (RVO), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branched retinal vein occlusion (BRVO), retinal angiomatous proliferation (RAP), polypoidal choroidal vasculopathy (PCV), vitreomacular adhesion (VMA), and /or Vitreomacular Traction (VMT).
實施態樣23為如實施態樣1至22中任一者之醫藥配方,其中該配方係以每眼0.03至10mg的劑量投予,較佳為每眼3.0至6.0mg,更佳地,該配方係以每眼4mg的劑量投予。 Embodiment 23 is a pharmaceutical formulation according to any one of embodiments 1 to 22, wherein the formulation is administered at a dose of 0.03 to 10 mg per eye, preferably 3.0 to 6.0 mg per eye, and more preferably, the formulation The formulation is administered at a dose of 4 mg per eye.
實施態樣24為如實施態樣23之醫藥配方,其中該配方係以每眼4mg的劑量投予。 Embodiment 24 is a pharmaceutical formulation as in Embodiment 23, wherein the formulation is administered at a dose of 4 mg per eye.
實施態樣25為一種醫藥配方,該配方包含:a)一濃度為40mg/mL之融合蛋白;b)25mM之組胺酸;c)190mM之海藻酸、蔗糖、或甘露醇;以及d)0.03%之聚山梨糖醇酯20或聚山梨糖醇酯80,其中該配方的pH值為6.0。 Embodiment 25 is a pharmaceutical formulation, which contains: a) a fusion protein with a concentration of 40mg/mL; b) 25mM histidine; c) 190mM alginic acid, sucrose, or mannitol; and d) 0.03 % of Polysorbate 20 or Polysorbate 80, where the formulation has a pH of 6.0.
實施態樣26為如實施態樣25之醫藥配方,其中該融合蛋白係自N-端至C-端以如下順序包含:a)一血管內皮生長因子受體(VEGFR)的細胞外結構域; b)一人類免疫球蛋白G的Fc結構域;以及c)結合一整合蛋白之蛋白或其片段。 Embodiment 26 is a pharmaceutical formulation as in Embodiment 25, wherein the fusion protein includes in the following order from N-terminus to C-terminus: a) an extracellular domain of vascular endothelial growth factor receptor (VEGFR); b) an Fc domain of human immunoglobulin G; and c) a protein or fragment thereof that binds an integrin.
實施態樣27為如實施態樣26之醫藥配方,其中該融合蛋白係包含SEQ ID NO:15、SEQ ID NO:16、SEQ ID NO:17、或SEQ ID NO:18。 Embodiment 27 is a pharmaceutical formulation as in embodiment 26, wherein the fusion protein includes SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18.
實施態樣28為如實施態樣25至27中任一者之醫藥配方,其中該配方在-70℃、-20℃、及/或5℃下安定性維持至少24個月。 Embodiment 28 is a pharmaceutical formulation according to any one of embodiments 25 to 27, wherein the formulation maintains stability at -70°C, -20°C, and/or 5°C for at least 24 months.
實施態樣29為如實施態樣25至28中任一者之醫藥配方,其中該配方在-70℃、-20℃、及/或2℃至8℃下(較佳在2℃至8℃下)至少6個月後係保持蛋白質的純度及活性。 Embodiment 29 is a pharmaceutical formulation as in any one of embodiments 25 to 28, wherein the formulation is at -70°C, -20°C, and/or 2°C to 8°C (preferably at 2°C to 8°C (Bottom) The purity and activity of the protein will be maintained after at least 6 months.
實施態樣30為如實施態樣25至29中任一者之醫藥配方,其中該配方更包含一濃度為10mM至50mM的鹽類。 Embodiment 30 is a pharmaceutical formula according to any one of Embodiments 25 to 29, wherein the formula further includes a salt at a concentration of 10mM to 50mM.
實施態樣31為如實施態樣30之醫藥配方,其中該鹽類係選自氯化鈉、氯化鎂、氯化鈣、或氯化鉀。 Embodiment 31 is a pharmaceutical formulation as in Embodiment 30, wherein the salt is selected from sodium chloride, magnesium chloride, calcium chloride, or potassium chloride.
實施態樣32為如實施態樣25至31中任一者之醫藥配方,其中該配方更包含至少一種胺基酸,該胺基酸的濃度為10mM至50mM。 Embodiment 32 is a pharmaceutical formulation according to any one of Embodiments 25 to 31, wherein the formulation further includes at least one amino acid, and the concentration of the amino acid is 10mM to 50mM.
實施態樣33為如實施態樣32之醫藥配方,其中該胺基酸係選自由以下所組成之群組:精胺酸、甲硫胺酸、脯胺酸、組胺酸、半胱胺酸、離胺酸、甘胺酸、天門冬胺酸、色胺酸、麩胺酸、及異白胺酸。 Embodiment 33 is a pharmaceutical formulation as in Embodiment 32, wherein the amino acid is selected from the group consisting of: arginine, methionine, proline, histidine, and cysteine. , lysine, glycine, aspartic acid, tryptophan, glutamic acid, and isoleucine.
實施態樣34為如實施態樣25至33中任一者之醫藥配方,其中該配方係用於一治療眼部疾病的方法。 Embodiment 34 is a pharmaceutical formulation according to any one of Embodiments 25 to 33, wherein the formulation is used for a method of treating eye diseases.
實施態樣35為如實施態樣34之醫藥配方,其中該眼部疾病係選自新生血管或缺血性眼色素層炎、視網膜血管炎、血管樣痕、色素性視網膜炎、角膜新生血管、虹膜新生血管、新生血管性青光眼、青光眼術後纖維化、增殖性玻璃體視網膜病變(PVR)、脈絡膜新生血管(CNV)、視神經盤新生血管、視網 膜新生血管、玻璃體新生血管、血管翳、翼狀贅肉、血管性視網膜病變、無糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、有糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、糖尿病黃斑水腫(DME)、滲出性(濕性)及非滲出性(乾性)之老年性黃斑退化(AMD)、黃斑水腫、視網膜靜脈阻塞後黃斑水腫(RVO)、視網膜靜脈阻塞(RVO)、中心性視網膜靜脈阻塞(CRVO)、分支性視網膜靜脈阻塞(BRVO)、視網膜血管瘤狀增殖(RAP)、息肉狀脈絡膜血管病變(PCV)、玻璃體黃斑沾黏(VMA)、及/或玻璃體黃斑牽引症(VMT)。 Embodiment 35 is a pharmaceutical formulation as in Embodiment 34, wherein the eye disease is selected from the group consisting of neovascularization or ischemic uveitis, retinal vasculitis, vascular scars, retinitis pigmentosa, corneal neovascularization, Iris neovascularization, neovascular glaucoma, postoperative glaucoma fibrosis, proliferative vitreoretinopathy (PVR), choroidal neovascularization (CNV), optic disc neovascularization, retina Membranous neovascularization, vitreous neovascularization, pannus, pterygium, vascular retinopathy, diabetic retinopathy (DR, non-proliferative and proliferative DR) without diabetic macular edema (DME), diabetic macular edema (DME) Diabetic retinopathy (DR, non-proliferative and proliferative DR), diabetic macular edema (DME), exudative (wet) and non-exudative (dry) age-related macular degeneration (AMD), macular edema, retinal veins Post-occlusive macular edema (RVO), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branched retinal vein occlusion (BRVO), retinal angiomatous proliferation (RAP), polypoidal choroidal vasculopathy (PCV) , vitreomacular adhesion (VMA), and/or vitreomacular traction (VMT).
實施態樣36為如實施態樣25至35中任一者之醫藥配方,其中該配方係以每眼0.03至10mg的劑量投予,較佳為每眼3.0至6.0mg,更佳地,該配方係以每眼4mg的劑量投予。 Embodiment 36 is a pharmaceutical formulation as in any one of embodiments 25 to 35, wherein the formulation is administered at a dose of 0.03 to 10 mg per eye, preferably 3.0 to 6.0 mg per eye, more preferably, the formulation The formulation is administered at a dose of 4 mg per eye.
實施態樣37為如實施態樣36之醫藥配方,其中該配方係以每眼4mg的劑量投予 Embodiment 37 is a pharmaceutical formulation as in Embodiment 36, wherein the formulation is administered at a dose of 4 mg per eye
實施態樣38為一種治療一個體之眼部疾病的方法,該方法包含對該個體投予一包含以下的醫藥配方:a)一濃度為0.5mg/mL至120mg/mL之融合蛋白;b)一濃度為1%至10%(重量/體積)之多元醇或醇類,該多元醇或醇類係選自由以下所組成之群組:蔗糖、海藻糖、甘露醇、山梨糖醇、苯甲醇、聚乙烯醇、及聚乙二醇(PEG)400-12000;c)一濃度為10mM至50mM之緩衝劑,該緩衝劑係選自由以下所組成之群組:磷酸鈉、組胺酸、檸檬酸鈉、醋酸鈉、碳酸氫鈉、及檸檬酸三鈉二水合物(trisodium citrate dihydrate);以及d)一濃度為0.01%至4%(重量/體積)之界面活性劑, 其中,該配方的pH值為5.5至7.5,且該配方視需要地更包含一選自由以下所組成之群組的多醣:羧甲基纖維素鈉、微晶纖維素、或透明質酸鈉。 Embodiment 38 is a method of treating an eye disease in an individual, the method comprising administering to the individual a pharmaceutical formulation including: a) a fusion protein at a concentration of 0.5 mg/mL to 120 mg/mL; b) A polyol or alcohol with a concentration of 1% to 10% (weight/volume) selected from the group consisting of: sucrose, trehalose, mannitol, sorbitol, benzyl alcohol , polyvinyl alcohol, and polyethylene glycol (PEG) 400-12000; c) a buffer with a concentration of 10mM to 50mM, which is selected from the group consisting of: sodium phosphate, histidine, lemon sodium acetate, sodium bicarbonate, and trisodium citrate dihydrate; and d) a surfactant with a concentration of 0.01% to 4% (weight/volume), Wherein, the pH value of the formula is 5.5 to 7.5, and the formula optionally further includes a polysaccharide selected from the group consisting of: sodium carboxymethylcellulose, microcrystalline cellulose, or sodium hyaluronate.
實施態樣39為如實施態樣38之方法,其中該界面活性劑係選自由以下所組成之群組:聚山梨糖醇酯20、聚山梨糖醇酯80、及泊洛沙姆188,較佳為聚山梨糖醇酯20。 Embodiment 39 is the method of embodiment 38, wherein the surfactant is selected from the group consisting of: polysorbate 20, polysorbate 80, and poloxamer 188, preferably Polysorbate 20 is preferred.
實施態樣40為如實施態樣39之方法,其中該界面活性劑係聚山梨糖醇酯20。 Embodiment 40 is the method of embodiment 39, wherein the surfactant is polysorbate 20.
實施態樣41為如實施態樣38至40中任一者之方法,其中該界面活性劑的濃度為0.03%(重量/體積)。 Embodiment 41 is the method of any one of embodiments 38 to 40, wherein the concentration of the surfactant is 0.03% (weight/volume).
實施態樣42為如實施態樣38至41中任一者之方法,其中該融合蛋白的濃度為1mg/mL至90mg/mL,較佳為40mg/mL至80mg/mL,更佳地,該融合蛋白的濃度為40mg/mL。 Embodiment 42 is a method as in any one of embodiments 38 to 41, wherein the concentration of the fusion protein is 1 mg/mL to 90 mg/mL, preferably 40 mg/mL to 80 mg/mL, more preferably, the fusion protein The concentration of fusion protein is 40mg/mL.
實施態樣43為如實施態樣42之方法,其中該融合蛋白的濃度為40mg/mL。 Implementation aspect 43 is the method as in implementation aspect 42, wherein the concentration of the fusion protein is 40 mg/mL.
實施態樣44為如實施態樣38至43中任一者之方法,其中該多元醇係海藻糖且濃度為150mM至230mM,較佳為190mM。 Embodiment 44 is the method of any one of embodiments 38 to 43, wherein the polyol is trehalose and the concentration is 150mM to 230mM, preferably 190mM.
實施態樣45為如實施態樣44之方法,其中該海藻糖的濃度為190mM。 Embodiment 45 is the method as in Embodiment 44, wherein the concentration of trehalose is 190mM.
實施態樣46為如實施態樣38至45中任一者之方法,其中該緩衝劑係組胺酸且濃度為20mM至40mM,較佳為20mM至30mM,更佳地,該組胺酸的濃度為25mM。 Embodiment 46 is a method as in any one of embodiments 38 to 45, wherein the buffer is histidine acid and the concentration is 20mM to 40mM, preferably 20mM to 30mM, more preferably, the histidine acid The concentration is 25mM.
實施態樣47為如實施態樣46之方法,其中該組胺酸的濃度為25mM。 Embodiment 47 is the method of embodiment 46, wherein the concentration of histidine is 25mM.
實施態樣48為如實施態樣38至47中任一者之方法,其中該融合蛋白係自N-端至C-端以如下順序包含:a)一血管內皮生長因子受體(VEGFR)的細胞外結構域;b)一人類免疫球蛋白G的Fc結構域;以及c)一結合整合蛋白之蛋白(integrin binding protein)或其片段。 Embodiment 48 is a method as in any one of embodiments 38 to 47, wherein the fusion protein includes in the following order from N-terminus to C-terminus: a) a vascular endothelial growth factor receptor (VEGFR) Extracellular domain; b) an Fc domain of human immunoglobulin G; and c) an integrin binding protein or a fragment thereof.
實施態樣49為如實施態樣38至48中任一者之方法,其中該融合蛋白係包含SEQ ID NO:15、SEQ ID NO:16、SEQ ID NO:17、或SEQ ID NO:18。 Embodiment 49 is the method of any one of embodiments 38 to 48, wherein the fusion protein comprises SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18.
實施態樣50為如實施態樣38至49中任一者之方法,其中該pH值為6.0至6.5,較佳地,該pH值為6.0。 Embodiment 50 is a method as in any one of embodiments 38 to 49, wherein the pH value is 6.0 to 6.5, preferably, the pH value is 6.0.
實施態樣51為如實施態樣50之方法,其中該pH值為6.0。 Implementation aspect 51 is the method of implementation aspect 50, wherein the pH value is 6.0.
實施態樣52為如實施態樣38至51中任一者之方法,其中該配方在-70℃、-20℃、及/或2至8℃下安定性維持至少24個月。 Embodiment 52 is the method of any one of embodiments 38 to 51, wherein the formulation maintains stability at -70°C, -20°C, and/or 2 to 8°C for at least 24 months.
實施態樣53為如實施態樣38至52中任一者之方法,其中該配方在-70℃、-20℃、及/或2℃至8℃下(較佳在2℃至8℃下)至少6個月後係保持蛋白質的純度及活性。 Embodiment 53 is a method as in any one of embodiments 38 to 52, wherein the formulation is at -70°C, -20°C, and/or 2°C to 8°C (preferably at 2°C to 8°C ) maintains protein purity and activity for at least 6 months.
實施態樣54為如實施態樣38至53中任一者之方法,其中該配方更包含一濃度為10mM至50mM的鹽類。 Embodiment 54 is the method of any one of embodiments 38 to 53, wherein the formulation further includes a salt with a concentration of 10mM to 50mM.
實施態樣55為如實施態樣54之方法,其中該鹽類係選自氯化鈉、氯化鎂、氯化鈣、或氯化鉀。 Embodiment 55 is the method of embodiment 54, wherein the salt is selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, or potassium chloride.
實施態樣56為如實施態樣38至55中任一者之方法,其中該配方更包含至少一種胺基酸,該胺基酸的濃度為10mM至50mM。 Embodiment 56 is the method of any one of embodiments 38 to 55, wherein the formulation further includes at least one amino acid, and the concentration of the amino acid is 10mM to 50mM.
實施態樣57為如實施態樣56之方法,其中該胺基酸係選自由以下所組成之群組:精胺酸、甲硫胺酸、脯胺酸、組胺酸、半胱胺酸、離胺酸、甘胺酸、天門冬胺酸、色胺酸、麩胺酸、及異白胺酸。 Embodiment 57 is the method of embodiment 56, wherein the amino acid is selected from the group consisting of: arginine, methionine, proline, histidine, cysteine, Lysine, glycine, aspartic acid, tryptophan, glutamic acid, and isoleucine.
實施態樣58為如實施態樣38至57中任一者之方法,其中該眼部疾病係選自新生血管或缺血性眼色素層炎、視網膜血管炎、血管樣痕、色素性視網膜炎、角膜新生血管、虹膜新生血管、新生血管性青光眼、青光眼術後纖維化、增殖性玻璃體視網膜病變(PVR)、脈絡膜新生血管(CNV)、視神經盤新生血管、視網膜新生血管、玻璃體新生血管、血管翳、翼狀贅肉、血管性視網膜病變、無糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、有糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、糖尿病黃斑水腫(DME)、滲出性(濕性)及非滲出性(乾性)之老年性黃斑退化(AMD)、黃斑水腫、視網膜靜脈阻塞後黃斑水腫(RVO)、視網膜靜脈阻塞(RVO)、中心性視網膜靜脈阻塞(CRVO)、分支性視網膜靜脈阻塞(BRVO)、視網膜血管瘤狀增殖(RAP)、息肉狀脈絡膜血管病變(PCV)、玻璃體黃斑沾黏(VMA)、及/或玻璃體黃斑牽引症(VMT)。 Embodiment 58 is the method of any one of embodiments 38 to 57, wherein the ocular disease is selected from the group consisting of neovascular or ischemic uveitis, retinal vasculitis, vascular scars, and retinitis pigmentosa. , corneal neovascularization, iris neovascularization, neovascular glaucoma, postoperative glaucoma fibrosis, proliferative vitreoretinopathy (PVR), choroidal neovascularization (CNV), optic disc neovascularization, retinal neovascularization, vitreous neovascularization, blood vessels Pannus, pterygoid, vascular retinopathy, diabetic retinopathy (DR, non-proliferative and proliferative DR) without diabetic macular edema (DME), diabetic retinopathy (DR, non-proliferative) with diabetic macular edema (DME) and proliferative DR), diabetic macular edema (DME), exudative (wet) and non-exudative (dry) age-related macular degeneration (AMD), macular edema, post-retinal vein occlusion macular edema (RVO), retina Venous occlusion (RVO), central retinal vein occlusion (CRVO), branched retinal vein occlusion (BRVO), retinal angiomatous proliferation (RAP), polypoidal choroidal vasculopathy (PCV), vitreomacular adhesion (VMA), and/or vitreomacular traction (VMT).
實施態樣59為如實施態樣38至58中任一者之方法,其中該配方係以每眼0.03至10mg的劑量投予,較佳為每眼3.0至6.0mg,更佳地,該配方係以每眼4mg的劑量投予。 Embodiment 59 is the method of any one of embodiments 38 to 58, wherein the formulation is administered at a dose of 0.03 to 10 mg per eye, preferably 3.0 to 6.0 mg per eye, more preferably, the formulation It is administered at a dose of 4 mg per eye.
實施態樣60為如實施態樣59之方法,其中該配方係以每眼4mg的劑量投予。 Embodiment 60 is the method of embodiment 59, wherein the formulation is administered at a dose of 4 mg per eye.
實施態樣61為一種治療一個體之眼部疾病的方法,該方法包含對該個體投予一包含以下之醫藥配方:a)一濃度為40mg/mL之融合蛋白;b)25mM之組胺酸;c)190mM之海藻酸、蔗糖、或甘露醇;以及d)0.03%之聚山梨糖醇酯20或聚山梨糖醇酯80,其中該配方的pH值為6.0。 Embodiment 61 is a method of treating an eye disease in an individual, the method comprising administering to the individual a pharmaceutical formulation including: a) a fusion protein at a concentration of 40 mg/mL; b) 25 mM histamine ; c) 190mM alginic acid, sucrose, or mannitol; and d) 0.03% polysorbate 20 or polysorbate 80, wherein the pH value of the formula is 6.0.
實施態樣62為如實施態樣61之方法,其中該融合蛋白係自N-端至C-端以如下順序包含:a)一血管內皮生長因子受體(VEGFR)的細胞外結構域;b)一人類免疫球蛋白G的Fc結構域;以及c)一結合整合蛋白之蛋白(integrin binding protein)或其片段。 Embodiment 62 is the method of embodiment 61, wherein the fusion protein includes in the following order from N-terminus to C-terminus: a) an extracellular domain of vascular endothelial growth factor receptor (VEGFR); b ) an Fc domain of human immunoglobulin G; and c) an integrin binding protein or a fragment thereof.
實施態樣63為如實施態樣62之方法,其中該融合蛋白係包含SEQ ID NO:15、SEQ ID NO:16、SEQ ID NO:17、或SEQ ID NO:18。 Embodiment 63 is the method of embodiment 62, wherein the fusion protein comprises SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18.
實施態樣64為如實施態樣61至63中任一者之方法,其中該配方在-70℃、-20℃、及/或5℃下安定性維持至少24個月。 Embodiment 64 is the method of any one of embodiments 61 to 63, wherein the formulation maintains stability at -70°C, -20°C, and/or 5°C for at least 24 months.
實施態樣65為如實施態樣61至64中任一者之方法,其中該配方在-70℃、-20℃、及/或2℃至8℃下(較佳在2℃至8℃下)至少6個月後係保持蛋白質的純度及活性。 Embodiment 65 is the method as in any one of embodiments 61 to 64, wherein the formulation is at -70°C, -20°C, and/or 2°C to 8°C (preferably at 2°C to 8°C ) maintains protein purity and activity for at least 6 months.
實施態樣66為如實施態樣61至65中任一者之方法,其中該配方更包含一濃度為10mM至50mM的鹽類。 Embodiment 66 is the method of any one of embodiments 61 to 65, wherein the formulation further includes a salt at a concentration of 10mM to 50mM.
實施態樣67為如實施態樣66之方法,其中該鹽類係選自氯化鈉、氯化鎂、氯化鈣、或氯化鉀。 Embodiment 67 is the method of embodiment 66, wherein the salt is selected from the group consisting of sodium chloride, magnesium chloride, calcium chloride, or potassium chloride.
實施態樣68為如實施態樣61至67中任一者之方法,其中該配方更包含至少一種胺基酸,該胺基酸的濃度為10mM至50mM。 Embodiment 68 is the method of any one of embodiments 61 to 67, wherein the formulation further includes at least one amino acid, and the concentration of the amino acid is 10mM to 50mM.
實施態樣69為如實施態樣68之方法,其中該胺基酸係選自由以下所組成之群組:精胺酸、甲硫胺酸、脯胺酸、組胺酸、半胱胺酸、離胺酸、甘胺酸、天門冬胺酸、色胺酸、麩胺酸、及異白胺酸。 Embodiment 69 is the method of embodiment 68, wherein the amino acid is selected from the group consisting of: arginine, methionine, proline, histidine, cysteine, Lysine, glycine, aspartic acid, tryptophan, glutamic acid, and isoleucine.
實施態樣70為如實施態樣61至69中任一者之方法,其中該眼部疾病係選自新生血管或缺血性眼色素層炎、視網膜血管炎、血管樣痕、色素性視網膜炎、角膜新生血管、虹膜新生血管、新生血管性青光眼、青光眼術後纖維化、 增殖性玻璃體視網膜病變(PVR)、脈絡膜新生血管(CNV)、視神經盤新生血管、視網膜新生血管、玻璃體新生血管、血管翳、翼狀贅肉、血管性視網膜病變、無糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、有糖尿病黃斑水腫(DME)之糖尿病視網膜病變(DR,非增生性及增生性DR)、糖尿病黃斑水腫(DME)、滲出性(濕性)及非滲出性(乾性)之老年性黃斑退化(AMD)、黃斑水腫、視網膜靜脈阻塞後黃斑水腫(RVO)、視網膜靜脈阻塞(RVO)、中心性視網膜靜脈阻塞(CRVO)、分支性視網膜靜脈阻塞(BRVO)、視網膜血管瘤狀增殖(RAP)、息肉狀脈絡膜血管病變(PCV)、玻璃體黃斑沾黏(VMA)、及/或玻璃體黃斑牽引症(VMT)。 Embodiment 70 is the method of any one of embodiments 61 to 69, wherein the ocular disease is selected from the group consisting of neovascular or ischemic uveitis, retinal vasculitis, vascular scars, and retinitis pigmentosa. , corneal neovascularization, iris neovascularization, neovascular glaucoma, postoperative glaucoma fibrosis, Proliferative vitreoretinopathy (PVR), choroidal neovascularization (CNV), optic disc neovascularization, retinal neovascularization, vitreous neovascularization, pannus, pterygoid, vascular retinopathy, diabetes without diabetic macular edema (DME) Retinopathy (DR, non-proliferative and proliferative DR), diabetic retinopathy (DR, non-proliferative and proliferative DR) with diabetic macular edema (DME), diabetic macular edema (DME), exudative (wet) and non-exudative (dry) age-related macular degeneration (AMD), macular edema, post-retinal vein occlusion macular edema (RVO), retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branched retinal vein occlusion (BRVO), retinal angiomatous proliferation (RAP), polypoidal choroidal vasculopathy (PCV), vitreomacular adhesion (VMA), and/or vitreomacular traction (VMT).
實施態樣71為如實施態樣61至70中任一者之方法,其中該配方係以每眼0.03至10mg的劑量投予,較佳為每眼3.0至6.0mg,更佳地,該配方係以每眼4mg的劑量投予。 Embodiment 71 is the method of any one of embodiments 61 to 70, wherein the formulation is administered at a dose of 0.03 to 10 mg per eye, preferably 3.0 to 6.0 mg per eye, more preferably, the formulation It is administered at a dose of 4 mg per eye.
實施態樣72為如實施態樣71之方法,其中該配方係以每眼4mg的劑量投予。 Embodiment 72 is the method of embodiment 71, wherein the formulation is administered at a dose of 4 mg per eye.
提供以下實施例來說明本發明,但本發明並不以此為限。本領域技藝人士將明瞭以下步驟可使用本領域具有通常知識者所知的方法進行修飾。 The following examples are provided to illustrate the present invention, but the present invention is not limited thereto. It will be apparent to those skilled in the art that the following steps may be modified using methods known to those of ordinary skill in the art.
於脈絡膜新生血管(CNV)之猴子模型的眼睛中評估融合蛋白1(一種具有多重標的之免疫球蛋白G1 Fc-融合蛋白)。 Fusion protein 1, a multitargeted immunoglobulin G1 Fc-fusion protein, was evaluated in the eyes of a monkey model of choroidal neovascularization (CNV).
於該CNV模型中,恆河猴(每組n=4隻眼睛)係使用光凝固術(photocoagulation)對視網膜進行雷射灼傷,並且使脈絡膜新生血管發展21天(第-21天至第0天)。在第0天時,藉由單次玻璃體內(IVT)注射將空白載劑(vehicle)、每眼0.5mg之Lucentis®(0.5mg/眼)、或融合蛋白1(0.6mg、1.0 mg、1.9mg/眼)注射至該猴子的眼睛。療效指標(efficacy endpoint)係於給藥前之基線(前2天(Day -2))、及注射後之第14天與第28天對所有組別進行評估。 In this CNV model, rhesus monkeys (n=4 eyes per group) were subjected to laser burns on the retina using photocoagulation and allowed choroidal neovascularization to develop for 21 days (day -21 to day 0 ). On day 0, vehicle, 0.5 mg of Lucentis® per eye (0.5 mg/eye), or fusion protein 1 (0.6 mg, 1.0 mg, 1.9 mg/eye) was injected into the monkey's eyes. Efficacy endpoints were evaluated for all groups at baseline before administration (Day -2), and on days 14 and 28 after injection.
於使用0.5mg之Lucentis®處理的眼睛中,平均滲漏區域分數相較於基線係分別在第14天與第28天下降了91%與92%(圖1)。相較於基線,平均視網膜厚度亦下降了117%與120%(圖2)。相較於使用空白對照處理之眼睛,Lucentis®係顯示統計上顯著的改善。 In eyes treated with 0.5 mg of Lucentis®, the mean leakage area fraction decreased by 91% and 92% compared to baseline at days 14 and 28, respectively (Figure 1). Compared with baseline, the average retinal thickness also decreased by 117% and 120% (Figure 2). The Lucentis® system showed a statistically significant improvement compared to eyes treated with placebo.
相較於基線及試驗前的數值,融合蛋白1之全部三個劑量組別皆展現出雷射誘導視網膜厚度、及滲漏區域的恢復。平均滲漏區域在第14天與第28天分別下降了87%至89%與79%至90%(圖1)。平均視網膜厚度亦分別下降了98%至121%與104%至129%(圖2)。相較於使用空白對照處理之眼睛,融合蛋白1係於0.6mg及1.0mg的劑量在第14天與第28天時顯示出統計上顯著的改善。由於全部的劑量皆顯示相似的療效,並未觀察到融合蛋白1的劑量依存作用。 All three dose groups of Fusion Protein 1 demonstrated laser-induced recovery of retinal thickness and leakage areas compared to baseline and pre-test values. The average leakage area decreased by 87% to 89% and 79% to 90% on days 14 and 28, respectively (Figure 1). The average retinal thickness also decreased by 98% to 121% and 104% to 129% respectively (Figure 2). Fusion protein 1 showed statistically significant improvement at doses of 0.6 mg and 1.0 mg on days 14 and 28 compared to placebo-treated eyes. As all doses showed similar efficacy, no dose-dependent effect of fusion protein 1 was observed.
使用Masson染色膠原蛋白(一種纖維化的前驅物)進行眼睛的組織學檢查,其係顯示融合蛋白1對於膠原蛋白厚度(眼纖維化)具有劑量依存性的減少,但此並未存在於空白載劑或Lucentis®處理的組別(圖3)。 Histological examination of eyes using Masson staining for collagen, a precursor to fibrosis, showed a dose-dependent reduction in collagen thickness (ocular fibrosis) with fusion protein 1, but this was not present in the blank. agent or Lucentis® treated groups (Figure 3).
因此,每眼0.6、1.0、及1.9mg之融合蛋白1的單次IVT注射係有效地在恆河猴之雷射誘導CNV模型中抑制血管滲漏、視網膜厚度、及纖維化。基於人類(4mL)與猴子(2mL)之間的玻璃體體積比,該些劑量相當於每眼1.2mg、2mg、及4mg的人類同等劑量。此可作為融合蛋白1於治療視網膜疾病(例如糖尿病黃斑水腫(DME)及新生血管老年性黃斑退化(nAMD))之建議劑量的支持。此外,該數據係意味著相較於傳統的抗VEGF單一療法,融合蛋白1具有使病患受益的加乘作用。 Therefore, a single IVT injection of 0.6, 1.0, and 1.9 mg of fusion protein 1 per eye was effective in inhibiting vascular leakage, retinal thickness, and fibrosis in a laser-induced CNV model in rhesus monkeys. Based on the vitreous volume ratio between humans (4 mL) and monkeys (2 mL), these doses are equivalent to human equivalent doses of 1.2 mg, 2 mg, and 4 mg per eye. This may support the recommended dosage of fusion protein 1 in the treatment of retinal diseases such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Furthermore, the data imply that Fusion Protein 1 has an additive effect in benefiting patients compared to traditional anti-VEGF monotherapy.
於博萊黴素誘導之肺纖維化小鼠模型中評估融合蛋白1(靜脈投予39毫克/公斤(mg/kg))可能的抗纖維化活性。該些小鼠係使用PENNCENTURYTM肺內噴霧器在第一天時以1.5U/kg之博萊黴素處理。該些小鼠係自第1天至第21天每日靜脈投予融合蛋白1、尼達尼布乙磺酸鹽(Nintedanib ethanesulfonate,Nintedanib)或空白載劑(配方緩衝劑),且於第22天時進行犧牲。用50%三氯乙酸處理收集的肺組織放在冰上20分鐘從中沉澱出全部的蛋白質。樣品進行離心,並將沉澱物與1mL之12N的氫氯酸(HCl)混合並在110℃下烘焙14至18小時,直到樣品燒焦且乾燥。藉由在室溫下溫育72小時將該樣品再次懸浮於2mL之去離子水中,同時間歇地進行震盪。將反-4-羥基-L-脯胺酸(trans-4-hydroxy-L-proline;來源:美國Sigma)之標準品自0.5mg/mL開始製備其序列稀釋。將500微升(μL)之1.4%氯氨T(於0.5M之醋酸鈉/10%之異丙醇中;來源:美國Fisher Sci)添加至200μL之經震盪的樣品(或標準品)中,並於室溫下溫育20分鐘。然後,添加500μL之Ehrlich溶液(於70%異丙醇/30%高氯酸中之1M的對二甲胺基苯甲醛(p-dimethylaminobenzaldehyde);美國Fisher Sci),並混合及在65℃下溫育15分鐘。樣品達到室溫後,在550nm下量測各樣品及標準品的吸光度,以及自羥脯胺酸(hydroxyproline)標準曲線計算肺羥脯胺酸的濃度(μg/肺)。脯胺酸為膠原蛋白的主要組分,其係用於確定纖維化形成的標誌物之一。 The possible anti-fibrotic activity of fusion protein 1 (39 mg/kg administered intravenously) was evaluated in a mouse model of bleomycin-induced pulmonary fibrosis. The mice were treated with 1.5 U/kg bleomycin on day 1 using PENNCENTURY ™ intrapulmonary nebulizer. These mice were intravenously administered fusion protein 1, nintedanib ethanesulfonate (Nintedanib) or blank vehicle (formulation buffer) daily from day 1 to day 21, and on day 22 time to sacrifice. The collected lung tissue was treated with 50% trichloroacetic acid and placed on ice for 20 minutes to precipitate all proteins. The sample was centrifuged and the pellet was mixed with 1 mL of 12N hydrochloric acid (HCl) and baked at 110°C for 14 to 18 hours until the sample was charred and dry. The sample was resuspended in 2 mL of deionized water by incubating at room temperature for 72 hours while shaking intermittently. Prepare serial dilutions of trans-4-hydroxy-L-proline (trans-4-hydroxy-L-proline; source: Sigma, USA) starting from 0.5 mg/mL. Add 500 microliters (μL) of 1.4% chloramine T (in 0.5M sodium acetate/10% isopropyl alcohol; source: Fisher Sci, USA) to 200 μL of the shaken sample (or standard), and incubate at room temperature for 20 minutes. Then, add 500 μL of Ehrlich solution (1M p-dimethylaminobenzaldehyde in 70% isopropyl alcohol/30% perchloric acid; Fisher Sci, USA), mix and warm at 65°C. Incubate for 15 minutes. After the samples reached room temperature, the absorbance of each sample and standard was measured at 550 nm, and the lung hydroxyproline concentration (μg/lung) was calculated from the hydroxyproline standard curve. Proline is a major component of collagen and is one of the markers used to determine the formation of fibrosis.
肺羥脯胺酸係在空白對照組中顯著地上升(p<0.05)(圖4),此意味著成功誘導肺纖維化。相較於空白對照,融合蛋白1的多次投予係明顯地抑制了羥脯胺酸水平(p<0.05),此表示融合蛋白1注射對於該些標誌物的加乘作用(圖4)。Nintedanib之連續口服暴露對於減少羥脯胺酸水平具有輕微影響(圖4)。 Pulmonary hydroxyproline increased significantly in the blank control group (p<0.05) (Figure 4), which means that pulmonary fibrosis was successfully induced. Compared with the blank control, multiple administrations of fusion protein 1 significantly inhibited hydroxyproline levels (p<0.05), which indicated the additive effect of fusion protein 1 injection on these markers (Figure 4). Continuous oral exposure to nintedanib had a slight effect on reducing hydroxyproline levels (Figure 4).
因此,39mg/kg之融合蛋白1每日一次靜脈投予21天係與肺羥脯胺酸的顯著下降相關,其中該肺羥脯胺酸為小鼠博萊黴素誘導肺纖維化的一種主要肺纖維化標誌物。 Thus, once-daily intravenous administration of fusion protein 1 at 39 mg/kg for 21 days was associated with a significant decrease in lung hydroxyproline, a major contributor to bleomycin-induced pulmonary fibrosis in mice. Pulmonary fibrosis markers.
進行融合蛋白1的預調配試驗以產生融合蛋白1的合適液體配方。該試驗之目的如下:1.評估使用所選緩衝劑之各種濃度的融合蛋白1(40mg/mL及80mg/mL)相容性及膠體安定性;2.評估短期儲存後在加速的條件(40℃、25℃、2至8℃)下品質屬性的改變;3.賦形劑選擇:滲壓劑、氯化鈉、多元醇(即,海藻糖、蔗糖、甘露醇、及山梨糖醇)及其他穩定劑(例如甲硫胺酸、精胺酸);4.透過實驗設計(DoE)計畫來評估所選緩衝劑與潛在的穩定劑的相容性;以及5.確定凍乾保護劑的效果。 Preformulation trials of Fusion Protein 1 were performed to generate a suitable liquid formulation of Fusion Protein 1. The purpose of this test is as follows: 1. To evaluate the compatibility and colloidal stability of various concentrations of fusion protein 1 (40 mg/mL and 80 mg/mL) using the selected buffer; 2. To evaluate the accelerated conditions (40 mg/mL) after short-term storage. ℃, 25 ℃, 2 to 8 ℃); 3. Excipient selection: osmotic agent, sodium chloride, polyols (i.e., trehalose, sucrose, mannitol, and sorbitol) and Other stabilizers (e.g., methionine, arginine); 4. Evaluate the compatibility of the selected buffer with potential stabilizers through a design of experiments (DoE) plan; and 5. Determine the lyoprotectant Effect.
使用一實驗設計手段開始針對原料藥物的配方開發工作,以鑑定合適的緩衝劑、多元醇、界面活性劑、及其他穩定劑。在配方開發期間測試二種濃度(40及80mg/mL)的融合蛋白1。在配方開發期間使用熱壓力及搖動與冷凍/解凍壓力。表2係統整在後續試驗中的成分及相關功效。 Begin formulation development work on the drug substance using a design of experiments approach to identify appropriate buffers, polyols, surfactants, and other stabilizers. Two concentrations (40 and 80 mg/mL) of fusion protein 1 were tested during formulation development. Use heat pressure as well as shaking and freeze/thaw pressure during recipe development. Table 2. System components and related efficacy in subsequent trials.
通常使用溶解度及擴散係數(D)來評估蛋白質-蛋白質交互作用,且亦可用來證明蛋白質的膠體安定性。膠體安定性為表示在分散後分子之長期完整性及其在溶液中對沉澱/析出之抗性的重要參數。此外,此方法可快速獲取緩衝劑對該分子的相容性。因此,對融合蛋白1使用可緩衝pH值之三種常用的眼科溶液緩衝劑,磷酸鈉(NaPi)、組胺酸(His)、及檸檬酸(Cit)(表3)。藉由粒徑排阻層析儀串聯高效液相層析儀(SEC-HPLC)(表4)、動態光散射(DLS)(表5)、及濁度(圖6)分析融合蛋白1的屬性。 Solubility and diffusion coefficient (D) are commonly used to evaluate protein-protein interactions and can also be used to demonstrate the colloidal stability of proteins. Colloidal stability is an important parameter indicating the long-term integrity of molecules after dispersion and their resistance to precipitation/segregation in solution. In addition, this method allows rapid access to buffer compatibility for this molecule. Therefore, three common ophthalmic solution buffers that can buffer the pH, sodium phosphate (NaPi), histidine (His), and citric acid (Cit), were used for fusion protein 1 (Table 3). The properties of fusion protein 1 were analyzed by size exclusion chromatography tandem high performance liquid chromatography (SEC-HPLC) (Table 4), dynamic light scattering (DLS) (Table 5), and turbidity (Figure 6) .
在磷酸鹽及檸檬酸緩衝劑中之融合蛋白1的擴散係數展現出對上升濃度的負相關,此表示蛋白質-蛋白質交互作用提升的可能性(圖5A、5B、5E、及5F)。相反地,觀察到在pH值為6.5及6.0之組胺酸緩衝劑中的融合蛋白1為排斥的蛋白質-蛋白質交互作用,且在擴散係數與融合蛋白1的各種濃度之間具有正相關(圖5C及5D)。因此,在組胺酸緩衝劑中融合蛋白1之排斥的蛋白質-蛋白質交互作用係表示融合蛋白1之有利的膠體安定性。 The diffusion coefficient of fusion protein 1 in phosphate and citrate buffers showed an inverse correlation with increasing concentration, indicating an increased likelihood of protein-protein interactions (Figures 5A, 5B, 5E, and 5F). In contrast, an exclusive protein-protein interaction was observed for fusion protein 1 in histidine buffer at pH 6.5 and 6.0, with a positive correlation between the diffusion coefficient and various concentrations of fusion protein 1 (Fig. 5C and 5D). Therefore, the exclusive protein-protein interaction of Fusion Protein 1 in histidine buffer indicates the favorable colloidal stability of Fusion Protein 1.
在將融合蛋白1的濃度提升到超過40mg/mL至60及80mg/mL時,所有的配方(即使是組胺酸緩衝劑配方)皆檢測到下降的擴散係數。對於組胺酸 緩衝劑配方,此表示一旦濃度提升到超過40mg/mL就有可能發生初步聚合。基於SEC-HPLC的結果,對於所有的緩衝劑及pH值(除了pH值為6.5之組胺酸緩衝劑以外)而言,調配為80mg/mL的蛋白質顯示在緩衝劑中較低的純度、以及較大的高分子量聚合物(表4)。相較於40mg/mL的樣品,在所有的80mg/mL配方中皆檢測到在顯微鏡下可見的粒子(subvisible particle)增加(100至1,000nm,透過DLS檢測)(表5)。在40及80mg/mL樣品之間的濁度沒有顯著差異(圖6A及6B)。綜合前述,透過DLS分析之粒子大小顯示在自40至80mg/mL的濃度提升時,所有緩衝劑的在顯微鏡下可見的粒子皆提升,透過SEC-HPLC檢測到所有的配方(除了pH 6.5的組胺酸緩衝劑以外)其高分子量物質的聚合物(HMW)皆有輕微的增加,以及觀察到任意配方的濁度都沒有顯著提升。 When increasing the concentration of Fusion Protein 1 beyond 40 mg/mL to 60 and 80 mg/mL, a decreased diffusion coefficient was detected in all formulations, even the histidine buffer formulation. For histamine Buffer formulation, this means that preliminary polymerization may occur once the concentration rises above 40 mg/mL. Based on the SEC-HPLC results, for all buffers and pH values (except histidine buffer at pH 6.5), the protein formulated at 80 mg/mL showed lower purity in the buffer, and Larger high molecular weight polymers (Table 4). An increase in microscopically visible particles (100 to 1,000 nm, detected by DLS) was detected in all 80 mg/mL formulations compared to the 40 mg/mL sample (Table 5). There was no significant difference in turbidity between the 40 and 80 mg/mL samples (Figures 6A and 6B). Based on the above, particle size analysis by DLS showed that as the concentration increased from 40 to 80 mg/mL, the microscopically visible particles of all buffers increased, which was detected by SEC-HPLC in all formulations (except the pH 6.5 group). There was a slight increase in the polymer of high molecular weight substances (HMW) except for the amino acid buffer, and no significant increase in turbidity was observed in any formulation.
#對照組1係以25mM組胺酸、6%蔗糖、20mM氯化鈉、0.03%聚山梨糖醇酯20(pH 6.0)調配。 #Control 1 is prepared with 25mM histidine, 6% sucrose, 20mM sodium chloride, and 0.03% polysorbate 20 (pH 6.0).
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
%Pd=多分散性的百分比(percent polydispersity) %Pd=percent polydispersity
測試調配於25mM檸檬酸或組胺酸緩衝劑(pH 6.0)中之40及80mg/mL融合蛋白1的可行性與加速的安定性。對於40及80mg/mL二種濃度而言,儲存在2℃至8℃下於檸檬酸及組胺酸中之融合蛋白1的非聚合(二聚體形式)的量顯示在儲存時無明顯變化(表6)。然而,於40℃的加速條件下,80mg/mL融合蛋白1的主要波峰係在28天後於檸檬酸緩衝劑中下降了約70%(表7)。相比而言,當以組胺酸緩衝劑調配時,融合蛋白1的含量係下降約50%。而且,相較於沒有下降的組胺酸緩衝劑,80mg/mL融合蛋白1的蛋白質濃度係於檸檬酸緩衝劑中下降29%。因此,在組胺酸緩衝劑中的融合蛋白1在pH 6.0下係比在檸檬酸緩衝劑中更加安定。 The feasibility and accelerated stability of 40 and 80 mg/mL fusion protein 1 formulated in 25 mM citric acid or histidine buffer (pH 6.0) were tested. For both concentrations of 40 and 80 mg/mL, the amount of non-polymerized (dimeric form) of fusion protein 1 stored in citric acid and histidine at 2°C to 8°C showed no significant change during storage. (Table 6). However, under accelerated conditions at 40°C, the main peak of 80 mg/mL fusion protein 1 decreased by approximately 70% in citrate buffer after 28 days (Table 7). In comparison, when formulated with histidine buffer, the content of fusion protein 1 decreased by approximately 50%. Furthermore, the protein concentration of 80 mg/mL fusion protein 1 decreased by 29% in citrate buffer compared to no decrease in histamine buffer. Therefore, fusion protein 1 in histidine buffer is more stable at pH 6.0 than in citrate buffer.
藉由在A280下的UV吸光值(濃度)及SEC-HPLC分析樣品。 Samples were analyzed by UV absorbance (concentration) at A 280 and SEC-HPLC.
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
#HHMW:更高分子量物質的聚合物,其係指具有滯留時間為7.6±0.1分鐘的波峰。 # HHMW: Polymer of higher molecular weight species, which refers to a wave peak with a residence time of 7.6 ± 0.1 minutes.
*LMW:低分子量物質,滯留時間為13.5±0.1分鐘 * LMW: Low molecular weight substance, residence time is 13.5±0.1 minutes
「-」:未偵測到 "-": Not detected
此外,在40℃溫育後,於檸檬酸緩衝劑中的融合蛋白1係在非還原SDS-PAGE中約250kDa的位置顯示出主要條帶(band)強度減少較多(圖7A至7E)。融合蛋白1的蛋白質降解特性使得產物降解片段及高分子量聚合物的條帶隨著時間增加。透過還原SDS-PAGE的分析係顯示在約75kDa之主要條帶強度減少且片段的條帶增加(圖8A至8E)。總體而言,蛋白質純度及完整性探討係表示相較於檸檬酸緩衝劑,融合蛋白1在pH 6.0之25mM組胺酸緩衝劑中展現出較好的安定性。 In addition, after incubation at 40°C, the fusion protein 1 line in citrate buffer showed a greater reduction in the intensity of the main band at approximately 250 kDa in non-reducing SDS-PAGE (Figures 7A to 7E). The protein degradation characteristics of fusion protein 1 cause the bands of product degradation fragments and high molecular weight polymers to increase over time. Analysis by reducing SDS-PAGE showed a decrease in intensity of the major band at approximately 75 kDa and an increase in fragmented bands (Figures 8A to 8E). Overall, the study of protein purity and integrity showed that fusion protein 1 showed better stability in 25mM histidine buffer at pH 6.0 compared to citric acid buffer.
亦對短期儲存的加速冷凍/解凍條件進行評估,以測試融合蛋白1樣品的品質屬性變化。將樣品在40℃下溫育4天。一個-70℃與室溫(RT)之冷凍-解凍循環測試顯示在沒有多元醇保護下融合蛋白1仍為安定的(表8)。 Accelerated freezing/thawing conditions for short-term storage were also evaluated to test changes in quality attributes of Fusion Protein 1 samples. Samples were incubated at 40°C for 4 days. A freeze-thaw cycle test at -70°C and room temperature (RT) showed that fusion protein 1 was stable without polyol protection (Table 8).
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
為了探討賦形劑的適用性,進行一前導研究以藉由SEC-HPLC評估經調配之融合蛋白1樣品的主要波峰純度變化。基於上述研究,選擇25mM組 胺酸緩衝劑(pH 6.0)進行後續的賦形劑篩選測試。所包括之三種型態的添加劑為多元醇、鹽類、及胺基酸。評估係經設計,以七種條件並透過在40℃的加速條件下4天進行測試(表9)。 To investigate the suitability of the excipients, a pilot study was conducted to evaluate the major peak purity changes of formulated Fusion Protein 1 samples by SEC-HPLC. Based on the above studies, the 25mM group was selected Amino acid buffer (pH 6.0) was used for subsequent excipient screening tests. The three types of additives included are polyols, salts, and amino acids. The evaluation system was designed to be tested under seven conditions and through accelerated conditions at 40°C for 4 days (Table 9).
註:融合蛋白1係經調配於25mM組胺酸緩衝劑(pH 6.0)中,並使用各種不同的多元醇(#1至#4)測試、或與40mM氯化鈉(#6至#9)組合。測試#5=在沒有多元醇或胺基酸情況下的40mM氯化鈉。測試#10及#11=蔗糖與2種胺基酸的組合。 Note: Fusion protein 1 was formulated in 25mM histidine buffer (pH 6.0) and tested with various polyols (#1 to #4), or with 40mM sodium chloride (#6 to #9) combination. Test #5 = 40mM sodium chloride without polyol or amino acid. Tests #10 and #11 = Combination of sucrose and 2 amino acids.
在使用各種多元醇(表10,測試#1至#4)、海藻糖與氯化鈉的組合(測試#6)、及蔗糖與甲硫胺酸的組合(測試#11)進行調配時,主要波峰純度≧90%。 When formulating with various polyols (Table 10, Tests #1 to #4), the combination of trehalose and sodium chloride (Test #6), and the combination of sucrose and methionine (Test #11), the main Peak purity ≧90%.
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
#HHMW:更高分子量物質的聚合物,其係指具有滯留時間為7.6±0.1分鐘的波峰。 # HHMW: Polymer of higher molecular weight species, which refers to a wave peak with a retention time of 7.6 ± 0.1 minutes.
*LMW:低分子量物質,滯留時間為13.5±0.1分鐘 * LMW: Low molecular weight substance, residence time is 13.5±0.1 minutes
「-」:未偵測到 "-": Not detected
相較於沒有氯化鈉的測試,留有多元醇與氯化鈉的組合輕微提升聚合物的%(表10,測試#6、#7、#8、#9)。於精胺酸與蔗糖的組合中,在加速條件下的儲存後,純度下降至73.88%且聚合物超過16%(表10,測試#10)。因此,選擇海藻糖、蔗糖、及甘露醇進行實驗設計的探討。 The combination of leaving polyol and sodium chloride slightly increased the % of polymer compared to the tests without sodium chloride (Table 10, tests #6, #7, #8, #9). In the combination of arginine and sucrose, after storage under accelerated conditions, the purity dropped to 73.88% and the polymer exceeded 16% (Table 10, Test #10). Therefore, trehalose, sucrose, and mannitol were selected for discussion of experimental design.
為了探討源自候選穩定劑的顯著性及明確氯化鈉與各個多元醇的交叉作用,藉由如表11所示之計畫的DoE測試所選的多元醇及各種濃度的氯化鈉。將加速試驗條件與分析統整於表12。根據SEC-HPLC的結果(表13),具有200mM多元醇/糖類(尤其是海藻糖及蔗糖)的25mM組胺酸(His)緩衝劑(pH 6.0)提供了融合蛋白1對於熱壓力的最佳保護,以維持融合蛋白1的高百分比純度。 In order to explore the significance derived from the candidate stabilizers and to clarify the cross-talk between sodium chloride and each polyol, the selected polyols and various concentrations of sodium chloride were tested through a planned DoE as shown in Table 11. The accelerated test conditions and analysis are summarized in Table 12. According to the results of SEC-HPLC (Table 13), 25mM histidine (His) buffer (pH 6.0) with 200mM polyols/saccharides (especially trehalose and sucrose) provided the best resistance of fusion protein 1 to thermal stress. Protection to maintain high percent purity of fusion protein 1.
*表示多元醇為海藻糖、蔗糖、或甘露醇,且各測試係個別地具有或不具有氯化鈉。 *Indicates the polyol is trehalose, sucrose, or mannitol, and each test system is individually with or without sodium chloride.
在80mg/mL融合蛋白1於40℃下儲存4及7天(表12)後,調配有200mM多元醇之25mM組胺酸緩衝劑(pH 6.0)使融合蛋白1對於熱壓力係安定的,維持相對純度>80%,且提供融合蛋白1之最佳的結果純度(表13之測試#4及#6)。具有多元醇與50mM氯化鈉的樣品(測試#2及#5)皆顯示低於僅具有多元醇之樣品的純度(測試#4及#6)。相較於具有25mM多元醇及50mM氯化鈉的樣品(測試#10及#11),亦在具有25mM多元醇且不具有氯化鈉的樣品(測試#7及#9)觀察到此效果。該些組合之間的差異在4℃及25℃下並無不同(未揭示數據)。 After 80mg/mL fusion protein 1 was stored at 40°C for 4 and 7 days (Table 12), 25mM histidine buffer (pH 6.0) with 200mM polyol was prepared to make fusion protein 1 stable to heat stress and maintain The relative purity was >80% and provided the best resulting purity for Fusion Protein 1 (Tests #4 and #6 of Table 13). The samples with polyol and 50mM sodium chloride (tests #2 and #5) both showed lower purity than the samples with polyol alone (tests #4 and #6). This effect was also observed in samples with 25mM polyol and no sodium chloride (tests #7 and #9) compared to samples with 25mM polyol and 50mM sodium chloride (tests #10 and #11). The differences between the combinations were not different at 4°C and 25°C (data not disclosed).
#表示使用T0樣品(基線)標準化之在40℃下樣品純度的相對純度。 # represents the relative purity of the sample at 40°C normalized using the T0 sample (baseline).
雖然具有200mM多元醇之較高組胺酸緩衝劑維持了蛋白質的品質屬性,必須要將滲透度維持在280-310mOsm/kg的眼部生理範圍。因此,設定300mOsm/kg作為目標DoE統計計算。選擇與80mg/mL融合蛋白調配之成分組合物為25mM組胺酸緩衝劑(pH 6.0)、190mM的海藻糖、蔗糖、或海藻糖與蔗糖的組合。 Although the higher histidine buffer with 200mM polyol maintains the quality attributes of the protein, it is necessary to maintain the permeability within the physiological ocular range of 280-310mOsm/kg. Therefore, 300mOsm/kg was set as the target DoE statistics calculation. The ingredient composition selected to be formulated with the 80 mg/mL fusion protein is 25 mM histidine buffer (pH 6.0), 190 mM trehalose, sucrose, or a combination of trehalose and sucrose.
為了評估在組合配方中之合適成分的相容性,進一步測試將80mg/mL融合蛋白1用於4種候選配方中。於此試驗中,一併添加0.03%之聚山梨糖醇酯20或聚山梨糖醇酯80與海藻糖或蔗糖,以確定在使用加速條件處理一週及/或一個月、各種介於-20℃及室溫(RT)間之冷凍-解凍循環、以及搖動24及48小時之後(表14A至14B)融合蛋白1的屬性。並行測試了該容器的短期相容性。 To evaluate the compatibility of suitable ingredients in combination formulations, 80 mg/mL Fusion Protein 1 was further tested in 4 candidate formulations. In this test, 0.03% polysorbate 20 or polysorbate 80 was added together with trehalose or sucrose to determine the effects of accelerated treatment at -20°C for one week and/or one month. Properties of Fusion Protein 1 after freeze-thaw cycles between and room temperature (RT), and after 24 and 48 hours of shaking (Tables 14A to 14B). The container was tested in parallel for short-term compatibility.
V=測試時間點;T=時間;D=天。 V=test time point; T=time; D=day.
該4個候選配方組合物對於熱壓力試驗之屬性改變顯示出相似的觀察結果。80mg/mL濃度之融合蛋白1對40℃溫度敏感,此造成在7天時主要波峰減少至小於95%且超過5%的聚合物。此現象未在4℃儲存至少一個月時觀察到(表15及16)。此外,相較於對照組,VEGF及/或整合蛋白αvβ3結合的相對活性係在目標範圍(70至130%)內,且顯示出在加速條件下儲存後,對於VEGF結合的輕微改變、以及對αvβ3結合的無顯著變化。 The four candidate formulation compositions showed similar observations regarding property changes in the thermal stress test. Fusion protein 1 at a concentration of 80 mg/mL was sensitive to a temperature of 40°C, which resulted in a reduction of the main peak to less than 95% and more than 5% of the polymer at 7 days. This phenomenon was not observed when stored at 4°C for at least one month (Tables 15 and 16). Additionally, the relative activity of VEGF and/or integrin αvβ3 binding was within the target range (70 to 130%) compared to controls and showed slight changes in VEGF binding after storage under accelerated conditions, as well as No significant changes in αvβ3 binding.
具體而言,粒徑排阻層析法的試驗表示相較於其他配方,25mM組胺酸、190mM海藻糖、及0.03%聚山梨醇酯20(pH 6.0)的配方在4℃及40℃下都可實現融合蛋白1的較佳安定性。 Specifically, particle size exclusion chromatography tests showed that compared to other formulations, the formulation of 25mM histidine, 190mM trehalose, and 0.03% polysorbate 20 (pH 6.0) performed better at 4°C and 40°C. All can achieve better stability of fusion protein 1.
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
#對照組1係以25mM組胺酸、6%蔗糖、20mM氯化鈉、0.03%聚山梨醇酯20(pH 6.0)調配。 #Control 1 is prepared with 25mM histidine, 6% sucrose, 20mM sodium chloride, and 0.03% polysorbate 20 (pH 6.0).
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
*係表示相較於對照組,預期在70至130%內的相對活性。 * stands for relative activity expected to be in the range of 70 to 130% compared to the control group.
NA係表示不適用。 NA means not applicable.
#對照組1係以25mM組胺酸、6%蔗糖、20mM氯化鈉、0.03%聚山梨醇酯20(pH 6.0)調配。 #Control 1 is prepared with 25mM histidine, 6% sucrose, 20mM sodium chloride, and 0.03% polysorbate 20 (pH 6.0).
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
*係表示相較於參考,預期在70至130%內的目標相對活性。 * stands for target relative activity expected to be within 70 to 130% compared to the reference.
NA係表示不適用。 NA means not applicable.
以候選配方調配之80mg/mL融合蛋白1係於進行以下操作3及6個循環後測試品質屬性:在-20℃下冷凍約23小時且在25℃下解凍至少1小時。透過SEC-HPLC之分析沒有在融合蛋白1之主要波峰及其聚合物的百分比中檢測到任何顯著的變化(表17)。殘留的蛋白質係大於95%且該聚合物係少於5%。此外,相較於對照組,融合蛋白1結合至VEGF及整合蛋白αvβ3的活性於候選組別#3及#4中下降至少於70%(表17)。 The quality attributes of 80 mg/mL fusion protein 1 formulated with the candidate formula were tested after 3 and 6 cycles of freezing at -20°C for approximately 23 hours and thawing at 25°C for at least 1 hour. Analysis by SEC-HPLC did not detect any significant changes in the main peak of Fusion Protein 1 and its polymer percentage (Table 17). The remaining protein system is greater than 95% and the polymer system is less than 5%. In addition, compared to the control group, the activity of fusion protein 1 binding to VEGF and integrin αvβ3 decreased to less than 70% in candidate groups #3 and #4 (Table 17).
#對照組1係以25mM組胺酸、6%蔗糖、20mM氯化鈉、0.03%聚山梨醇酯20(pH 6.0)調配。 #Control 1 is prepared with 25mM histidine, 6% sucrose, 20mM sodium chloride, and 0.03% polysorbate 20 (pH 6.0).
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
*係表示相較於參考,預期在70至130%內的目標相對活性。 * stands for target relative activity expected to be within 70 to 130% compared to the reference.
NA係表示不適用。 NA means not applicable.
搖動試驗係測試蛋白質安定性,以模擬融合蛋白1在液體形式中可能的處理及運輸。透過在25℃環境下以每分鐘220轉(rpm)搖晃小瓶24及48小時來加速條件。相較於處於靜置條件及基線的樣品,在此一嚴格條件下處理蛋白質樣品係衝擊蛋白質純度及與主要目標的結合(表18)。 The shaking test tests protein stability to simulate possible handling and transport of Fusion Protein 1 in liquid form. Conditions were accelerated by shaking the vials at 220 revolutions per minute (rpm) for 24 and 48 hours at 25°C. Processing protein samples under these stringent conditions impacts protein purity and binding to the primary target compared to samples under standing conditions and baseline (Table 18).
#對照組1係以25mM組胺酸、6%蔗糖、20mM氯化鈉、0.03%聚山梨醇酯20(pH 6.0)調配。 #Control 1 is prepared with 25mM histidine, 6% sucrose, 20mM sodium chloride, and 0.03% polysorbate 20 (pH 6.0).
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
*係表示相較於參考,預期在70至130%內的目標相對活性。 * stands for target relative activity expected to be within 70 to 130% compared to the reference.
NA係表示不適用的。 NA means not applicable.
除了關鍵的品質屬性(例如:含量、純度及活性),在壓力條件後在顯微鏡下可見的粒子的形成及分布也被檢視。根據動態光散射(DLS)分析, 將觀察到的在顯微鏡下可見的粒子以尺寸、%多分散性、及粒子不同尺寸的比例進行分類。該結果表示無法對獲得所欲濃度80mg/mL之濃縮融合蛋白1的過程進行合適的監測,於此,在基線(D0)時,不僅檢測到有半徑約5nm之主要的融合蛋白1分子,還有可被視為較大尺寸粒子(即,10-100nm或100-1000nm)的聚合體。無法透過DLS總結出何種候選配方緩衝劑具有最佳作用。 In addition to key quality attributes (such as content, purity and activity), the formation and distribution of particles visible under the microscope after stress conditions were also examined. According to dynamic light scattering (DLS) analysis, The observed particles visible under the microscope are classified by size, % polydispersity, and the proportion of different particle sizes. This result indicates that the process of obtaining concentrated fusion protein 1 at the desired concentration of 80 mg/mL cannot be properly monitored. Here, at the baseline (D0), not only the main fusion protein 1 molecule with a radius of about 5 nm was detected, but also There are aggregates that can be considered larger size particles (ie, 10-100 nm or 100-1000 nm). It is not possible to conclude through DLS which candidate formulation buffer will work best.
此外,非還原及還原SDS-PAGE分析無法於壓力條件處理後分辨出融合蛋白1之完整性的變化。該些測試的候選配方的滲透度(表19)係顯示除了候選配方#4(所示滲透度較低)以外,其他的配方係有相似的範圍。 In addition, non-reducing and reducing SDS-PAGE analysis cannot distinguish changes in the integrity of fusion protein 1 after treatment under pressure conditions. The penetrations of the tested candidate formulations (Table 19) show that with the exception of candidate formulation #4 (showing lower penetration), the other formulations have similar ranges.
基於該些結果,係使用具有25mM組胺酸(His)且含有190mM海藻糖及0.03%聚山梨醇酯20(pH 6.0)的配方1,以進行一前導藥物產物之12個月安定性試驗的測試。 Based on these results, a 12-month stability study of a lead drug product was conducted using Formulation 1 with 25mM histidine (His) and containing 190mM trehalose and 0.03% polysorbate 20 (pH 6.0). test.
進行安定性試驗以開發融合蛋白1的最終配方。 Stability testing was performed to develop the final formulation of Fusion Protein 1.
為了透過製造過程選擇合適濃度以支持融合蛋白1的最終原料藥,將40及80mg/mL的融合蛋白1調配於主要配方組成(25mM組胺酸、190mM海藻糖、及0.03%聚山梨醇酯20,pH 6.0)中。具有二種濃度之融合蛋白1的配方係在短期加速條件下測試,以透過SEC-HPLC、DLS、及SDS-PAGE分析來確定關鍵品質屬性的任何變化。 In order to select the appropriate concentration to support the final API of fusion protein 1 through the manufacturing process, 40 and 80 mg/mL of fusion protein 1 were formulated in the main formulation composition (25mM histidine, 190mM trehalose, and 0.03% polysorbate 20 , pH 6.0). Formulations with two concentrations of Fusion Protein 1 were tested under short-term accelerated conditions to determine any changes in critical quality attributes through SEC-HPLC, DLS, and SDS-PAGE analysis.
蛋白質的量係在40℃短期儲存7天的40mg/mL樣品及80mg/mL樣品中展現出不同(表20)。觀察到在80mg/mL時聚合物的量些微較多。儲存於40℃之樣品的結果表示,在第4天及第7天時,相較於80mg/mL,40mg/mL之融合蛋白1形成較少的高分子量聚合物。該測試#2蛋白質樣品(40mg/mL,具有氯化鈉)展現出>5%的檢測聚合物。冷凍/解凍循環測試未顯示出40及80mg/mL樣品之聚合物%或純度有顯著變化(數據未示出)。 The amount of protein showed differences between the 40 mg/mL sample and the 80 mg/mL sample stored short-term at 40°C for 7 days (Table 20). A slightly higher amount of polymer was observed at 80 mg/mL. The results of samples stored at 40°C showed that 40 mg/mL of fusion protein 1 formed less high molecular weight polymers compared to 80 mg/mL on days 4 and 7. The Test #2 protein sample (40 mg/mL with sodium chloride) exhibited >5% detected polymer. Freeze/thaw cycle testing did not show significant changes in polymer % or purity for the 40 and 80 mg/mL samples (data not shown).
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
使用DLS以分析在顯微鏡下可見的粒子及其分布,且所有蛋白質樣品皆含有基線之尺寸範圍在10nm至100nm及/或100至1000nm間的粒子,其可能會使得壓力測試後無法分辨變化。 DLS is used to analyze particles and their distribution visible under a microscope, and all protein samples contain particles with a baseline size range of 10nm to 100nm and/or 100 to 1000nm, which may make it impossible to discern changes after stress testing.
基於上述試驗且融合蛋白1維持基於SEC-HPLC之最一致的純度,融合蛋白1之所選配方組成如下:40mg/mL融合蛋白1、25mM組胺酸、190mM海藻糖及0.03%聚山梨醇酯20(pH 6.0)。為了驗證且評估容器系統的相容性、以及為了收集初始安定性,以此配方製備40mg/mL的融合蛋白1,並填充於硼矽酸第I型玻璃瓶(以橡膠堵塞及翻蓋密封)且在以下三種條件下溫育:-25℃至-15℃、2℃至8℃、及25℃/60%之相對溼度(RH)(表21)。 Based on the above experiments and that fusion protein 1 maintains the most consistent purity based on SEC-HPLC, the selected formula of fusion protein 1 is as follows: 40mg/mL fusion protein 1, 25mM histidine, 190mM trehalose and 0.03% polysorbate 20 (pH 6.0). In order to verify and evaluate the compatibility of the container system and to collect the initial stability, 40 mg/mL of fusion protein 1 was prepared according to this formula and filled into borosilicate type I glass bottles (sealed with rubber plugs and flip caps) and Incubation was performed under the following three conditions: -25°C to -15°C, 2°C to 8°C, and 25°C/60% relative humidity (RH) (Table 21).
X=確認蛋白質品質屬性的時間點 X = time point to confirm protein quality attributes
Wks=週;M=月;T=時間 Wks=weeks; M=months; T=time
試驗的結果表示,40mg/mL融合蛋白1在-20℃下儲存至少12個月時係安定的(表22)。在4℃之儲存條件下6個月,純度有輕微的下降且聚合物提升(表23)。於25℃之加速儲存期間,SEC-HPLC檢測到經過6個月聚合物%提升,但主要波峰仍維持≧95%,以及該分子特異性活性及完整性(即,十二烷基硫酸鈉毛細管電泳(CE-SDS)的數據)係維持最小變化(表24)。 The results of the test showed that 40 mg/mL fusion protein 1 was stable when stored at -20°C for at least 12 months (Table 22). After 6 months of storage at 4°C, there was a slight decrease in purity and an increase in polymer (Table 23). During accelerated storage at 25°C, SEC-HPLC detected an increase in polymer % after 6 months, but the main peak still maintained ≧95%, as well as the specific activity and integrity of the molecule (i.e., sodium dodecyl sulfate capillary tube Electrophoresis (CE-SDS) data) maintained minimal changes (Table 24).
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
@:相較於基線(D0),基於EC50計算的相對活性。 @ : Relative activity calculated based on EC50 compared to baseline (D0).
#:Z19003為該測試物品的批號(Lot No.)。 # : Z19003 is the lot number (Lot No.) of the test item.
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
@:相較於基線(D0),基於EC50計算的相對活性。 @ : Relative activity calculated based on EC50 compared to baseline (D0).
#:Z19003為該測試物品的批號(Lot No.)。 # : Z19003 is the lot number (Lot No.) of the test item.
aHMW:高分子量物質的聚合物,滯留時間為8.3±0.1分鐘。 a HMW: Polymer of high molecular weight substances, residence time is 8.3±0.1 minutes.
b主要波峰的滯留時間為9.5±0.1分鐘,此表示融合蛋白1的非聚合二聚體形式。 b The retention time of the main peak is 9.5 ± 0.1 minutes, which represents the non-polymerized dimer form of fusion protein 1.
#HHMW:更高分子量物質的聚合物,其係指具有滯留時間為7.6±0.1分鐘的波峰。 # HHMW: Polymer of higher molecular weight species, which refers to a wave peak with a retention time of 7.6 ± 0.1 minutes.
@:相較於基線(D0),基於EC50計算的相對活性。 @ : Relative activity calculated based on EC50 compared to baseline (D0).
#:Z19003為該測試物品的批號(Lot No.)。 # : Z19003 is the lot number (Lot No.) of the test item.
根據DLS分析,將物品儲存在-20℃及4℃下至少12個月未檢測到在顯微鏡下可見的粒子,除了一樣品係儲存在4℃下的樣品係於12個月的時間點進行一冷凍/解凍循環並形成微量(2%)的較大尺寸的粒子(半徑2208nm)。在25℃儲存下於3及6個月時檢測到較大尺寸的粒子(半徑2195及2264nm)。 According to DLS analysis, no microscopically visible particles were detected in items stored at -20°C and 4°C for at least 12 months, except for one strain where samples stored at 4°C were analyzed at the 12-month time point. Freeze/thaw cycles and formed trace amounts (2%) of larger sized particles (radius 2208 nm). Larger size particles (radii 2195 and 2264 nm) were detected at 3 and 6 months of storage at 25°C.
分析儲存在4℃之備份樣品,以確認在12個月時觀察到的在顯微鏡下可見的粒子。亦將此樣品儲存12個月且經歷一冷凍/解凍循環。在試驗的備份樣品中觀察到在顯微鏡下可見的粒子。因此,融合蛋白1在4℃下儲存12個月係對冷凍/解凍壓力敏感。此即,在沒有冷凍/解凍循環的情況下,融合蛋白1可在4℃下儲存至少12個月。然而,若融合蛋白1將儲存超過6個月,則建議儲存在-20℃下。 Backup samples stored at 4°C were analyzed to confirm microscopic particles observed at 12 months. This sample was also stored for 12 months and subjected to a freeze/thaw cycle. Microscopically visible particles were observed in backup samples of the test. Therefore, fusion protein 1 is sensitive to freezing/thawing stress when stored at 4°C for 12 months. That is, Fusion Protein 1 can be stored at 4°C for at least 12 months without freeze/thaw cycles. However, if Fusion Protein 1 will be stored for more than 6 months, storage at -20°C is recommended.
配方的黏度測量係使用一黏度計而獲得。該受測配方(於具有所選成分之25mM組胺酸緩衝劑溶液中的40mg/mL融合蛋白1)具有5.402cP(釐泊,centipoise)的低黏度(表25)。所選配方具有好的蛋白質熱特性,如圖9之代表性的差示掃描熱分析儀(DSC)熱譜圖所示。反摺積熱譜圖(deconvoluted thermogram)具有4個熱傳導波峰,Tm值為61.47℃、66.51℃、81.55℃、及84.21℃。 The viscosity measurement of the formulation was obtained using a viscometer. The formulation tested (40 mg/mL Fusion Protein 1 in 25 mM histidine buffer solution with selected ingredients) had a low viscosity of 5.402 cP (centipoise) (Table 25). The selected formulation has good protein thermal properties, as shown in the representative Differential Scanning Calorimeter (DSC) thermogram in Figure 9. The deconvoluted thermogram has four heat conduction peaks, with Tm values of 61.47°C, 66.51°C, 81.55°C, and 84.21°C.
表25.在4℃下溶液中之融合蛋白1及配方溶液的黏度
*:自三或四位個體測試結果獲取平均值。 *: Average obtained from three or four individual test results.
鑒於此試驗的結果,於25mM組胺酸、190mM海藻糖及0.03%聚山梨醇酯20(pH 6.0)中調配的40mg/mL融合蛋白1可與所選容器封蓋系統(container closure system)相容,並在-20℃及2℃至8℃下儲存至少12個月仍保持安定。 Based on the results of this trial, 40 mg/mL Fusion Protein 1 formulated in 25 mM histidine, 190 mM trehalose, and 0.03% polysorbate 20 (pH 6.0) is compatible with the selected container closure system. Capacity, and remains stable when stored at -20℃ and 2℃ to 8℃ for at least 12 months.
進行一試驗以測試於25mM組胺酸、190mM海藻糖及0.03%聚山梨醇酯20(pH 6.0)中調配的40mg/mL融合蛋白1在各種溫度下的長期安定性。在儲存於-70℃下,融合蛋白1係展現出超過二年的安定性(表26)。觀察到αvβ3及α5β1結合在第9、18、及24個月(T9、T18、及T24)與第9、12、及24個月(T9、T12、及T24)時αvβ3及α5β1的EC50差異性(variation)。對此差異進行探討並認為,這可能是源於測試試劑失效。 An experiment was conducted to test the long-term stability of 40mg/mL fusion protein 1 formulated in 25mM histidine, 190mM trehalose and 0.03% polysorbate 20 (pH 6.0) at various temperatures. Fusion protein 1 showed stability for over two years when stored at -70°C (Table 26). Differences in the EC 50 of αvβ3 and α5β1 binding were observed at 9, 18, and 24 months (T9, T18, and T24) and at 9, 12, and 24 months (T9, T12, and T24). Variation. This discrepancy was discussed and believed to be due to the failure of the test reagent.
T=材料儲存的月安定性 T = monthly stability of material storage
BY=棕黃色 BY=brown
*α5β1結合ELISA在0個月後進一步優化,T1數據係用於α5β1結合ELISA安定性的趨勢分析。 *The α5β1 binding ELISA was further optimized after 0 months, and the T1 data was used for trend analysis of the stability of the α5β1 binding ELISA.
對在25mM組胺酸、190mM海藻糖及0.03%聚山梨醇酯20(pH 6.0)中調配的40mg/mL且接著儲存於-20℃的融合蛋白1進行檢視研究持續36個月。儲存於-20℃下9個月後的安定性結果統整係如表27所示。 Fusion protein 1 was examined at 40 mg/mL formulated in 25mM histidine, 190mM trehalose, and 0.03% polysorbate 20 (pH 6.0) and then stored at -20°C for 36 months. The stability results after 9 months of storage at -20°C are shown in Table 27.
T=材料儲存的月安定性;BY=棕黃色;NT=未測試;TBD=待確定;TO=省略測試;*自滲透度探討收集的數據。 T=monthly stability of material in storage; BY=brown; NT=not tested; TBD=to be determined; TO=testing omitted; *Data collected from permeability study.
此外,對在25mM組胺酸、190mM海藻糖及0.03%聚山梨醇酯20(pH 6.0)中調配的40mg/mL且接著儲存於5℃的融合蛋白1進行檢視研究持續36個月。正立(upright)或倒立(inverted)儲存於5℃下9個月後的安定性結果統整係分別如表28及29所示。 Additionally, a study was conducted on Fusion Protein 1 formulated at 40 mg/mL in 25mM histidine, 190mM trehalose, and 0.03% polysorbate 20 (pH 6.0) and then stored at 5°C for 36 months. The stability results after being stored upright or inverted at 5°C for 9 months are shown in Tables 28 and 29 respectively.
T=材料儲存的月安定性;BY=棕黃色;TBD=待確定。 T=monthly stability of material storage; BY=brown; TBD=to be determined.
T=材料儲存的月安定性;BY=棕黃色;NT=未測試;TBD=待確定 T=monthly stability of material storage; BY=brown; NT=not tested; TBD=to be determined
此外,對在25mM組胺酸、190mM海藻糖及0.03%聚山梨醇酯20(pH 6.0)中調配的40mg/mL且後續儲存於25℃的融合蛋白1安定性進行檢視研究持續6個月。在25℃下儲存6個月後的安定性結果統整係如表30所示。 In addition, the stability of fusion protein 1 formulated at 40mg/mL in 25mM histidine, 190mM trehalose and 0.03% polysorbate 20 (pH 6.0) and subsequently stored at 25°C was examined for 6 months. The stability results after 6 months of storage at 25°C are shown in Table 30.
T=材料儲存的月安定性;BY=棕黃色;NT=未測試 T=monthly stability of material storage; BY=brown; NT=not tested
進行一體內試驗以測試調配於上述感興趣之配方(於25mM組胺酸、190mM海藻糖及0.03%聚山梨醇酯20(pH 6.0)之40mg/mL融合蛋白1)中 的融合蛋白1的各種劑量的效果。人類VEGF誘導視網膜滲漏係透過經定義之滲漏分數(基於標準化之螢光血管攝影(FA)評分影像)於荷蘭黑帶兔中測試。將滲漏分數自0至4進行分類(0:主要血管非常直,有一些彎曲的小血管;1:主要血管彎曲增加及/或血管擴張;2:主要血管間產生滲漏;3:主要血管及次要血管間產生滲漏,次要血管仍然可分辨;4:主要及次要血管間產生滲漏,次要血管無法分辨)。 An in vivo assay was conducted to test the above formulation of interest (40 mg/mL Fusion Protein 1 in 25mM histidine, 190mM trehalose, and 0.03% polysorbate 20 (pH 6.0)). Effects of various doses of fusion protein 1. Human VEGF-induced retinal leakage was tested in Dutch black-banded rabbits via defined leakage fractions based on standardized fluorescein angiography (FA) scoring images. The leakage score is classified from 0 to 4 (0: main blood vessels are very straight with some small curved blood vessels; 1: main blood vessels have increased curvature and/or blood vessel dilation; 2: leakage occurs between major blood vessels; 3: main blood vessels Leakage occurs between the primary and secondary blood vessels, and the secondary blood vessels can still be distinguished; 4: Leakage occurs between the primary and secondary blood vessels, and the secondary blood vessels cannot be distinguished).
兔子皆各自以50μL進行雙側的單次玻璃體內注射,每組具有一共3隻兔子及6隻眼睛。在第0天時,對兔子投予50μL的空白對照緩衝液、Avastin®(每眼1.25mg)、Eylea®(每眼0.625mg)、以及遞增濃度的融合蛋白1(即,每眼0.03mg、0.1mg、0.3mg及1mg)。然後,使用1000ng的人類VEGF-A165在第2天時對兔子進行刺激,並且在第5天時使用FA確定滲漏分數。 Rabbits each received a single intravitreal injection of 50 μL bilaterally, with a total of 3 rabbits and 6 eyes in each group. On day 0, rabbits were administered 50 μL of blank control buffer, Avastin® (1.25 mg per eye), Eylea® (0.625 mg per eye), and increasing concentrations of fusion protein 1 (i.e., 0.03 mg, 0.1mg, 0.3mg and 1mg). Rabbits were then stimulated with 1000 ng of human VEGF-A 165 on day 2 and leakage fractions were determined on day 5 using FA.
使用低至0.03mg之融合蛋白1治療的兔子係展現出下降的血管滲漏分數(圖10)。此即,低至0.03mg之融合蛋白1可有效減少血管滲漏。 Rabbit lines treated with as little as 0.03 mg of Fusion Protein 1 exhibited reduced fractional vascular leakage (Figure 10). That is, as little as 0.03 mg of fusion protein 1 can effectively reduce vascular leakage.
融合蛋白1的該等劑量係在抑制VEGF誘導之視網膜滲漏的能力與Avastin®及Eylea®相當。這些數據係支持融合蛋白1適用於治療血管性視網膜疾病(例如:DME、nAMD、及RVO) These doses of Fusion Protein 1 are comparable to Avastin® and Eylea® in their ability to inhibit VEGF-induced retinal leakage. These data support the suitability of fusion protein 1 for the treatment of vascular retinal diseases (e.g., DME, nAMD, and RVO).
本申請係含有一序列表,其係透過EFS-Web以ASCII格式之序列表進行電子遞交(檔名為「SequenceListing7WO1」;創建日期:2022年5月12日;且檔案大小為45.0kb)。該透過EFS-Web遞交之序列表為本說明書的一部分且其全文係藉由引用而併入本文中。 This application contains a sequence listing, which was submitted electronically through EFS-Web as a sequence listing in ASCII format (file name "SequenceListing7WO1"; creation date: May 12, 2022; and file size is 45.0kb). The sequence listing submitted via EFS-Web is part of this specification and is incorporated herein by reference in its entirety.
Claims (44)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW111118082A TWI831202B (en) | 2022-05-13 | 2022-05-13 | Vegfr fusion protein pharmaceutical composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW111118082A TWI831202B (en) | 2022-05-13 | 2022-05-13 | Vegfr fusion protein pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202344265A TW202344265A (en) | 2023-11-16 |
TWI831202B true TWI831202B (en) | 2024-02-01 |
Family
ID=89720268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111118082A TWI831202B (en) | 2022-05-13 | 2022-05-13 | Vegfr fusion protein pharmaceutical composition |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI831202B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019055902A1 (en) * | 2017-09-18 | 2019-03-21 | Amgen Inc. | Vegfr-fc fusion protein formulations |
TW202023603A (en) * | 2017-12-22 | 2020-07-01 | 南韓商三星Bioepis股份有限公司 | Liquid composition comprising vegf antagonist |
WO2022025660A1 (en) * | 2020-07-31 | 2022-02-03 | (주)셀트리온 | Stable pharmaceutical preparation |
-
2022
- 2022-05-13 TW TW111118082A patent/TWI831202B/en active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019055902A1 (en) * | 2017-09-18 | 2019-03-21 | Amgen Inc. | Vegfr-fc fusion protein formulations |
TW202023603A (en) * | 2017-12-22 | 2020-07-01 | 南韓商三星Bioepis股份有限公司 | Liquid composition comprising vegf antagonist |
WO2022025660A1 (en) * | 2020-07-31 | 2022-02-03 | (주)셀트리온 | Stable pharmaceutical preparation |
Also Published As
Publication number | Publication date |
---|---|
TW202344265A (en) | 2023-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108430489B (en) | Fusion proteins for inhibiting angiogenesis | |
JP2018515435A (en) | Pharmaceutical composition for prevention and treatment of eye diseases comprising as an active ingredient a fusion protein in which a tissue-permeable peptide and an anti-vascular endothelial growth factor preparation are fused | |
US20230364185A1 (en) | VEGFR Fusion Protein Pharmaceutical Composition | |
TWI831202B (en) | Vegfr fusion protein pharmaceutical composition | |
WO2023092324A1 (en) | Multispecific ligand binding molecule and application thereof | |
TW202421185A (en) | Vegfr fusion protein pharmaceutical composition | |
US20230279090A1 (en) | Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery | |
CN116162148A (en) | Multispecific ligand binding molecules and uses thereof | |
CN115551529A (en) | Methods for enhancing aqueous humor outflow and lowering intraocular pressure | |
CN116761634A (en) | Non-covalent protein-hyaluronic acid conjugates for long-acting ocular delivery |